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Introduction: Mutations in the NOD2 gene are associated with the development of 
Crohn’s disease,  an  inflammatory disorder of the  gastrointestinal tract.  The NOD2 
protein  induces  cellular  activation  in  response  to  the  bacterial  antigen  muramyl 
dipeptide  (MDP).  The  NOD2  gene  is  mainly  expressed  by  circulating  blood 
monocytes although NOD2-associated Crohn’s disease involves mainly the terminal 
ileum. Paneth cells, which are most numerous in the terminal ileum, are specialised 
intestinal  epithelial  cells that secrete antimicrobial peptides  in response to bacterial 
products and are critically important in enteric antibacterial defence. I hypothesised 
that Paneth  cells express the NOD2  gene:  this thesis  describes the  expression and 
quantification  of the NOD2  gene  in Paneth cells  in  inflammatory  diseases  such  as 
Crohn’s disease and necrotizing enterocolitis.  I  also  identified  factors that regulate 
NOD2 gene expression in intestinal epithelial cells and peripheral blood mononuclear 
cells (PBMC).
Methods:  In  situ  hybridisation  and  immunohistochemistry  were  used  to  localize 
NOD2  mRNA  and  protein  expression  in  intestinal  tissue.  Laser  capture 
microdissection  (LCM),  and  calcium  chelation  followed  by  mechanical  disruption 
were used to isolate intestinal crypt and villus epithelial cells. Real-time RT-PCR was 
used to determine NOD2 gene expression in intestinal epithelial cells and PBMC. 
Results: NOD2 mRNA and protein expression was readily detected in Paneth cells in 
normal and Crohn’s disease affected terminal ileum; NOD2 was also expressed by 
monocytes,  but  not  by  mature  macrophages  in  the  lamina  propria  or  within 
granulomas. NOD2 mRNA levels were enriched in isolated crypt compared to villous 
epithelial cells, and NOD2 expression was mainly detected in LCM-acquired Paneth 
cells but not villous epithelial cells. In vitro, tumour necrosis factor alpha (TNFa) up- 
regulates NOD2  gene expression in  intestinal epithelial cells. There is a possibility 
that Paneth cell  antimicrobials are reduced  in patients  with NOD2-related  Crohn’s 
disease.
Conclusions: Paneth cells express NOD2 and could therefore play an important and 
hitherto unrecognized role in the development of NOD2-associated Crohn’s disease.Table of contents
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1. Introduction
Crohn’s disease and ulcerative colitis are the major forms of inflammatory bowel 
disease (IBD), and are recognised as important causes of gastrointestinal disease 
in  children  and  adults  (Hendrickson  2002).  Both  illnesses  are  chronic  and 
although medical therapy alleviates symptoms in many patients, it does not cure 
illness.  The  aetiology  of IBD  remains  unknown,  although  a  common  postulate 
states that IBD develops as a consequence of an excessive or unregulated mucosal 
inflammatory  reaction  mounted  in  response  to  intestinal  microflora  (Bouma 
2003).  Interestingly,  some  forms  of  IBD  develop  in  genetically  susceptible 
individuals:  for example,  individuals  carrying mutations  in the NOD2  gene  are 
predisposed  to  develop  Crohn’s  disease  (Hugot  2001,  Ogura  2001).  It  is 
postulated that NOD2 proteins, which sense bacterial antigens, play a role in the 
protective immune responses against pathogens (Inohara 2005). Nonetheless, the 
reasons why individuals with NOD2 mutations are predisposed to develop Crohn's 
disease remain unknown.
In the  present thesis,  I  will  determine  whether Paneth  cells  express  the  NOD2 
gene.  Paneth  cells  are  specialised  for  innate  intestinal  defence  (Wilson  1999, 
Salzman 2003) and may also play a role in intestinal inflammation (Porter 2002): 
mutant NOD2  proteins  may  therefore  disrupt  normal  Paneth  cell  function  and 
predispose to the development of intestinal inflammation.
1.1  Crohn's disease
Crohn’s  disease,  an  inflammatory  disorder  affecting  any  part  of  the 
gastrointestinal  tract  from  the  oropharynx  to  the  perianal  area,  is  prevalent  in 
about 10-200 per 100 000 individuals in Western countries (Kurata 1992, Probert 
1996).  Crohn's  disease  is a chronic  disorder that  is  characterised by  alternating 
periods of active intestinal inflammation and resolution.
1The clinical features of Crohn's disease vary as any region of the gastrointestinal 
tract can be  involved.  The  clinical presentation also  depends  on the  extent and 
severity of inflammation. In Crohn’s disease, inflammation of the terminal ileum 
(ileitis)  and colon (colitis)  is  most frequent and often co-exist.  In patients with 
ileocolonic  involvement,  abdominal  pain  is  usually  postprandial  and  may  be 
referred  to  the  periumbilical  area,  especially  in  children.  On  abdominal 
examination,  tenderness  often  localises  to  the  right  lower  quadrant,  and  an 
inflammatory mass may occasionally be palpated (Hendrickson 2002). Ileitis may 
be  complicated  by  intestinal  stricturing  that  causes  intestinal  obstruction,  or 
intestinal fistulae that may communicate with other intestinal and pelvic organs, 
or develop into enterocutaneous fistulae (Keshav 2004).
Colitis causes diarrhoea, which usually contains blood, mucus and pus.  Patients 
with  colitis  usually  have  cramp-like  abdominal  pain  that  is  often  relieved  by 
defecation.  Patients  with  gastroduodenal  involvement  often  experience  early 
satiety,  nausea  and  vomiting,  epigastric  pain  and  dysphagia.  Extensive  small 
bowel disease causes diffuse abdominal pain, anorexia, diarrhoea and weight loss, 
and may result in lactose malabsorption (Hendrickson 2002).
In IBD, fever, malaise and weight loss may occur due to systemic inflammatory 
responses,  and  these  symptoms  are  often  more  severe  in  patients  with  Crohn's 
disease. Extra-intestinal manifestations of Crohn's disease  include arthralgia and 
arthritis,  pyoderma  gangrenosum  and erythema nodosum,  and  iritis  and uveitis. 
As there is no curative therapy for Crohn's disease, patients usually require long 
term therapy with immunosuppressive therapy to reduce intestinal  inflammation 
(Keshav 2004).  Surgical resection of the inflamed intestine is usually performed 
in those patients that do not respond to medical therapy (Podolsky 1991).
1.1.1  Pathophysiology of Crohn's disease
The  aetiology  of  Crohn's  disease  is  unknown.  Many  investigators,  however, 
hypothesise that IBD develops from an unregulated mucosal immune response to 
the intestinal microbiota that is, in part, genetically determined (Podolsky 2002, 
Bouma  2003).  It  is  postulated  that  microbiota  initiate  different  types  of
2inflammatory responses in Crohn’s disease and ulcerative colitis  (Bouma 2003). 
In Crohn’s disease, mucosal inflammation is mediated by an excessive T helper 1  
(ThI)-ccII  response that is  associated with increased  secretion of interleukin-12 
(IL-12), interferon y (IFNy) and tumour necrosis factor a (TNFa) (Bouma 2003). 
Evidence  from experimental models of intestinal  inflammation,  as well  as  from 
patients with IBD supports the hypothesis that inflammation in Crohn’s disease is 
mediated by ThI -cells. For example, macrophages isolated from intestinal tissue 
produce increased amounts of inflammatory cytokines such as interleukin (IL)-12 
(IL-12) (Monteleone  1997, Parronchi  1997, Liu  1999), and patients treated with 
anti-IL-12 antibody demonstrate clinical improvement (Mannon 2004).
In murine  models of IBD,  intestinal  inflammation can develop  in several ways, 
and Bouma (2003) has categorised these models into four broad groups. Firstly, 
inflammation may occur spontaneously as a result of naturally occurring genetic 
abnormalities  (Madara  1985,  Sundberg  1994,  Matsumoto  1998,  Rivera-Nieves 
2003). Secondly, inflammation may occur as a consequence of targeted disruption 
of a specific gene or introduction of a transgene (Panwala  1998, Mashimo  1996, 
Sadlack  1993, Willerford  1995, Spencer 1998, Shull  1992, Hahm 2001, Rudolph 
1995,  Watanabe  1997,  Mombaerts  1993,  Erdman  2001,  Beg  1995,  Lee  2000, 
Hammer  1990,  Snapper  1998,  Steinhoff 1999,  Kontoyiannis  1999,  Wirtz  1999, 
Kuhn 1993, Hermiston 1995). In the third group, inflammation may be induced by 
exogenous  agents  (Boirivant  1998,  Morris  1989,  MacPherson  1978,  Yamada 
1993,  Okayasu  1990,  Stewart  1980,  Marcus  1969).  Finally,  transfer  of T-cell 
populations lacking regulatory cells into a severely lymphopenic  host that lacks 
endogenous  regulatory  cells,  causes  colitis  in  the  recipient  (Powrie  1994, 
Hollander 1995).
The information garnered from these murine studies highlights several important 
and  widely  accepted  concepts  or  principles  that  are  relevant  to  human  IBD. 
Bouma (2003) has proposed that seven principles are important in understanding 
the pathogenesis of IBD. The first principle states that entirely different genetic 
abnormalities  can  lead  to  the  clinical  features  of intestinal  inflammation.  The 
second  principle  states  that  the  host  genetic  background  determines  the 
susceptibility to  intestinal  inflammation,  even when  a major  genetic  defect that
3predisposes to inflammation is present. Thirdly, the normal mucosal microflora is 
required to initiate or sustain the inflammatory response (Sartor 1997). The fourth 
principle states that experimental inflammation is due to either excessive effector 
T-cell  function  or  deficient  regulatory  T-cell  function.  Also,  despite  the  wide 
variety  of causes,  intestinal  inflammation  is  usually  mediated  by  excessive  T 
helper 1   (THl)-cell or Th2- cell responses (the fifth principle). The sixth principle 
states  that  the  epithelium  of the  intestinal  mucosa  has  an  essential  role  in  the 
physical separation of potentially stimulating microflora and the reactive cells of 
the  immune  system  (Podolsky  1999,  Hermiston  1995).  Finally,  the  seventh 
principle states that mucosal inflammation can also arise due to specific defects in 
the innate immune system and genetic abnormalities of innate immunity involving 
the  function  of antigen-presenting  cells  (APCs),  macrophages,  or  natural  killer 
(NK)  cells  cause  mucosal  inflammation (Takeda  1999).  In the  present thesis,  I 
will propose that Paneth cells, which are likely to be integral to intestinal innate 
defence, also play a role in the pathogenesis of Crohn’s disease.
1.1.2  Intestinal inflammation in patients with Crohn’s disease
Although  murine  models  provide  insights  into  the  pathogenesis  of  mucosal 
inflammation,  an  analysis  of mucosal  inflammation  in  patients  with  Crohn’s 
disease  is  essential  to  provide  an  unequivocal  understanding  of the  disease.  In 
Crohn’s disease, a substantial body of evidence suggest that disease results from 
an  excessive  ThI -cell-mediated  inflammation  (Bouma  2003).  Mucosal 
inflammation,  however,  may  also  be  caused  by  a  defect  in  regulatory  T-cell 
function  although  functional  tests  of this  hypothesis  are  difficult to  perform  in 
patients  with  Crohn’s  disease.  In  patients,  excessive  ThI-cell-mediated 
inflammation is the best characterised pathophysiologic feature of Crohn's disease 
although  it  is  possible  that  the  inflammation  occurs  in  response  to  an,  as  yet, 
undefined trigger or infectious agent.
There  is  emerging  evidence  to  suggest  that  defects  in  innate  immunity  may 
predispose patients to IBD.  Wehkamp and colleagues  (2004) have reported that 
expression of the antimicrobial peptides alpha defensin 5  (HD5) and 6 (HD6) is 
lower  in patients  with  Crohn’s  disease  as  compared to  patients  with  ulcerative
4colitis.  In Crohn’s  disease, HD5  and HD6 expression is  especially low in those 
patients carrying mutations in their NOD2 gene. Some studies assessing the role 
of innate  immunity  in  intestinal  inflammation  have  analysed  toll-like  receptor 
(TLR)  expression  in  intestinal  epithelial  cells  as  it  is  hypothesised  that  pro- 
inflammatory cellular pathways are initiated by putative interaction between TLR 
and bacterial antigens in intestinal epithelial cells (Cario 2000, Abreu 2002, Abreu 
2005). There are no studies that show that a functional innate defect predisposes 
patients to IBD; for example, the respiratory burst capacity of macrophages does 
not appear to be defective in macrophages isolated from IBD-affected colon and 
ileum (Mahida 1989).
There is, however, firm epidemiologic evidence that environmental and genetics 
factors predispose to the development of Crohn's disease (Bonen 2003). Out of the 
potentially  relevant  environmental  risk  factors  implicated  in  Crohn's  disease, 
smoking  or tobacco  exposure  predicts  an  adverse  outcome  in patients  (Calkins 
1989). The identification of other environmental risk factors has proved difficult 
although, on the other hand, there is an accumulating body of evidence that has 
identified  potential  genetic  defects  that  may  predispose  to  the  development  of 
Crohn's disease.
1.1.3  The genetic epidemiology of Crohn's disease
Crohn's  disease  is  usually  diagnosed  in early  adulthood,  with  a peak  incidence 
occurring  between  15  and  30  years.  The  incidence  of Crohn's  disease  is  also 
dependant on racial or ethnic backgrounds, and on geographical locations. Crohn's 
disease  is  most  prevalent  in  Caucasians  (approximately  6-8  per  100  000),  and 
rarer amongst African and Asian populations (Bonen 2003).
Epidemiologic data strongly suggest a genetic predisposition to Crohn's disease. 
There  are  racial  and  ethnic  differences  in  Crohn's  disease  incidence  and 
prevalence,  and  familial  aggregation because  there  is  an  increased  risk  among 
first-degree  relatives  of affected  individuals  with  a  low  prevalence  in  spouses 
(Bonen 2003).  Twin studies support the role of genetic  susceptibility in Crohn's 
disease as concordance rates in monozygotic twins are higher than dizygotic twins
5(Tysk  1988,  Thompson  1996).  Furthermore,  Crohn's  disease  is  associated  with 
other  genetic  syndromes  resembling  IBD,  and  with  diseases  with  recognised 
genetic susceptibility such as ankylosing spondylitis and psoriasis (Bonen 2003).
Crohn's  disease  clusters  within  families,  and  in  population-based  studies, 
approximately 5-10% of all IBD-affected patients report a positive family history, 
indicating that the greatest risk factor for developing IBD is having other family 
members with the disease (Farmer 1980, Monsen 1991, Russel 1997). Cohort and 
case-control  studies  indicate  that  first-degree  relatives  have  14-  to  15-fold 
increased  risk  of  developing  Crohn's  disease  (Orholm  1991,  Satsangi  1994, 
Peeters  1996).  Also,  about  75%  of  multiply  affected  families  with  IBD  are 
concordant with disease type (Binder 1998), confirming the importance of genetic 
factors in disease pathogenesis.
Disease  aggregation  in  families  may,  however,  be  due  to  shared  genetic  and 
environmental  factors.  Twin  concordance  studies,  however,  provide  stronger 
evidence  to  evaluate  genetic  and environmental  factors  in  Crohn's  disease.  The 
monozygotic  twin  concordance  for  Crohn's  disease  ranges  from  42%  to  58%, 
whereas  the  dizygotic  twin concordance  rate  (7%)  is  not  significantly  different 
from that of all siblings (Tysk 1988, Thompson 1996). Although the concordance 
among monozygotic twins  is  significantly  less than  100%,  which indicates  that 
there is a reduced penetrance for the Crohn’s disease genotype that is most likely 
due  to  non-genetic  factors  such  as  environmental  triggers,  these  observations 
establish the role of genetic predisposition in the pathogenesis of Crohn's disease 
(Bonen 2003).
Overall, multiple lines of epidemiological evidence favour genetic predisposition 
to Crohn's disease, and two broad and complementary approaches, namely genetic 
linkage and candidate gene association studies, have been used to identify genetic 
determinants  of  IBD  susceptibility.  Using  genetic  linkage  studies,  numerous 
genome-wide  scans  and  replication  studies  have  identified  at  least  nine  IBD 
susceptibility loci (Hugot 1996, Satsangi  1996, Cho  1998, Duerr 1998, Ma 1999, 
Rioux  2000,  Duerr 2000).  The  gene  in the  IBD1  gene  locus  has  been recently
6identified (Hugot 2001, Ogura 2001), and this discovery promises further insight 
into the pathogenesis of Crohn's disease.
1.1.4 The identification of the NOD2 gene in the IBD1  gene locus
In  1996,  Hugot  and  colleagues,  using  genetic  linkage  studies,  identified  a  gene 
locus on chromosome  16ql2, named IBD1, which is specifically associated with 
Crohn's  disease  (Hugot  1996).  Numerous  other  investigators  have  subsequently 
confirmed the IBD1  gene linkage with Crohn's disease (Ohmen 1996, Brant 1998, 
Cavanaugh 1998, Annese  1999, Curran 1998 and Cavanaugh 2001). In 2001, two 
groups of investigators working independently,  identified the NOD2 gene in the 
IBD1  gene  locus,  and  showed  that  mutations  of the  NOD2  gene  are  strongly 
associated with Crohn's disease (Hugot 2001, Ogura 2001). Hugot and colleagues 
(2001) screened 235  Crohn's disease families to identify the NOD2 gene on the 
IBD1  locus  using  a  positional-cloning  strategy,  based  on  linkage  analysis 
followed  by  linkage  disequilibrium  mapping,  then  on  pedigree  disequilibrium 
mapping,  and finally on very extensive  sequence  analysis  of the  best candidate 
gene.  Three  independent associations  with Crohn's  disease,  a frameshift variant 
and two missense variants of NOD2 were identified by this approach. Ogura and 
colleagues  (2001),  on  the  other  hand,  identified  the  NOD2  gene  whilst 
investigating  apoptotic  proteins,  and  intuitively  considered  NOD2  a  candidate 
gene on the IBD1  locus as this gene is located in the peak region of linkage on 
chromosome  16.  Using  the  transmission  disequilibrium  test  and  case-control 
analysis,  these  investigators  identified  a  frameshift  mutation  that  is  associated 
with Crohn's disease (Ogura 2001).
1.1.5  Mutations  in  the  NOD2  gene  associated  with  Crohn's 
disease
There are three common genetic variants  of the NOD2  gene that are associated 
with  Crohn's  disease.  The  frameshift mutation,  identified  by  Hugot  (2001)  and 
Ogura (2001), is caused by a cytosine insertion in exon  11  at nucleotide position 
3020 (3020insC), which results in a frameshift at the second nucleotide of codon 
1007,  and  substitutes  proline  for  leucine  in  the  tenth  LRR,  followed  by  a 
premature  stop  codon.  This  mutation  (Leul007fsinsC)  encodes  for  a  NOD2
7protein  containing  1007  amino  acids,  instead  of  1040.  Hugot  and  colleagues 
(2001) identified two other single  nucleotide polymorphisms (SNP),  designated 
with the marker names SNP8 (a point mutation, substituting C for T, at nucleotide 
position 2104) and  SNP 12 (a point mutation,  substituting G for C,  at nucleotide 
position  2722),  which  are  associated  with  Crohn's  disease.  These  missense 
mutations encode the amino acid substitutions, Arg702Trp (tryptophan substituted 
for arginine  at  codon  702)  and  Gly908Arg  (arginine  substituted  for glycine  at 
codon 908),  and occur within or near the leucine-rich repeats (LRRs)-encoding 
region of the gene (Figure  1.1). All three common variants occur together with a 
background  mutation,  Pro268Ser (serine  substituted  for  proline  at  codon  268). 
Hugot  and  colleagues  (2001)  also  describe  over  30  other  amino  acid 
polymorphisms occurring near or within the LRRs-encoding region of the gene. 
These mutations, however, are rare and the study sample size did not permit the
investigators to reliably determine an association with Crohn's disease.
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Figure 1.1. The genomic structure of the NOD2 gene, showing the location of 
Crohn’s  disease-associated  variants,  and  predicted  structural  domains.  The
three  major  coding  region  polymorphisms  Arg702Trp  (R702W),  Gly908Arg 
(G908R),  and  Leul007fsinsC  (3020insC)  are  indicated.  All  three  common 
variants occur together with a background mutation, Pro268Ser (P268S). CARD: 
Caspase-recruitment domains; NOD: Nucleotide-binding domain; LRR: Leucine 
rich repeats. Figure adapted  from Bonen (2003).Individuals  with  N0D2  mutations  are  at  increased  risk  of developing  Crohn's 
disease. Possessing one copy of a NOD2 risk allele confers a small risk of 1.5- to 
4-fold for developing  Crohn's  disease.  Possessing two  copies  of the NOD2 risk 
alleles,  however,  confers  an  increased  risk  of  20-  to  40-fold  for  developing 
Crohn's disease (Hugot 2001, Bonen 2003, Hampe 2001, Cuthbert 2002, Vermeire 
2002, Ahmad 2002, Vavassori 2002).  The risk of developing Crohn's disease  is 
much greater in individuals who are homozygous or compound heterozygotes for 
the  NOD2  mutations,  which  suggests  that  NOD2  functions  in  an  autosomal 
recessive manner (Bonen 2003), or that the risk alleles confer Toss-of-function’ to 
NOD2 (Kelsall 2005).
Subsequently, more than thirty other studies have consistently shown the presence 
of higher allelic  frequencies  for Arg702Trp,  Gly908Arg,  and  Leul007fsinsC  in 
Caucasian  Crohn's  disease-affected  patients  (shown  in  Appendix  A).  Overall, 
approximately 8 to  17% of Crohn’s disease-affected patients carry two copies of 
the major NOD2 risk alleles compared to less than  1% of the control Caucasian 
population. About 27% to 32% of Caucasians patients carry one copy of these risk 
alleles  compared  with  about  20%  of controls  (Economou  2004).  The  genetic 
association between the  rarer polymorphisms  and Crohn's  disease  is  difficult to 
ascertain due to the infrequent occurrence of these mutations.
Even with these defined genotypic risks, however, disease penetrance is modest as 
less than  10% of individuals who are homozygous for the NOD2 mutations will 
develop Crohn's disease (Bonen 2003). Also, it is likely that a complex interaction 
of other, as yet unidentified, genetic factors play a role in disease progression - for 
example,  in  a  Flemish  cohort,  paternal  transmission  of NOD2  risk  alleles  was 
associated with a higher proportion of Crohn's disease-affected patients compared 
to maternal transmission (Esters 2004). This suggests that the  genetic regulation 
of other,  as yet undefined,  factors that interact with NOD2 will be  important in 
determining the pathogenesis of NOD2-associated Crohn's disease.1.1.6 The N0D2 genotype and ulcerative colitis
The  overwhelming  majority  of published  reports  indicated  that  carriage  of the 
NOD2  variant  haplotype  does  not  confer  increased  susceptibility  to  ulcerative 
colitis. Andriulli and colleagues (2004), however, report a significant association 
between  Leul007fsinsC  mutation  and  ulcerative  colitis  in  Italian  patients.  The 
frameshift mutation occurs at a lower frequency in comparison to Crohn's disease- 
affected  patients,  and  there  are  no  associations  between  the  Arg702Trp  and 
Gly908Arg  alleles  and  ulcerative  colitis.  These  investigators  have  previously 
reported an ulcerative colitis-associated susceptibility locus in the pericentromeric 
region  of chromosome  16,  although  it  is  uncertain  whether  this  is  due  to  the 
presence  of  rarer  NOD2  single  nucleotide  polymorphisms  or  variations  of  a 
completely  independent  gene  (Annese  2003).  McGovern  and  colleagues  (2003) 
have also reported that the Leul007fsinsC mutation occurs at a higher frequency 
in  ulcerative  colitis  compared  to  healthy  controls  and,  in  addition,  these 
investigators  report  an  association  between  NODI  polymorphisms  and  IBD 
(McGovern 2005). Although other studies are required to confirm the role of other 
NOD2 and NODI polymorphisms and IBD, these findings suggest that there may 
be shared genetic predisposition to inflammation in Crohn's disease and ulcerative 
colitis.
1.1.7  Racial  and  ethnic  differences  in  NOD2  genotypic 
expression
In specific  racial populations,  the three  common variant NOD2  alleles  occur at 
much lower frequency and are not associated with an increased risk of developing 
Crohn's disease. In the Oriental and Australian populations, NOD2 gene mutations 
do not appear to make a significant contribution to the  development of Crohn's 
disease.  In Japan, Inoue and colleagues (2002) were unable to detect any of the 
common NOD2  mutations  in  350 patients  with  Crohn's  disease,  and  Yamakazi 
and  colleagues  (2002)  identified  one  patient  with  the  Arg702Trp  variant  allele 
from a cohort of 483 patients. In China, the three common NOD2 variants alleles 
are  either undetectable  or occur at frequencies  of less  than  1%  in patients with 
Crohn's  disease  (Leong  2003,  Guo  2004).  In  some  population  groups,  such  as
10Australians and Tunisians, the common variant alleles occur at lower frequencies 
in  patients  with  Crohn's  disease  (Cavanaugh  2003,  Zouiten-Mekki  2005).  The 
Leul007fsinsC  allele  also occurs at a low frequency  and  is not associated with 
Crohn's  disease  in  Cretan  (Roussomoustakaki  2003)  and  Scottish  populations 
(Crichton 2002).
1.1.8  NOD2 genotype and the clinical course of Crohn's disease
Crohn's disease, a complex heterogeneous disorder, is usually classified according 
to  the  Vienna  classification  by  defining  subgroups  on  the  basis  of  disease 
localisation,  age  of diagnosis,  disease  behaviour  and  surgical  history  (Gasche 
2000).  Disease  site  is  generally  categorised  into  four  broad  groups:  upper 
gastrointestinal (involvement of the oesophagus,  stomach, duodenum or jejunum 
without  ileal  disease),  ileal,  ileo-colonic  or  colonic  only.  In  addition,  perianal 
disease  may  be  associated  with  any  disease  site,  although  it  occurs  most 
frequently in patients with colonic Crohn's disease. Disease behaviour is usually 
categorised  as  fistulizing  (penetrating),  stricturing  or  inflammatory  (non- 
stricturing non-penetrating) and age of diagnosis based on whether the diagnosis 
is made before or after 40 years (Appendix B).
Several  investigators  have  correlated  NOD2  genotype  with  the  phenotypic 
manifestations  of Crohn’s  disease  to  determine  the  influence  of the  common 
NOD2  variant  alleles  on  the  clinical  course  of this  disorder.  Of the  clinical 
variables,  disease  localisation  is  the  major  determinant  of  disease  behaviour 
(Louis 2001) and ileal involvement is associated with an earlier age of onset and 
family history of Crohn's disease. For this reason, many investigators determined 
whether an  association between disease  localisation  and  carriage  of the  variant 
NOD2 alleles existed.
1.1.8.1  Disease localisation
Numerous studies have established that NOD2 variant allele carriage is associated 
with ileal  disease,  not colitis,  in patients  (Ahmad  2002,  Cuthbert  2002,  Lesage
2002).  In  European  patients,  the  frequency  of  the  NOD2  variant  alleles  is
11significantly higher in patients with exclusive ileal disease (26.9%), intermediate 
in those with ileocolitis (19.7%), and lowest in those with colonic disease (12.7%) 
(Cuthbert  2002).  Lesage  and  colleagues  (2002)  have  reported  that  in  French 
patients with Crohn's disease, colonic involvement is significantly less common in 
individuals  carrying two  copies of the variant NOD2  alleles than in individuals 
carrying wild-type alleles.
This  site  specific  association  has  been  confirmed  in  an  analysis  of American 
patients  with  Crohn's  disease  (Brant  2003).  Using  logistic  regression  analysis, 
these  investigators  determined that carriage  of two NOD2 variant alleles,  either 
homozygous or compound heterozygous carriage, was the strongest predictor of 
ileal disease. NOD2 mutations were associated with a  10-fold risk of developing 
ileal disease,  after adjusting for the risks associated with cigarette  smoking and 
age at diagnosis.
Other  studies  have  subsequently  confirmed  that  the  NOD2  variant  alleles 
specifically confer risk for ileal disease. In a recent meta-analysis, Economou and 
colleagues (2004) assessed the effects of NOD2 variants alleles on Crohn's disease 
phenotype  in non-Jewish Caucasian populations,  and  showed  that the  strongest 
genetic  effect  of NOD2  mutations  was  predisposition  to  small  bowel  or  ileal 
disease. This meta-analysis showed that the presence of at least one NOD2 variant 
allele  does  not confer  any  large  risk  for Crohn's  disease  when cases  with  only 
colonic disease are considered.
1.1.8.2  Age at diagnosis
The NOD2  variant  haplotype  is  associated  with  an  earlier  age  of diagnosis  in 
Crohn's  disease,  and  the  disorder  is  diagnosed  on  average  3-5  years  earlier  in 
European  and  American  patients  who  are  homozygous  or  compound 
heterozygotes for the NOD2 mutations. A meta-analysis of 13 studies showed that 
the presence of at least one high-risk variant allele increases the risk of familial 
disease 1.4-fold (Economou 2004).
121.1.8.3  Disease behaviour
Disease  behaviour  is  difficult  to  study  as  it  changes  over  time,  and  a  longer 
duration  of inflammation  makes  it  more  likely  that  stricturing  or  penetrating 
complications will develop in an individual with Crohn's disease. This difficulty is 
exacerbated  by  the  different  approaches  used  by  investigators  in  categorising 
disease behaviour.  Given these caveats, some studies have  shown an association 
between NOD2 variant allele carriage and stricturing or fistulizing (penetrating) 
phenotype (Lesage 2002, Brandt 2003, Helio 2003). A meta-analysis of 13 studies 
showed that the presence of at least one high-risk variant allele increases the risk 
of stricturing disease 1.9-fold (Economou 2004).
Most studies have also shown that the NOD2 variant haplotype does not influence 
the  need  for  surgery  independently  of disease  location  (Economou  2004).  In 
conclusion,  patients  carrying  the  NOD2  mutations  are  more  likely  to  have 
stricturing disease,  be  diagnosed at a younger age, but most likely to have  ileal 
disease.
1.1.9  NOD2 variant allele associations with other diseases
Since  the  association  between NOD2  variants  haplotypes  and  Crohn's  disease, 
other investigators  have  therefore  determined whether similar associations  exist 
between NOD2 variant haplotypes and other inflammatory diseases. Mutations in 
the NOD-encoding region of the NOD2 gene are associated with Blau syndrome, 
a rare  autosomal-dominant disorder characterised by  arthritis,  uveitis,  skin rash 
and  granulomatous  inflammation  (Miceli-Richard  2001,  Kurokawa  2003,  Rose 
2005,  van  Duist  2005).  There  is  also  a  strong possibility that  Crohn's  disease- 
associated NOD2  mutations  may  be  associated  with  intestinal  graft-versus-host 
disease  (GvHD)  and  colorectal  carcinoma  (Holler  2004,  Kurzawski  2004, 
Papaconstantinou 2005).
Holler  and  colleagues  (2004)  analysed  NOD2  mutations  in  a  cohort  of  169 
recipients of allogeneic blood stem cell transplantation (SCT) and their respective 
donors.  NOD2  mutations  were  associated  with  an  increased  frequency  of 
intestinal  GvHD,  overall  GvHD,  and  transplant-related  mortality  (TRM).
13Multivariate  analysis  showed that the NOD2  mutations  were  highly  significant 
independent risk factors for the development of GvHD and TRM. The presence of 
NOD2  mutations  in  both  recipients  and  their respective  donors  was  associated 
with increased TRM, which increased from 24% in patients without the mutations 
to 60% in cases where both the donor and recipient harboured NOD2 mutations. 
These  authors  speculate  that the NOD2  mutations  allow  for  increased bacterial 
translocation across the  gastrointestinal  epithelium, which results in septicaemia 
and multi-organ failure (The putative role of NOD2 will be discussed later).
Some reports  indicate that the  Leul007fsinsC  mutation may be  associated with 
colorectal  cancer  in  Polish  and  Greek  populations  (Kurzawski  2004, 
Papaconstantinou 2005), although this association in not seen in Finnish patients 
(Alhopuro 2004). A preliminary study reports an association between individuals 
with  the  Leul007fsinsC  allele  and  early-onset  breast  cancer  (Huzarski  2005). 
Additional studies are therefore required to confirm a link between carcinoma and 
Crohn's disease-associated NOD2 mutations.
Published  reports  suggest  that  there  is  no  association  between  NOD2  gene 
mutations  and  systemic  lupus erythematosus  (Ferreiros-Vidal  2003),  Wegener’s 
granulomatosis  (Newman  2003),  Behcet’s  disease  (Uyar  2004),  sarcoidosis 
(Martin  2003),  psoriasis  (Young  2003,  Plant  2004),  multiple  sclerosis  (Sawcer
2003),  rheumatoid  arthritis  (Steer  2003,  Ferreiros-Vidal  2003a)  and  ankylosing 
spondylitis (Ferreiros-Vidal 2003b). With regard to infectious diseases, there is no 
association between NOD2 gene mutations and pulmonary tuberculosis (Stockton
2004)  and periodontitis  (Folwaczny 2004,  Laine  2004),  although  a preliminary 
report  suggests  that  NOD2  mutations  may  predispose  very  low  birth  weight 
infants to neonatal septicaemia (Ahrens 2004).
In summary,  the  presence  of NOD2 mutations  is  most  strongly  associated with 
Crohn's  disease  and  Blau  syndrome.  The  role  of NOD2  mutations  in  neonatal 
septicaemia  and  colorectal  carcinoma  needs  further  clarification,  whereas  the 
association  between  Crohn's  disease-associated  NOD2  mutations  and  GvHD 
needs urgent investigation.
141.2  N0D2
1.2.1  Identification of the NOD2 gene
NOD2 (also known as CARD 15) was initially identified by Ogura and colleagues 
(2001a), during a search of public genomic data bases for genes encoding proteins 
with homology  to  NODI  (CARD4).  The NOD2  protein  is  encoded  by  a  gene, 
containing  12  exons,  that  is  located  at the  ql2  region  of chromosome  16.  The 
NOD2 nucleotide sequence contains two in-frame translation initiation sites that 
are  separated by  81  nucleotides,  and expression  studies  using mammalian  cells 
show that the  longer  reading  frame,  encoding  an  additional  27  amino  acids,  is 
preferentially translated (Ogura 2001a).
1.2.2 The structure of the NOD2 protein
The  NOD2  protein,  comprising  of  1040  amino  acids,  is  composed  of two  N- 
terminal  caspase-recruitment  domains  (CARD)  (residues  28-220)  fused  to  a 
centrally located nucleotide binding domain (NBD) (residues 273-577) containing 
consensus nucleotide-binding motifs followed by  10 tandem leucine-rich repeats 
(LRRs) (residues 744-1020) (Figure  1.1). The NOD2 LLR, which contain a helix 
and p sheet sequences, are prototypically horseshoe shaped.
The  NOD2  protein  belongs  to  the  family  of  NOD  (nucleotide-binding 
oligomerization  domain)  proteins.  Over  20  NOD  containing  proteins,  with  a 
structure similar to NODI and NOD2, have been identified in humans, nematodes 
and Arabidopsis  (plants)  (Inohara  2005).  Some  of these  proteins  are  shown  in 
Figure  1.2. This family of proteins includes Apaf-1  (apoptotic protease activating 
factor 1), Ipaf, Cryopyrin, and NALP1, and are also referred to as the NOD-LRR 
proteins  (Inohara  2002).  The  NOD-LRR  proteins  are  alternatively  classed  as 
belonging  to  the  CATERPILLER  [CARD,  transcription  enhancer,  R  (purine)- 
binding,  pyrin,  lots  of leucine  repeats]  family  of proteins  (Ting  2005).  In  this 
classification,  the  central  domain  is  referred  to  as  the  NATCH  domain.  The 
majority of animal and plant NOD-LRR proteins are comprised of three distinct 
domains: an amino-terminal effector domain, a centrally located regulatory NOD 
domain, and a carboxyl-terminal LRR domain.
15EBD LRD
N0D1, IPAF  c a r d  NOD
NOD2  CARD  CARD  NOD
pyd j  NOD
Cryopyrin and 
related proteins
NAIP  BIR  BIR  BIR  NOD
(DC)-CIITA  (.jSjSls)  A D   NOD 
NOD3, NOD9  |  X   U B B
NALP1 
NOD8
LRR
LRR
LRR
LRR
LRR
LRR
Human
pyd  NOD 
pyd  NOD
APAF-1 CARD  NOD 3 G & N N
CED-4 
95 R proteins 
49 R proteins
c a r d  NOD
tir  NOD 
a   NOD
LRR
LRR
Nematode
Arabidopsis
RRS1  TIR  t ir   NOD  LRR  !  WRKY
Figure  1.2.  The  domain  structure  of  the  NOD  proteins  found  in  humans, 
nematodes and Arabidopsis share structural homology. Most NOD proteins are 
composed of variable  amino-terminal effector-binding domains  (EBD),  a centrally 
located  nucleotide-binding  oligomerization  domain  (NOD)  that  mediates  self­
oligomerization,  and  a  carboxyl-terminal  ligand-recognition  domain  (LRD).  The 
putative  EBD  of NOD3  and NOD9  (represented  by X)  do  not  share  significant 
homology with any known protein.  The caspase-recruitment domain (CARD) shown 
in parenthesis is present in CIITA expressed in dendritic cells. An incomplete pyrin 
domain (PYD) is present in the carboxyl-terminal region of terminus of NALP1.  The 
number of leucine-rich repeats (LRRs) varies in NOD proteins.  The WRKY domain is 
a zinc finger-like domain found in plant W-box-binding transcription factors.  Other 
abbreviations:  a,  a-helix/coiled-coil  rich;  NC,  NALP  1/CARDINAL  expanded 
homology domain;  WD40R,  WD40  repeat;  BIR,  baculoviral inhibitor-of-apoptosis 
repeat; TIR, Toll interleukin-1 receptor domain. Figure adaptedfrom Inohara (2005)
16The CARD domains of NOD2 share significant sequence similarity with CARD 
motifs found in a variety of apoptotic  signalling molecules,  such as  CED-4 and 
Apaf-1  (Bertin  1999). The CARD domain is a protein fold consisting of a tightly 
packed,  six-membered  a-helical  bundle,  and  was  first  identified  in  a  subset  of 
caspases  and  caspase  adaptor proteins  by Hofmann and  colleagues  (1997).  The 
CARD  motif  functions  as  effector  domains  that  mediate  specific  homophilic 
interactions  with  down-stream  CARD-containing  signalling  molecules.  It  is 
believed that proteins with CARD domains are centrally involved in assembling 
protein complexes that drive activation of either caspases or IkB kinase (IKK) by 
facilitating close proximity of the latter molecules  (Martin 2001).  It is therefore 
assumed that CARD-containing proteins play a role in the regulation of apoptosis 
and nuclear factor kappa B (NF-kB) activation.
The centrally located nucleotide oligomerization domain (NOD) of NOD2, which
0  4- contains  near  its  amino-terminal  region  a  P-loop  and  the  Mg  -binding  site,  is 
thought to mediate self-oligomerization. The NOD region has residues at catalytic 
sites which are essential  for binding and hydrolysis of Mg2+-ATP or -GTP, and 
are  predicted  to  share  common  nucleotide  binding  folds  with  ATP-binding 
cassettes  (ABC)  of members  of the ABC  ATPase/GTPase  superfamily  (Inohara 
2000).  Point  mutations  in  the  phosphate  chain  binding  site  (also  known  as 
Walker’s A box or P-loop) are predicted to result in loss-of-function of NOD2, 
since  corresponding point mutations  in NODI  P-loop  result in  loss-of-function. 
(Inohara 1999).
Each of the NOD2 LRRs have structural homology to LRRs of the plant disease 
resistance  (R) proteins,  and each LRR contains  a predicted a helix  and P  sheet 
sequence that is consistent with the prototypical horseshoe-shaped structure of R 
protein LRRs (Ogura 2003). There are 5 classes of plant R proteins, of which two 
have  extracellular  LRR  domains  (Dangl  2001).  The  LRRs  of  these  proteins 
recognise distinct effector molecules from pathogenic bacteria, and it is currently 
inferred that the NOD2 LRRs perform a similar function.  The NOD- and LRR- 
containing proteins, however, are relatively abundant and functionally diverse in
17mammalian cells, and an interaction between the LRRs and bacterial products in 
mammalian cells has never been proven (Beutler 2001).
1.2.3  Signalling pathways induced through NOD2
1.2.3.1  NOD2 induces NF-kB activation
The  gene  sequences for NOD2 and for its closest related homolog NODI  were 
identified after searching the human genomic database for sequences that shared 
homology  with  the  CARD-containing  apoptotic  regulator,  Apaf-1,  and  it  was 
assumed  that  these  proteins  would  perform  a  similar  function.  However,  after 
cloning the  open reading frames of the genes  into  expression vectors that were 
then transiently transfected into HEK293T mammalian cells,  it was  noted these 
cells  did  not  undergo  apoptosis,  as  was  the  case  for  Apaf-1  expressing  cells. 
Instead,  overexpression  of  either  NOD2  or  NODI  induced  marked  NF-kB 
activation in HEK293T cells (Inohara 1999, Ogura 2001a).
The transcription factor nuclear factor-xB (NF-kB) is present in the cytoplasm in 
an inactive form, bound to the inhibitory protein called IkB  (or inhibitor of NF- 
kB). Phosphorylation of IkB, mediated by IkB kinase (IKK; a complex of IKKa, 
IKKp, and IKKy) results in degradation of IkB, and translocation of NF-kB to the 
nucleus  where  it  induces  gene  transcription  (Li  2002).  NOD2-induced  NF-kB 
activation was  inhibited in mammalian cells expressing mutant forms  of IKKa, 
IKKp,  IKKy,  and  IkB a  which  indicates  that NOD2  acts  upstream  of the  IKK 
complex. This was verified by expression studies using parental Rati  fibroblasts 
and 5R cells,  a Rati-derivative cell line that does not contain the  IKKy protein 
(Yamaoka  1998).  These  studies  showed that NOD2  expression  induced NF-kB 
activation  in  Rati  but  not  5R  cells.  However,  co-expression  of IKKp  (which 
functions  downstream  of  IKKy)  in  5R  cells  restored  NOD2-induced  NF-kB 
activation, confirming that NOD2 acts up-stream of IKK (Inohara 2000).
Further analysis revealed that NOD2 interacts with RICK (a protein identified by 
Inohara and colleagues in  1998), upstream of the IKK complex, before inducing
18NF-kB  activation (Inohara 2000). Firstly, NOD2-induced NF-kB  activation was 
inhibited in cells expressing mutant RICK proteins. Then, the association between 
NOD2 and RICK proteins was proven in a series of experiments where cellular 
extracts  from  mammalian  HEK293T  cells,  which  were  cotransfected  with 
plasmids  expressing  wild-type  or  mutant  forms  of  NOD2  and  RICK,  were 
analysed by immunoprecipitation and immunoblotting. However, this association 
was  only evident between native RICK and wild-type or mutant NOD2 protein 
that contained both CARD domains. Similarly, native NOD2 only interacted with 
either  wild-type  or  mutant  RICK  proteins  containing  the  CARD  domain.  In 
addition, NOD2 did not associate with other CARD-containing proteins including 
as  Apaf-1,  caspase-1  and  procaspase-9,  indicating  that  the  NOD2-RICK 
interaction  is  specific  and  mediated  by  a homophilic  CARD-CARD  interaction 
(Ogura 2001a).
Ogura  and  colleagues  (2001a)  determined the  essential  motifs  from  the  NOD2 
molecule  required  for NF-kB  activation  by  expressing  variant  NOD2  proteins, 
genetically  engineered  so  that they  lacked  one  or more  of the  major  structural 
motifs, in HEK293T cells. These investigations showed that both CARD domains 
were  essential  for  NF-kB  activation,  as  variant  proteins  containing  only  one 
CARD  domain,  NOD  or  LRRs  motifs  could  not  induce  cellular  activation.  In 
addition, these  studies also suggested that the LRR motif may play a regulatory 
role, as engineered NOD2 proteins lacking the LRR motif caused more profound 
activation  of NF-kB  than  wild  type  protein.  Interestingly,  expression  studies 
performed using equivalent amounts of expression-vectors show that the mutated 
proteins encoded by the three major Crohn's disease-associated NOD2 mutations, 
all of which involve the LRR motif, do not change NF-kB activation significantly 
in  comparison  to  wild-type  protein  in  mammalian  cells  (Ogura  2001,  Bonen 
2003a).
1.2.3.2  NOD2 interacts with the TAK1 signalling pathway
There is evidence that NOD2 activation of NF-kB  is dependant on transforming 
growth factor-P-activated kinase  1   (TAK1), a MAP kinase kinase enzyme (Chen
192004). The complex of NF-kB proteins is inhibited by I-kappa-B (IkB) proteins, 
which inactivate NF-kB  by trapping it in the cytoplasm.  Phosphorylation of the 
IkB  proteins  by  IkB  kinases  marks  them  for  destruction  via  the  ubiquitination 
pathway,  thereby  allowing  activation  and  nuclear  translocation  of the  NF-kB 
complex. By transfecting HEK293 cells with NOD2 and dominant negative forms 
of various enzymes that phosphorylate IkB proteins, Chen and colleagues (2004) 
showed that the dominant negative form of TAK1  (TAK1DN) inhibited NOD2- 
induced  NF-kB  activation.  TAK1DN  also  inhibited  MDP-induced  NF-kB 
activation in HEK293T cells that expressed NOD2.  These  investigators  showed 
further  that  TAK1  induces  NF-kB  activation  in  RICK-deficient  embryonic 
fibroblasts, which suggests that TAK1 -induced NF-kB activation is not dependant 
on  RICK.  In  RICK-deficient  embryonic  fibroblasts,  NOD2  inhibited  TAK1- 
induced  NF-kB  activation,  suggesting  that  NOD2  negatively  regulates  TAK1- 
induced NF-kB activation.
Using  immunoblot  detection  of immunoprecipitated  cell  lysates  and  confocal 
microscopy, these investigators showed an interaction between NOD2 and TAK1 
proteins.  It  would  appear  that  the  LRR  motif of NOD2  interacts  with  TAK1. 
Interestingly, whilst the wild-type NOD2-LRR motif inhibits TAK1-induced NF- 
kB  activation,  the  mutant  NOD2  protein  encoded  by  the  3020insC  mutation 
causes less inhibition of NF-kB activation (Chen 2004).
TAK1 mediates NF-kB activation induced by bacterial products, such as LPS, and 
pro-inflammatory  cytokines,  such  as  IL-1,  TNFa,  and  IL-18  (Wang  2001). 
Additionally,  there  is  some  evidence  to  suggest that  TAK1  may play  a role  in 
innate  defence.  In  flies,  null  mutations  in the  Drosophila dTAKl  gene result in 
diminished  production  of antibacterial  peptides  in  vivo,  resulting  in  increased 
susceptibility  to  gram-negative  bacterial  infection  (Vidal  2001).  Chen  and 
colleagues (2004) used in vitro systems that relied on overexpression of proteins 
to demonstrate an association between NOD2 and TAK1  proteins. Nevertheless, 
their  results  suggest  that  TAK1  may  mediate  interactions  between  bacterial 
products,  inflammatory  cytokines  and NOD2.  Using  RICK-deficient embryonic 
fibroblasts, Chen and colleagues showed that NOD2 inhibited TAK1 -induced NF- 
kB activation. This study also suggests that NOD2 interacts with TAK1  through
20its  LRR  domain  to  mediate  its  inhibitory  effect  on  TAK1-induced  NF-kB 
activation. Interestingly, mutant NOD2 proteins that are encoded by the 3020insC 
mutation caused less inhibition of TAK1-induced NF-kB activation as compared 
to  wild-type  NOD2  proteins.  This  study  offers  an  alternative  explanation  to 
disease pathogenesis in NOD2-affected Crohn's disease by suggesting that mutant 
NOD2 proteins do not down-regulate NF-kB activation.
1.2.3.3  Role in apoptosis
Beutler  (2001)  has  suggested  that  NOD2  may  play  a  role  in  Crohn's  disease- 
pathogenesis through altered regulated of apoptotic pathways. There is, however, 
no  evidence  to  suggest that  overexpression of NOD2  induces  apoptosis  in  cell 
transfectants,  although  NOD2  enhances  apoptosis  induced  by  caspase-9 
expression in these cells (Ogura 2001a). NOD2 and NODI  promote activation of 
caspases, however, and their role in apoptosis needs to be evaluated under more 
physiological conditions including knock-out mice. Indeed, Maeda and colleagues 
(2005)  have  shown  that,  in  colitis,  an  increase  in  apoptotic  lamina  propria
?030ir macrophages  is  observed  in  NOD2  mice,  which  encode  for  a  truncated 
protein homologous to the  Leul007fsinsC  protein  (discussed  later).  Thus,  there 
remains  a  possibility  that  NOD2-dependent  apoptosis  plays  a  role  in  the 
development of intestinal inflammation, but this remains to be confirmed.
211.2.4  Proposed functions of the NOD2 protein
1.2.4.1  Interactions with bacterial products: lipopolysaccharide (LPS)
To  elucidate  the  fimction(s)  of NOD2,  Ogura  and  colleagues  (2001a)  reasoned 
that  the  assumed  structural  assembly  of the  molecule  will  yield  clues  to  its 
function.  Functional  analyses,  based  largely  on NOD1-HEK293T  transfectants, 
suggest  that  the  NOD  domain  is  essential  for  oligomerization,  and  that  self­
association of NOD molecules mediates proximity to RICK (Inohara 2000). The 
NOD  molecules,  i.e.  NODI  and  NOD2,  then  interact  with  RICK  through 
homophilic CARD-CARD interactions. RICK associates with the y subunit of IkB 
kinase (IKKy) that complexes with IKKa and IKKp to induce the degradation of 
IkB which, subsequently results in NF-kB activation (Inohara 2000).
In  mammalian  cells,  toll-like  receptors  (TLR)  are  signalling  receptors  of the 
innate immune system and initiate intracellular signalling cascades. For example, 
LPS  binds  to  the  extracellular  LRR  motif of TLR4,  with  subsequent  NF-kB 
activation (Poltorak  1998,  Beutler 2001).  It was  therefore  reasoned that NOD2 
binds LPS  as the LRRs  of NOD2  and TLR4 bear structural homology.  Inohara 
and  colleagues  (2001a)  stimulated  NODI-expressing  mammalian  cells  with 
various bacterial molecules to determine a role for NODI  in bacterial detection. 
The  bacterial  products,  which  included  lipopolysaccharide  (LPS),  lipoteichoic 
acid  (LTA),  peptidoglycan  (PGN),  mannan  and  synthetic  bacterial  lipoprotein 
(sBLP),  were  introduced  into  the  cells  by  simultaneous  transfection  with  the 
NODI  expression plasmid,  and a NF-kB  reporter construct.  These  experiments 
showed that NF-kB activation was increased in response to LPS stimulation and 
not in response to stimulation with other bacterial antigens. In NOD2-expressing 
transfectants, NF-kB activation increased in response to LPS stimulation and, to a 
lesser extent, to PGN stimulation (Inohara 2001a).
Using mutational analyses, Inohara and colleagues (2001a) showed that the LRR 
domain  of NODI  and NOD2  was  essential  for  mediating NF-kB  activation  in 
mammalian cells exposed to LPS. These studies suggest that the LRR motifs are 
essential for enabling the NOD proteins to respond to LPS, which was consistent
22with the prevailing view that LPS interacts with LRR domains of R proteins and 
mammalian toll-like receptors (Inohara 2001a).  These transfection-based studies 
suggested that NODI  is associated with an LPS binding activity in the cytosolic 
fraction  of mammalian  cells,  although  a  direct  interaction  between NODI  and 
LPS  could  not  be  demonstrated  (Inohara  2001a).  Interestingly,  in  mammalian 
cells transfected with an expression plasmid encoding the mutant Leul007fsinsC- 
NOD2 protein, LPS induced less NF-kB activation and it was therefore postulated 
that mutant NOD2 proteins fail to mediate cellular activation in response to LPS 
(Ogura 2001).  Based on these findings,  it was  widely accepted at the time that 
NODI and NOD2 were ‘intracellular receptors’ for LPS (Hugot 2001).
The role  of NODI  and NOD2  as  intracellular receptors  for LPS  was,  however, 
questioned  by  Beutler  (2001).  He  cautioned  that  simultaneous  transfection  of 
mammalian cells  with LPS  and an expression vector does  not ensure  that LPS 
enters the cells. In addition, HEK294T cells that were used for transfection, do not 
express TLR4, and the vast majority of mammalian cells are unresponsive to LPS 
that  is  presented  extracellularly.  Furthermore,  even  if LPS  is  internalised  and 
reaches the cytosol within a cell, which occurs if LPS is presented to a cell in an 
aggregated  form,  TLR4  mutations  abrogate  cellular  responses  to  LPS.  Beutler 
(2001) reasoned that while it is conceivable that,  in vivo,  epithelial  cells  should 
possess mechanisms to sense and respond to LPS, few studies have addressed this 
issue. Studies that determine the presence of a putative intracellular LPS receptor 
would  require  an  exclusive  route  of  presentation  of  LPS,  for  example,  by 
microinjection, and are technically difficult to perform.
Inohara and colleagues (2001a) used high doses of LPS during transfection when 
determining whether NOD2 functions as an intracellular receptor for LPS. Again, 
Beutler (2001)  cautions that treatment with exceedingly high  doses  of LPS  (10 
pg/mL)  is  fraught  with  difficulty.  In  similar  studies  using  HEK293T  cells 
transfected with a TLR2 expression vector, it was initially thought that LPS binds 
TLR2 (Yang 1998, Kirschning 1998). Later, it became apparent that contaminants 
in  the  LPS  preparations  mediated  these  cellular  responses  that  were  initially 
ascribed to LPS (Hirschfeld 2000).
23In  the  N0D2  studies,  LPS  binding  was  not  shown  to  be  of high  affinity  or 
specificity and, therefore, to test the hypothesis that NOD2 acts as an intracellular 
receptor  for  LPS,  would  require  microinjection  of chemically  synthesised  LPS 
into cells lacking TLR4.  Subsequently, Beutler’s  (2001) criticisms proved to be 
valid  and  Inohara  and  colleagues  (2003),  using  purified  preparations  of LPS, 
showed  that  LPS  does  not  interact  with  NODI  or  NOD2.  It  appears  that  the 
stimulatory effects ascribed to LPS were due to the presence of a contaminant in 
the LPS preparations, namely peptidoglycan (Inohara 2003a).
1.2.4.2  Interactions with  bacterial products:  Peptidoglycan  (PGN)  and 
muramyl dipeptide (MDP)
Bonen and  colleagues  (2003a),  using HEK293T transfectants,  first  showed that 
PGN,  as  well  as  unpurified  LPS,  mediated  NOD2-induced  cellular  activation. 
Later,  two  independent  groups  of  investigators  showed  that  a  component  of 
bacterial peptidoglycan (PGN), called muramyl dipeptide (MDP), induces NOD2- 
mediated cellular activation (Girardin 2003, Inohara 2003).
Girardin and colleagues (2003) showed that PGN, treated with polymixin B  and 
Proteinase  K,  and  boiled to  remove  LPS  and  lipo-proteins,  activates  NF-kB  in 
mammalian  cells  that  were  simultaneously  transfected  with  NOD2  expression 
plasmids.  They  subsequently  determined  that  cellular  activation  mediated  by 
NOD2  was  due to MDP,  a component of gram-positive  and  -negative  bacteria. 
Using chemically synthesised MDP (or MDP-LD) and its isomer MDP-LL, they 
verified that MDP mediates NOD2-induced NF-kB activation. These investigators 
showed that macrophages, but not epithelial cells, were responsive to extracellular 
stimulation  with  MDP  in  vitro.  Furthermore,  epithelial  cells  remained 
unresponsive to MDP introduced into these cells by microinjection. As MDP did 
not induce cellular activation in cells expressing NODI, TLR1, TLR2 and TLR6, 
Girardin and colleagues (2003) described NOD2 as the first protein that mediates 
cellular activation in response to MDP.
24Inohara and colleagues (2003) used various purified LPS preparations to further 
characterise  the  bacterial  moiety  that  interacts  with NOD2.  They  demonstrated 
that purified  LPS  did not result in NOD2-mediated NF-kB  activation,  and also 
showed  that  MDP  induces  NOD2-mediated  cellular  activation  in  mammalian 
cells.  Using  a  variety  of synthetic  muropeptides,  they  showed  that  only  MDP 
specifically induces NOD2-mediated NF-kB activation.
1.2.4.3  The  structure  of peptidoglycan  (PGN)  and  muramyl  dipeptide 
(MDP)
Peptidoglycan  (PGN)  is  a  major  constituent  of the  cell  wall  of gram  positive 
bacteria  and  consists  of  glycan  chains  of  alternating  N-acetylglucosamine 
(GlcNAc)  and  N-acetylmuramic  acid  (MurNAc)  that  are  cross-linked  to  each 
other by short peptides, forming a rigid polymer surrounding the bacterial cell. In 
gram-negative bacteria, a thinner layer of PGN is located in the periplasmic space 
(Figure  1.3) (Girardin 2003a). During the bacterial life cycle, PGN is constantly 
degraded  by  specific  hydrolases  and  newly  synthesized  subunits,  called 
muropeptides,  are  integrated  into  the  polymeric  structure,  enabling  biological 
processes, such as cell division, to occur. Apart from the thickness and the degree 
of stem peptide cross-linking, an important difference between gram-positive and 
gram-negative PGN resides in the nature of the third amino acid of the peptidic 
moiety  (Figure  1.3).  In  gram-positive  bacteria,  this  amino  acid  is  commonly  a 
lysine, whereas a diaminopimelic acid is found in most gram-negative bacteria.
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Figure  1.3.  The  structure  of peptidoglycan  showing  the  muropeptides  that 
are postulated to interact with NODI and NOD2. A thin layer of  peptidoglycan 
is found in  the periplasmic  space  of gram-negative  bacterial  cell walls  (left). 
Cross-linking of two parallel glycan strands through stem peptides occurs at low 
frequency.  This cross-linking is made by a direct link between a mesoDAP amino 
acid and the D-Alanine in position four from a peptide anchored on a parallel 
glycan strand.
In  gram-positive  bacteria,  peptidoglycan  represents  a  thick  structure  that 
surrounds the  bacterial membrane  (right).  Glycan strands are generally cross- 
linked to a high degree.  In contrast to gram-negative bacteria,  the cross-linking 
requires  additional  bridging amino  acids, for  example,  through penta-glycine 
bridges,  which  are  a  characteristic  of Staphylococcus  aureus peptidoglycan 
(shown  in the figure).  The structure  ‘sensed’  by NODI,  GM-TriDAP (GlcNAc- 
MurNAc-L-Ala-D-Glu-mesoDAP),  is  a  muropeptide  found  mostly  in  gram- 
negative bacterial peptidoglycan. NOD2  ‘ senses  ’ two types of muropeptides: GM- 
Di  (GlcNAc-MurNAc-L-Ala-D-Glu,  also  known  as  GMDP)  present  in 
peptidoglycans from gram-negative and gram-positive bacteria,  and GM-TriLys 
(GlcNAc-MurNAc-L-Ala-D-Glu-L-Lys),  a  muropeptide  found  only  in 
peptidoglycans from  gram-positive  bacteria.  Abbreviations:  LTA,  lipoteichoic 
acid; LPS, lipopolysaccharide; TA, teichoic acid. Figure from Girardin (2003a)
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261.2.5  N0D2  interacts  with  the  PGN  motif,  muramyldipeptide 
(MDP)
Specific components of PGN induce cellular activation in transfectants expressing 
either NODI  or NOD2  (Girardin 2003,  Inohara 2003). NODI  mediates  cellular 
activation in reponse to stimulation with a single muropeptide from gram-negative 
bacterial  peptidoglycan,  GM-TriDAP  (GlcNAc-MurNAc-L-Ala-D-Glu- 
mesoDAP).  GM-TriDAP,  which  contains  the  motif y-D-Glu-mesoDAP,  with  a 
terminal mesoDAP, is a naturally occurring muropeptide generated by the action 
of lytic enzymes from either the host or the bacteria (Girardin 2003b).
NOD2  senses GM-TriLys  (GlcNAc-MurNAc-L-Ala-D-Glu-L-Lys) and muramyl 
dipeptide (MDP), whose corresponding natural muropeptide is GM-Di (GlcNAc- 
MurNAc-L-Ala-D-Glu).  The  MDP  motif is  not  found  as  a  naturally  occurring 
bacterial  product  but  the  corresponding  muropeptide,  GM-Di,  is.  In contrast  to 
NODI, NOD2-mediated  cellular activation is  dependent  on the  presence  of the 
MurNAc sugar moiety (Girardin 2003c). With regard to NODI-mediated cellular 
activation  in  response  to  muropeptide  stimulation,  the  mesoDAP  has  to  be  in 
terminal position, but the terminal amino acid of the MDP motif (i.e D-Glu) can 
be  substituted  at the  C-terminus  with  an  L-Lysine  or  an  L-Omithine  but  not  a 
mesoDAP (Girardin 2003c). GM-Di is found in all bacteria (with the exception of 
the  few  bacteria  that  do  not  display  peptidoglycan  in  their  cell  wall,  such  as 
Mycoplasma spp.), whereas GM-TriLys only occurs in gram-positive bacteria.
Although  it  is  widely  stated  that NODI  and NOD2  are  “intracellular  bacterial 
receptors”  that  detect  muropeptides,  there  is  no  evidence  showing  direct 
interaction between muropeptides and NODI  or NOD2 molecules (Murray 2005). 
NODI  and NOD2 are intracellular proteins with motif similarity, not necessarily 
primary structural homology, to defensive proteins of plants -  NODI  and NOD2 
do  mediate  cellular  responses,  for  example  NF-kB  activation,  in  response  to 
muropeptide  stimulation  and  are  commonly  referred  to  as  “intracytoplasmic 
microbial sensors” (Girardin 2004).
271.2.5.1  MDP and mammalian cell interactions
It  is  widely  accepted  that  the  synthetic  muropeptide  MDP  induces  NOD2- 
dependant NF-kB  activation.  What remains  unclear,  however,  is  the  process  or 
mechanisms by which MDP or other muropeptides enter the cytosol of cells. In 
vivo, MDP is believed to be generated by proteolysis in phagocytic cells, although 
non-specific  uptake  through pinocytosis  may  occur.  Thus  far,  two  mechanisms 
have  been  proposed  to  account  for  the  internalisation  of  MDP  and/or 
peptidoglycan into epithelial cells. These mechanisms suggest that muropeptides 
are  internalised  into  cells  by  epithelial  surface  receptors  or  bacterial  secretion 
systems (Vavricka 2004, Viala 2004).
Recently,  Vavricka  and  colleagues  (2004)  have  shown  that  the  apical  di- 
/tripeptide  transporter,  hPepTl,  transports  MDP  into  intestinal  epithelial  cells. 
hPepTl  transports various peptides with H+, but also transports peptide-derived 
drugs  and  the  bacterial  chemotactic  peptide,  N-formyl-Methionyl-Leucyl- 
Phenylalanine.  In  Caco-2/bbe  (C2)  cells,  MDP  competitively  inhibits  uptake  of 
glycosylsarcosine  (Gly-Sar),  a  substrate  of  hPepTl.  Furthermore,  the 
physiologically inactive isomers of MDP (MDP-LL and MDP-DD) do not inhibit 
glycosylsarcosine  uptake.  MDP  uptake  by  hPepTl  was  confirmed  using  [ H]- 
MDP that was later recovered from the cytosol of C2 cells. The binding affinity of 
MDP  is  similar to  glycosylsarcosine,  and  MDP  or  glycosylsarcosine  uptake  is 
inhibited  by  decreasing  hPepTl  expression  with  silencing  RNA  (siRNA). 
Moreover,  both  NOD2  and  hPepTl  siRNA  reduced  IL-8  secretion  in  MDP- 
stimulated  C2  cells,  suggesting a role  for hPepTl  in MDP  uptake  by  intestinal 
epithelial cells (Vavricka 2004).
Next, Vavricka and colleagues (2004) demonstrated the presence of MDP in vivo 
in intestinal contents by high-performance liquid chromatography and TLC. MDP 
could be recovered from faecal and colonic fluid, but not from duodenum, where 
bacterial  colonisation  is  minimal.  These  investigators  show  that  the  affinity  of 
hPepTl  for MDP is higher than the predicted levels of MDP in the normal colon. 
Nonetheless, as hPepTl  expression is increased in intestinal inflammation, these 
findings suggest that hPepTl may play a role in MDP-mediated innate responses.
28In comparison, Viala and colleagues (2004) described a mechanism by which a 
non-invasive  bacterial  pathogen  initiates  innate  immune  signalling  in  epithelial 
cells through ‘cag’ pathogenicity island (cagPAI)-dependant presentation of PGN 
to  intracellular  NODI.  cagPAI  is  a  cluster  of  approximately  30  genes  in 
Helicobacter pylori  that  are  proposed  to  encode  a  type  VI  secretion  system 
(T4SS),  a  complex  of about  30  proteins  that  assembles  into  a  ‘needle’,  which 
extends through the bacterial cell wall envelope as an external spike that can be 
inserted into the plasma membrane of host cells. The secretion apparatus allows 
for the translocation  of specific  bacterial  effectors  into  the  cytoplasm  of target 
cells.  H pylori  strains  containing  cagPAI  are  more  virulent,  and  induce NF-kB 
activation in gastric epithelial cells (Fischer 2001).
Viala and colleagues (2004) showed that cagPAI-positive Hpylori induce NOD1- 
mediated  NF-kB  activation  in  HEK293T  transfectants.  Transfecting  cagPAI- 
positive  H  pylori-infected  cells  with  a  dominant  negative  NODI  construct 
abrogated  NF-kB  activation  by  up  to  90%.  Using  radio-labelled  PGN,  these 
investigators confirmed that a functional cag PAI is required for the delivery of H. 
pylori  PGN  into  host  cells.  They  showed  that  PGN  detection  is  based  on 
recognition  of  a  peptidoglycan-derived  muropeptide,  weso-diaminopimelate 
(mDAP),  the  structure  specifically  detected  by  NODI.  In  addition,  NOD1- 
deficient mice have an increased susceptibility to infection with cagPAI-positive
H. pylori, demonstrating a function for NODI  in host defence against virulent H. 
pylori.  These  results  raise  the  possibility  that  secretion  systems  may  not  only 
deliver  mDAP  into  host  target  cells,  but  could  be  a  widespread  mechanism 
allowing for MDP delivery from other bacteria.
I.2.5.2 Effect of Crohn’s disease-associated  NOD2  mutations  on  PGN- 
and MDP-mediated cellular responses
Bonen  and  colleagues  (2003a)  showed  that  PGN-induced  cellular  activation  is 
diminished  in  mammalian  cells  expressing  mutant  NOD2  proteins.  Using 
HEK293T cells that were transfected with expression plasmids encoding for wild-
29type or mutant NOD2 protein, they showed that NF-kB activation was reduced or 
absent in PGN-treated cells that expressed mutant NOD2 proteins encoded by the 
Leul007fsinsC, Arg702Trp and Gly908Arg mutations. In a similar way, Girardin 
and colleagues (2003) showed that mutant NOD2 proteins do not mediate NF-kB 
activation in response to PGN and MDP stimulation. Both groups showed that no 
MDP-induced  NF-kB  activation  was  noted  in  HEK293T  cells  expressing  the 
Leul007fsinsC-encoded  NOD2  mutant  protein  whereas  lesser  degrees  of 
activation were noted in cells expressing the Arg702Trp- and Gly908Arg-encoded 
NOD2 proteins.
Inohara and colleagues (2003) verified this finding by showing that MDP-induced 
NF-kB  activation  was  abrogated  in  mammalian  cells  encoding  mutant  NOD2 
proteins. These investigators obtained primary peripheral blood mononuclear cells 
(PBMC) from healthy volunteers and Crohn's disease-affected patients that were 
either homozygous  or  heterozygous  for the  Leul007fsinsC  mutation.  Using  an 
electrophoretic mobility shift assay, they showed that MDP did not induce NF-kB 
activation in PBMC obtained from patients homozygous for NOD2 mutations. In 
contrast,  MDP-induced NF-kB  activation was  demonstrated  in PBMC  obtained 
from normal controls or patients who were heterozygous for the NOD2 mutations. 
Using quantitative real-time PCR, they showed that transcription of IL-lp and A1 
(NF-kB  target  genes)  was  diminished  in  MDP-stimulated  mononuclear  cells 
obtained from patients who were homozygous for the L1007fsinsC mutation.  In 
contrast, LPS stimulation induced IL-1B and A1  gene transcription in all PBMC, 
suggesting that NOD2 mediates cellular responses to MDP.
These  studies  show that  the  bacterial  product  MDP  induces  NF-kB  activation, 
which appears to be solely mediated by NOD2. These studies highlight a new role 
for  NOD2  and  many  investigators  have  accepted  that  NOD2  functions  as  a 
‘pathogen  recognition  receptor’  (PRR).  There  are,  however,  many  unanswered 
questions regarding the role of NOD2 as a PRR. There is no evidence to show a 
direct  interaction  between  MDP  and  NOD2,  and  an  explanation  is  sought  to 
account for the discrepancy between the size of the much smaller MDP molecule 
and the binding site of the NOD2 LRRs. It is proposed that digestion of the PGN
30backbone by muramidases generates MDP molecules in vivo, but evidence for this 
is lacking. Nevertheless, despite these limitations, emerging evidence from human 
studies  and  in  vivo  models  confirm  the  role  of  MDP  in  mediating  NOD2- 
dependant cellular responses.
1.2.5.3  In vivo studies assessing NOD2 function
The  role  of MDP  in the  pathogenesis  of NOD2-associated  Crohn's  disease  has 
been  demonstrated  by  Maeda  and  colleagues  (2005)  using  homozygous 
NOD22939lC  mice.  NOD22939lC  mice encode for a truncated NOD2 protein lacking 
the  last  33  amino  acids,  which is homolog of the human NOD2  protein that  is 
encoded  by  the  3020insC  mutation.  In  this  model,  MDP  stimulation  caused 
increased  levels  of NF-kB  activation in macrophages  isolated  from NOD22939lC  
mice  relative  to  macrophages  from  control  wild-type  mice.  Furthermore,  the 
expression  of  several  NF-kB  target  genes  was  increased  in  MDP-treated
?Q 3Q if NOD2  macrophages relative to wild-type controls.
IL-ip,  a  proinflammatory  cytokine,  is  overexpressed  in  lamina  propria 
macrophages in Crohn's disease, and MDP induced increased secretion of IL-lp 
from NOD22939iC  macrophages relative to wild-type controls. Furthermore, MDP 
was  the  only  microbial  product that  stimulated  IL-ip  secretion  by  NOD22939lC  
macrophages.
Maeda  and  colleagues  (2005)  showed,  for the  first  time,  that  truncated  NOD2 
proteins  influence  the  development  of  intestinal  inflammation  in  vivo.  Using 
dextran sodium sulphate (DSS) to disrupt the intestinal barrier, these investigators 
assessed  the  effects  of NOD2  on  intestinal  inflammation  in  NOD22939lC   and 
control wild-type mice. DSS administration clearly caused more severe colitis in 
NOD22939lC  mice than wild-type controls: NOD22939lC  mice suffered from greater 
body weight loss and exhibited greater mortality relative to wild type mice. The 
severity and extent of inflammatory lesions, as assessed by the degree of mucosal 
ulceration  and  macrophage  infiltration  of the  lamina  propria,  was  greater  in 
NOD22939lC   mice  compared  to  wild-type  controls.  Following  DSS  exposure,
31NOD22939iC  mice expressed greater amounts of IL-lp, I L-6 and cyclooxygenase-2 
(Cox-2) protein and mRNA.
Furthermore, these investigators suggest that bacteria or their products initiate the 
development  of intestinal  inflammation  in  DSS-treated  NOD22939lC   mice.  Oral 
antibiotic  therapy  dramatically  reduces  DSS-induced  intestinal  inflammation. 
Both wild-type and NOD22939lC  mice died after receiving high doses of DSS, but 
mice  that  received  oral  antibiotics  with  DSS  developed  mild  inflammation, 
without  any  genotype-linked  differences.  These  observations  support  the 
hypothesis  that  bacteria  or  their  products  induce  the  development  of intestinal 
inflammation, which is, in part, mediated by NOD2 (Maeda 2005).
Maeda and colleagues (2005) suggest that NOD2 also regulates apoptosis and IL- 
lp  secretion  in  lamina  propria  macrophages.  DSS  treatment  induced  greater 
apoptosis of macrophages in NOD22939lC  mice than wild-type controls. Activation 
of caspase-1,  an enzyme required for IL-lp  secretion (Thomberry  1998,  Greten
2004), is associated with an increase in macrophage apoptosis (Le Feuvre 2002). 
Interestingly,  DSS  treatment  induced  greater  IL-ip  secretion  in  NOD22939lC  
macrophages  than  wild-type  controls.  Furthermore,  although  various  bacterial 
products  such as LPS, PGN, and Pan^Cys  induced comparable increases in IL- 
la,  IL-6  and  TNFa  secretion in NOD22939lC   and wild-type  macrophages,  MDP 
induced  a  significant  increase  in  IL-ip  release  from  NOD22939lC   macrophages 
only. Treatment with an IL-1 receptor antagonist (IL-l-RA) reduced DSS-induced 
intestinal inflammation in NOD22939lC  mice, and no differences in weight loss and
90^ 0iP histological  inflammatory  scores  were  seen  in NOD2  and  wild-type  mice. 
Overall,  these  results  suggest  that  IL-ip  contributes  to  increased  intestinal 
inflammation in NOD22939lC  mice (Maeda 2005).
Human  studies,  on  the  other  hand,  show  that  MDP  does  not  stimulate  IL-lp 
secretion  in  PBMC  (Li  2004).  Li  and  colleagues  (2004)  show  that  MDP  and 
TNFa synergistically induce IL-lp secretion in PBMC from wild-type normal and 
Crohn's disease-affected patients. In contrast, MDP and TNFa did not induce IL- 
ip  secretion  in  PBMC  isolated  from  patients  homozygous  for  the  NOD2
321007insC mutation.  IL-lp  gene transcription is  appropriately increased in MDP 
and TNFa-stimulated PBMC from NOD2 homozygotes, and the authors suggest 
that  post-translational  processing  of  IL-ip  secretion  is  defective  in  NOD2 
homozygotes. Thus, the results from human and murine studies show that IL-ip 
secretion is altered, and suggest that this cytokine plays a role in the pathogenesis 
of NOD2-associated Crohn's disease.
1.2.6  The  potential  role  of  NOD2  as  an  antibacterial  factor  in 
intestinal epithelial cells
In addition to inducing NF-kB activation, NOD2 may also act as an antibacterial 
factor in intestinal epithelial cells.  It is hypothesised that NOD2 functions as an 
intracellular bacterial  sensor and is  a  component  of the  innate  cellular  defence 
mechanisms (Ogura 2001). Hisamatsu and colleagues (2003) therefore determined 
if the survival of intracellular bacteria is altered in cells expressing mutant NOD2 
protein  encoded  by  the  Crohn's  disease-associated  Leul007fsinsC  mutation 
sequence.  Caco-2 cells that were stably transfected with vectors encoding either 
wild-type  or  truncated  NOD2  proteins  were  infected  with  Salmonella 
typhimurium for 60 minutes. Thereafter viable intracellular bacteria were cultured 
from cell extracts using a gentamicin protection assay. These results showed that 
the  survival  of intracellular bacteria was  significantly  diminished  in those  cells 
expressing  wild-type  NOD2  compared  to  untransfected  Caco-2  cells  or  those 
transfected with a control vector. In contrast, there was no significant difference in 
the percentage  of viable  bacteria recovered  from  cellular  lysates  obtained  from 
Caco-2  cells  expressing  truncated  NOD2  (Leul007fsinsC-encoded)  and 
untransfected Caco-2 cells and those transfected with control vector only. These 
results  suggest  that  NOD2  expression  protects  intestinal  epithelial  cells  by 
enhancing  the  clearance  of intracellular  S.  typhimurium  bacteria,  and  that  this 
antibacterial  property  is  defective  in  intestinal  cells  expressing  mutant  NOD2 
proteins.
To  gain  further  insight  into  the  mechanism  of  NOD2-mediated  antibacterial 
function,  Bamich  and  colleagues  (2005)  showed that  GRIM-19,  a protein with
33homology  to  the  NADPH  dehydrogenase  complex,  interacts  with  endogenous 
NOD2  in  intestinal  epithelial  cell  lines  such  as  HT29  and  Caco-2  cells.  These 
investigators showed, using transfected HEK293  cells, that GRIM-19 is required 
for NF-kB activation following NOD2 mediated recognition of bacterial muramyl 
dipeptide (MDP). In Caco-2 cells that were transfected with GRIM-19 and NOD2 
expression  plasmids,  and  then  infected  with  Salmonella  typhimurium  (as 
described  before),  increased  GRIM-19  expression  was  associated  with  lower 
numbers  of intracellular  bacteria within these  transfected  cells  and  the  authors 
suggest that GRIM-19 controls pathogen invasion of intestinal epithelial cells. In 
patients  with  IBD,  GRIM-19  mRNA  expression  was  decreased  in  inflamed 
mucosal tissue as compared to uninflamed and healthy mucosal tissue. Therefore, 
these authors  suggest that GRIM-19 plays a key role  in NOD2-mediated  innate 
mucosal responses.
1.2.7  Expression of NOD2
Ogura and colleagues (2001a) initially determined the tissue expression of NOD2 
by  northern  blot  analysis.  Using  commercially  available  membranes,  which 
contained purified polyadenylated mRNA obtained from various human adult and 
foetal  organs  and  tissues,  they  localised  NOD2  expression  to  peripheral  blood 
leukocytes,  with  little  or no  expression  in other tissues.  They  also  fractionated 
peripheral  blood  leukocytes  into  its  granulocytic,  monocytic  and  lymphocytic 
components  and established, by PCR analysis, that NOD2  expression was most 
abundant in monocytes (Ogura 2001a).
Other investigators have, however, showed that NOD2 mRNA is also expressed 
in myelomonocytic haematopoietic cell lineages and in intestinal epithelial cells. 
Gutierrez  and  colleagues  (2002)  have  shown  that  NOD2  is  also  expressed  in 
monocyte-derived haematopoietic cell lines, such as monoblastic U937 cells and 
mature  monocyte-like  THP-1  cells.  NOD2  is  also  weakly  expressed  in  CD34+ 
progenitor cells isolated from human peripheral blood, and the level of expression 
in  these  cells  increases  as  they  are  differentiated  towards  granulocytes  and 
monocytes using G-CSF and M-CSF. These in vitro studies suggest that NOD2 is 
up-regulated  in  differentiating  myelomonocytic  cells.  In  peripheral  blood  cells, 
quantitative  real-time  PCR  analysis  showed  that  granulocytes,  monocytes  and
34dendritic  cells  expressed  the  highest  levels  of NOD2  mRNA.  T  cells  weakly 
expressed NOD2 and no expression could be detected in B cells.
Using  RT-PCR  analysis,  several  investigators  have  shown  that  NOD2  is 
expressed  in  intestinal  epithelial  cells  (Hisamatsu  2003,  Rosenstiel  2003). 
Rosenstiel  and colleagues  (2003) have  also  detected NOD2  protein in inflamed 
intestinal tissue from patients with Crohn's colitis. The cellular sources of NOD2, 
however,  remain undefined and it is  not known whether NOD2  is  prominently 
expressed in epithelial cells or tissue macrophages. Nonetheless,  it is postulated 
that, within intestinal epithelial cells, NOD2 interacts with bacterial products to 
modulate cellular responses to infection (Inohara 2002, Inohara 2003a).
In  the  present  thesis,  I  will  seek  to  identify  the  cells  that  express  NOD2  in 
intestinal tissue.  In particular,  I will determine  if NOD2  is  expressed  in Paneth 
cells, which are discussed further in the next section.
351.3  Paneth cells
1.3.1  Introductory comments and description
Paneth cells, described over a century ago, are located at the bases of the crypts of 
Lieberkuhn in the small intestinal tract (Paneth  1888, Schwalbe  1872) with each 
crypt containing approximately 5-15 Paneth cells (Bry 1994, Porter 2002). These 
cells are found in the  small intestines of humans, primates, rodents, horses, and 
pigs (Porter 2002). Paneth cells are distributed throughout the length of the small 
intestine, and are most numerous in the terminal ileum (Bry 1994, Porter 2002). In 
the  developing  human  embryo,  Paneth  cells  are  detected  at  12  -  13.5  weeks 
gestation and  gradually increase  in number throughout  gestation although these 
cells  are  less  numerous  in  newborn  infants  than  adults  (Moxey  1978,  Mallow 
1996).
1.3.2 Structural characteristics
Paneth cells are pyramidal shaped columnar epithelial cells that originate from the 
multipotent intestinal stem cells that are located within the intestinal crypts (Booth 
2000, Bach 2000). Intestinal stem cells give rise to the other intestinal epithelial 
cell lineages (absorptive enterocytes, goblet cells and enteroendocrine cells) that 
migrate upwards to form the villous epithelium.  Differentiating Paneth cells, on 
the other hand, migrate downwards towards the crypt base and fill with granules 
so that mature Paneth cells are characterised by the presence of prominent apical 
granules. Paneth cells are easily identified as their apical granules stain intensively 
with  eosin,  phloxine-tartrazine  (Figure  1.4)  (Lendrum  1947),  and  periodic  acid 
Schiff s stain (Porter 2002).
36Figure  1.4.  Human  terminal  ileal  tissue  stained  with  phloxine-tartrazine.
Prominent apical secretory granules are noted in Paneth cells that are located at 
the bases of the intestinal crypt.  The section is viewed under the 20x objective (a) 
and JOOx objective (b).
Paneth cells have the morphological characteristics of secretory cells. Paneth cells 
have an extensive endoplasmic reticulum and Golgi network,  and contain large 
secretory granules in the apical region of the cell  (Lehrer 2004).  Under electron 
microscopy,  the  granules  can  be  visualised  discharging  their  contents  onto the 
intestinal lumen (Satoh 1986). In humans, the granules of Paneth cells contain an 
array of antimicrobial peptides including alpha defensins, lysozyme and secretory 
phospholipase A2 Group HA (5PLA2). The alpha defensins are the most abundant 
antimicrobial  peptides  found  in  Paneth  cells  (Bevins  2004).  Other  granule 
proteins,  such  as  secretory  leukocyte  inhibitor  (SLI)  (Bergenfeldt  1996), 
hepatocarcinoma-intestine-pancreas  protein  (HIP;  also  known  as  pancreatitis- 
associated protein, PAP) (Christa 1996), and immunoglobulins G (Rodning 1976) 
and A (Satoh  1986),  may potentially  have antimicrobial  properties.  In the  non­
granule cell region, Paneth cells contain numerous molecules such as guanylin (de 
Sauvage 1992), epidermal growth factor (Poulsen 1986), pancreatic lipase related- 
protein 2 (Lowe 2000), and tumour necrosis factor alpha (TNFa) (Keshav 1990, 
Beil  1995,  Schmauder-Chock  1994,  Tan  1993).  These  components  suggest that 
Paneth  cells  are  potentially  involved  in  the  regulation  of  luminal  ionic
37composition,  crypt  development,  digestion  and  intestinal  inflammation  (Porter 
2002).
1.3.3  Function
Paneth cells  are  essential components of the innate intestinal defences  and have 
been proposed to play a regulatory role  in intestinal  inflammation (Porter 2002, 
Bevins  2004).  The  secretory  granules  in  Paneth  cells  contain  an  array  of 
antimicrobial  peptides  which,  when released into the  gut lumen,  are  thought to 
provide  protection  to  the  stem  cells  that  are  found  above  Paneth  cells  in  the 
intestinal crypt. Nonetheless, it is the role of Paneth cells in mediating innate host 
defences in response to ingested intestinal pathogens that is more clearly defined 
(Wilson  1999,  Salzman  2003).  Paneth  cell  antimicrobials  may  regulate  the 
composition and number of the intestinal microflora, thus creating unfavourable 
conditions  for  the  growth  of  pathogenic  bacteria.  Paneth  cells  also  mediate 
intestinal  angiogenesis  (Stappenbeck  2002),  indicating  that  these  cells  have  a 
broader range of functions than appreciated.
1.3.3.1  Innate immunity
A  role  for  Paneth  cells  in  innate  immunity  was  alluded  to  by  histological 
observations showing Paneth cells discharging their granules into the crypt lumen 
in response to bacterial infection (Satoh  1986). Moreover, a role for Paneth cells 
in  innate  intestinal  defences  was  inferred  from  in  vitro  studies,  which 
demonstrated the antimicrobial properties of Paneth cell granule peptides (Selsted 
1992,  Porter  1997,  Laine  1999,  Laine  2000,  Gronroos  2001).  In  particular,  the 
alpha defensins,  or cryptdins,  are potent antimicrobial peptides.  Initial  attempts, 
however,  to  confirm  the  role  of Paneth  cells  in  innate  immunity  in  vivo  by 
targeted  disruption  (‘knockout’)  of alpha  defensin  genes  was  not  feasible  as  a 
large number (>20) of similar genes encode for these peptides in the mouse (Ganz 
2000).  Nonetheless,  two  elegant  studies  have  shown  that,  in  vivo,  Paneth  cell 
defensins are crucial in mediating host defence against potentially lethal intestinal 
pathogens (Wilson 1999, Salzman 2003).
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for cleaving anionic peptide segments from inactive defensin precursors to yield 
active defensin peptides. This enzyme, a matrix metalloproteinase 7, or matrilysin 
(MMP-7)  localises  to  Paneth  cells,  and  is  secreted  together  with  defensin 
molecules into the crypt lumen. By disrupting matrilysin gene expression, these 
investigators engineered matrilysin ‘knockout’  (MAT"7 ') mice that lacked mature 
alpha  defensins  but  contained  abundant  precursor  molecules.  Crypt  secretions 
isolated  from  MAT'7 "   mice  were  less  bactericidal  than  secretions  isolated  from 
wild-type mice, and in vivo, exogenously administered E coli survived in greater 
numbers and were more virulent in MAT'7 ' mice. In addition, MAT'7 ' strains were 
more  susceptible  to  infection  by  invasive  pathogens  such  as  Salmonella 
typhimurium,  in  comparison  to  wild-type  mice  (Wilson  1999).  Although  it  is 
possible that matrilysin-dependant systemic responses may render mice resistant 
to  oral  infection  with  intestinal  pathogens,  these  results  strongly  suggest  that 
matrilysin-processed  defensins  play  a pivotal  role  in mediating  innate  defences 
against oral pathogens.
Salzman and colleagues (2003) developed a transgenic mouse model using a 2.9- 
kilobase human alpha-defensin 5  (HD5) minigene  containing 2  HD5  exons  and 
1.4 kilobases of 5’-flanking sequence. In the HD5 transgenic mice, HD5 mRNA 
and protein expression faithfully localises to Paneth cells, thereby implying that 
the flanking sequence contains tissue-specific promoter elements. This transgenic 
murine  model  allowed  investigators  to  determine  whether  Paneth  cell-specific 
HD5  conferred  protection  against  intestinal  pathogens,  and  this  ‘knock-in’-like 
model  avoided  potential  confounding  (systemically  mediated)  effects  that  are 
inherent  in  ‘knockout’  models.  Following  oral  inoculation  with  Salmonella 
typhimurium  (1.5  x  109   c.f.u.),  a  striking  difference  was  noted  in  the  HD5 
transgenic mice and wild-type  control  strains.  The HD5  trangenic  mice  showed 
some  initial  signs  of  illness  but  consistently  recovered  with  no  mortality  or 
morbidity whereas all control mice succumbed to  infection i.e.  100% mortality. 
Also,  after  oral  inoculation  with  sub  lethal  doses  of S typhimurium,  increased 
bacterial translocation was observed in the wild-type strain. HD5 mediates innate 
responses to luminal intestinal pathogens as there was no difference in survival in 
HD5  transgenic  and  control  mice  following  intraperitoneal  infection  with  S.
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are  resistant to  infection  by S.  typhimurium  as,  in  vitro,  HD5  and  endogenous 
mouse cryptdin peptides have comparable killing activity against S typhimurium 
(Ouellette  2005).  It  is  therefore  possible  that  Paneth  cell  secretions  mediate 
protection  by  direct  killing  of  bacterial  pathogens  or  by  influencing  the 
composition of the  resident microflora by  selecting  for commensal  species that 
release bactericides  which protect against S typhimurium  (Ouellette  2005).  The 
HD5  transgenic  mice  is  a model,  however,  that  can be  used to  analyse  human 
defensin expression and function to more precisely define the role of Paneth cells 
as key mediators of innate defence against intestinal pathogens.
In  addition  to  the  potent  antimicrobial  alpha  defensin  peptides,  Paneth  cells 
express  angiogenin,  a  newly  described  family  of  endogenous  antimicrobial 
proteins (Hooper 2003). Human angiogenin (ANG) was initially isolated based on 
its ability to stimulate vasculogenesis; however, more recent observations suggest 
that it may be involved in human defence. Hooper and colleagues (2003), using 
laser capture microdissection and quantitative real time RT-PCR, have shown that 
murine  Paneth  cells  express  angiogenin-4  (Ang4).  Using  immunoblot  analysis, 
these investigators showed that Paneth cells release Ang4 into the crypt lumen in 
response  to  bacterial  products.  Ang4,  a  member  of the  RNase  superfamily,  is 
bactericidal  against  specific  intestinal  pathogens  although,  interestingly,  it  does 
not  have  major  bactericidal  activity  against  Beta  thetaiotamicron,  a  dominant 
intestinal  commensal  microbe.  Indeed,  colonisation  with  intestinal  microbiota, 
including Beta thetaiotamicron, increases Ang4 expression in Paneth cells in vivo. 
During  the  weaning  period,  which  is  associated  with  changes  in  the  intestinal 
microbiota, Ang4 expression is increased in conventionally raised mice but not in 
mice raised in germ-free conditions. These observations provide further evidence 
of Ang4  regulation  by  intestinal  microbiota.  In  humans,  ANG  is  bactericidal 
against  systemic  pathogens  such  as  Streptococcus  pneumoniae  and  Candida 
albicans although it is not certain whether ANG is expressed in Paneth cells  in 
vivo (Hooper 2003).  These investigations suggest that Paneth cell antimicrobials 
have  the  potential  to  regulate  the  composition  of  the  intestinal  microbiota, 
allowing  commensal  bacteria  to  populate  the  intestinal  lumen  whilst  affording 
protection against intestinal pathogens.
401.3.3.2 Angiogenesis
Paneth  cells,  in  addition to  their role  in  intestinal  innate  immune  system,  also 
regulate  the  growth  of new  blood  vessels  within  the  intestinal  villous.  Using 
quantitative three-dimensional imaging analysis in germ-free and conventionally 
raised mice, Stappenbeck and colleagues (2002) determined that the growth of the 
intestinal  villous  capillary  network  coincides  with  bacterial  colonisation  of the 
intestinal  tract.  Adult  mice  that  were  raised  in  germ-free  environments  have 
arrested  villous  capillary  network  formation.  Next,  using  transgenic  mice  that 
lacked  Paneth  cells  (Garabedian  1997),  these  investigators  showed  that  the 
microbial  regulation  of villous  angiogenesis  is  also  dependant  on  Paneth  cells. 
The  capillary  networks  in  germ-free  Paneth  cell-deficient  mice  were  less 
developed  as  compared to  germ-free  control  mice,  suggesting that Paneth cells 
produce  factors  that  regulate  the  growth  of the  villous  microvasculature.  The 
growth of the villous  capillary network was  increased  in germ-free  control  and 
Paneth  cell-deficient  mice  that  were  colonised  with  Beta  thetaiotamicron,  a 
prominent commensal in murine intestine. The most dramatic increase in vascular 
growth  was  observed  in  Paneth  cell-containing  control  mice,  suggesting  that 
Paneth cells  promote  villous  capillary  maturation  by producing  factors  that  act 
directly on the villous microvasculature, or indirectly by regulating expression of 
angiogenic  factors  in other intestinal  cells  (Stappenbeck  2002).  These  findings, 
which highlight the multifunctional role of Paneth cells,  suggest that these cells 
play a role in the regulation of angiogenesis.
1.3.3.3 Inflammation
Paneth cells may also be involved in the regulation of inflammation, and there is 
emerging, although speculative, evidence that Paneth cells play a role in intestinal 
inflammation.  Paneth  cells  produce  a  variety  of  cytokines  and  mediators  of 
inflammation (Porter 2002) and there is evidence to  suggest that Paneth cell-a- 
defensins  may  also  function  as  paracrine  agonists  by  regulating  inflammatory 
responses  in  intestinal  epithelial  cells  (Lin  2004).  A  role  for  Paneth  cells  in 
inflammation  is  also  suggested  by  reports  describing  the  induction  of  pro-
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regulation  of Paneth  cell  numbers  by  mucosal  T  cells  in  intestinal  infection 
(Kamal 2001).
Murine  alpha  defensins,  or  cryptdins,  kill  microbes  by  forming  pores  in  their 
limiting membranes (Ouellette  1994, Ouellette  1997).  Certain cryptdin isoforms, 
such  as  cryptdins  2  and  3,  also  form  apical  anion-conductive  channels  in 
eukaryotic cell membranes of crypt epithelial cells. This channel causes a salt and 
water  secretory  response  that  flushes  the  intestinal  crypt  of  noxious  agents 
(Lencer  1997).  Pore  formation  in  eukaryotic  cells,  however,  may  also  cause 
cytokine  release  in  these  cells,  and  Lin  and  colleagues  (2004)  determined  if 
cryptdins could induce cytokine release in intestinal epithelial cells. Using an in 
vitro  cell  culture  model,  these  investigators  show  that  cryptdin-3  induces  IL-8 
secretion from T84 intestinal epithelial cells, presumably after forming channels 
in  the  apical  membranes  of these  cells.  Signal  transduction  in  epithelial  cells 
treated  with  cryptdin-3  are  likely  to  occur  through  pathways  involving  the 
transcription factor NF-kB and the kinase MAPK as these factors are activated in 
cryptdin-3-stimulated cells. However, as NF-kB  and MAPK are activated a few 
hours after cryptdin-3  stimulation,  as compared to  rapid activation after TNFa- 
stimulation, it is possible that other signal transduction pathways are invoked in 
response  to  cryptdin-3  stimulation.  In  addition  to  inducing  IL-8  secretion, 
cryptdin-3 also induces the secretion of other pro-inflammatory cytokines such as 
macrophage  inhibitory  protein  (MIP)-l-alpha,  MIP-l-beta,  MIP-1-delta,  IL-17, 
IL-12 p70 and IL-8 from epithelial cells. Although it is unclear if HD5 and HD6 
exert  similar  effects,  these  observations  suggest  that  cryptdins  may  further 
enhance innate defences by triggering the secretion of epithelial cell cytokines that 
may recruit inflammatory cells, including neutrophils, into the lamina propria.
Paneth  cells  may  also  contribute  to  the  development  of systemic  inflammatory 
responses  following  local  intestinal  injury.  It  is  hypothesised  that  bacterial 
translocation  across  the  intestinal  epithelial  barrier,  which  occurs  in  conditions 
such  as  haemorrhagic  shock,  is  a  major  contributor  to  the  development  of 
systemic inflammatory responses (Chen 2003). TNFa is an important mediator of
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murine  model  of haemorrhagic  shock,  have  shown  that  increased tissue  TNFa 
production  is  solely  observed  in  those  animals  with  evidence  of  bacterial 
translocation. Interestingly, increased TNFa production was only noted in Paneth 
cells and leukocytes present in the mesenteric lymph nodes  and spleen, and not 
detected  in  hepatic,  renal  or  pulmonary  tissue.  As  TNFa  over-production  is 
implicated  in  the  pathogenesis  of  systemic  inflammatory  response  syndrome 
(SIRS) following gut ischaemia and bacterial translocation, these findings suggest 
that Paneth cells may play an important role in initiating inflammation.
Paneth  cell  products,  such  as  TNFa  and  cryptdins,  may  also  play  a  role  in 
intestinal  and  systemic  inflammation  by  regulating  NF-kB  activation  in 
enterocytes  (Tani  2000,  Lin  2004,  Chen  2003).  In  animal  models,  intestinal 
ischaemia can trigger acute systemic inflammation, which manifests clinically as 
systemic inflammatory response syndrome (SIRS). In this scenario, increased NF- 
kB  activity  is  typically  observed  in  enterocytes.  Chen  and  colleagues  (2003), 
using  Cre~loxP  technology  to  silence  NF-kB  activity  specifically  in  murine 
intestinal epithelial cells, have elegantly shown that NF-kB activation in intestinal 
enterocytes  is  required  for  the  initiation  and  development  of  systemic 
inflammation and is not just a marker of inflammation. The abrogation of NF-kB 
activation  in  intestinal  epithelial  cells  prevents  the  development  of  systemic 
inflammation in response to intestinal ischaemia.  Crucially, however, abrogation 
of NF-kB  activation  also  results  in  an  increased  rate  of apoptosis  and  tissue 
damage in intestinal epithelial cells. These results show that NF-kB regulation is 
crucially  important  to  maintain  intestinal  homeostasis  and  prevent  systemic 
inflammation,  and Paneth cell products,  such as TNFa and alpha-defensins, can 
potentially regulate NF-kB activation in intestinal epithelial cells.
There  is  evidence  to  suggest  that  Paneth  cell-derived  TNFa  plays  a  role  in 
maintaining the integrity of the epithelial barrier (Seno 2002). In rats treated with 
diphenylthiocarbazone  (dithizone),  Seno  and  colleagues  (2002)  noted  increased 
NF-kB  activation  in  intestinal  epithelial  cells.  Dithizone,  a  zinc  chelator, 
reportedly induces the selective killing of Paneth cells that results in the release of
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lumen. Seno and colleagues suggest that Paneth cell-derived TNFa mediates NF- 
kB  activation in intestinal epithelial cells, as prior administration of neutralising 
anti-TNFa antibody or pentoxifylline, which inhibits TNFa synthesis, abrogates 
NF-kB  activation  in  epithelial  cells  in  dithizone-treated  rats.  Using 
immunohistochemistry,  these  investigators  suggest  that  TNFa  localises  to  the 
secretory granules of Paneth cells, and demonstrated exfoliated Paneth cells that 
are immunoreactive for TNFa protein in the crypt lumen in dithizone-treated rats. 
Seno and colleagues showed that increased NF-kB activation was associated with 
intestinal epithelial cell proliferation, which is consistent with the results reported 
by Chen and colleagues (2003). Further studies, however, are needed to confirm 
that this effect is mediated by Paneth cell- derived TNFa.
Kamal and colleagues (2002) have shown that Paneth cell numbers are increased 
in  mice  that  are  infected  with  parasites  such  as  Nippostrongylus  brasiliensis, 
Heligmosomoides  polygyrus,  Schistosoma  mansoni  and  Trichinella  spiralis. 
Furthermore,  Paneth  cell  numbers  were  increased  in  athymic  mice  that  were 
infected with  T.  spiralis, but not in infected mice deficient in the T-cell antigen 
receptor TCR (p/8)'7 ’  (Kamal  2001).  Interestingly,  transfer of mesenteric  lymph 
node cells from wild-type mice results in an increase in Paneth cell numbers in T. 
spiralis-infected  TCR  (p/8)"7 "  mice,  suggesting  that  Paneth  cells  numbers  are 
regulated  by  a  specific  population  of mucosal  T  cells  in  response  to  enteric 
infection. Although the functional consequences of these changes in Paneth cell 
number  are  unclear,  it  is  possible  that  Paneth  cells  act  in  concert  with  T-cell 
mediated immune responses to eradicate intestinal parasitic infection.
Various other cytokines  and mediators of inflammation are expressed in Paneth 
cells  although  the  functional  significance  of these  observations  is  not  known. 
Several  investigators  have  shown,  using  in  situ  hybridisation  and 
immunohistochemistry,  that  transforming  growth  factor  (TGF)-P,  TNFa, 
prostaglandin  E2  (a  pleiotropic  mediator  of inflammation)  and  osteopontin  (a 
glycosylated phosphoprotein with proposed functions in cell-mediated immunity) 
are  expressed  by  Paneth  cells  (Hauer-Jensen  1998,  Keshav  1990,  Schmauder-
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postulated as these cells express CD1  (Lacasse  1992).  Paneth cells also express 
FAS  ligand  (or CD95)  at their basolateral  membrane  (Moller  1996,  Lee  1999), 
which suggests that these cells could induce apoptosis in FAS+ immune cells of 
the surrounding tissue.  If this is true, then Paneth cells could also enhance host 
defence  by  removing  diseased  cells  and  down  regulating  immune  responses 
through  apoptosis.  Fukuzawa  and  colleagues  (2003)  have  shown  Paneth  cells 
express  GM-CSF.  GM-CSF  enhances  the  expression  of  the  co-stimulatory 
molecules such as CD80 and CD86 in antigen-presenting cells and increases the 
capacity  of  these  cells  to  stimulate  T  cells  (Holowachuk  2001).  GM-CSF 
increases  CD80  and  CD86  expression  in  intestinal  epithelial  cells,  which  are 
capable of presenting MHC Class II antigens. As the GM-CSF receptor p-chain is 
present in both Paneth and non-Paneth cells, it is possible that GM-CSF secreted 
from  Paneth  cells  acts  via  autocrine  and  paracrine  mechanisms  to  enhance 
expression of costimulatory molecules in epithelial cells of the  intestinal crypts. 
Although the functional significance of these observations is unclear, partly due to 
a lack of a Paneth cell-like  cell line and suitable reagents, these results  suggest 
that  Paneth  cells  may  have  a  repertoire  of functions  beyond  the  provision  of 
antimicrobial defence.
1.3.4  Paneth cells and Crohn's disease
The  role  of Paneth  cells  in the  pathogenesis  of intestinal  inflammation has  not 
been  suitably  investigated  in  animal  models.  In  humans,  the  expression  of the 
Paneth cell products such as HD5, lysozyme and 5PLA2 has been analysed by in 
situ  hybridisation  and  immunohistochemistry,  and  these  observations  do  not 
suggest an obvious role for Paneth cells in the pathogenesis of Crohn’s disease.
1.3.4.1  Alpha defensin expression
The  alpha  defensins  5  (HD5)  and  6  (HD6)  are  potent  antimicrobials  peptides 
which are likely to confer resistance to infection by intestinal pathogens (Bevins 
2004). In normal and Crohn's disease-affected terminal ileum, expression of HD5 
peptides  is  restricted  to  Paneth  cells  (Porter  1997,  Cunliffe  2001).  In  Crohn's
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strongest in Paneth cells, although staining is observed in isolated epithelial cells 
located near the villous tip in terminal ileal sections (Cunliffe 2001).  In Crohn's 
and ulcerative colitis, metaplastic Paneth cells express HD5  (Cunliffe 2001). By 
in  situ  hybridisation,  HD5  and  HD6  mRNA  expression  is  highly  restricted  to 
Paneth  cells  in  histologically  normal  small  intestinal  tissue  (Salzman  1998), 
although mRNA expression has not been analysed in inflammatory bowel disease. 
HD6  peptide  expression  has  not  been  quantitated  by  immunoblot  analysis  in 
normal  and  Crohn's  disease-affected  intestinal  tissue,  and  there  is  no  suitable 
antibody for immunohistochemical analysis of HD6.
Measurement  of HD5  and  HD6  mRNA  expression  in  intestinal  tissue,  using 
quantitative  real-time  RT-PCR and microarray  gene  profiles,  suggest that HD5 
and HD6 mRNA levels are not significantly different in histologically normal and 
Crohn's disease-affected small intestinal tissue (Fahlgren 2003, Lawrance 2001). 
These  studies,  however,  show  that  HD5  and  HD6  mRNA  expression  is 
significantly increased in Crohn's and ulcerative colitis (Lawrance 2001, Fahlgren 
2003), which is most likely accounted for by the presence of metaplastic Paneth 
cells. Interestingly, microarray gene profile shows that HD5 mRNA expression is 
increased approximately 40-fold in Crohn's colitis, higher than any other gene on 
the  microarray  gene  profile  (Lawrance  2001).  It  should  be  noted  that  mRNA 
quantitation  using  microarray  gene  profiling  is  not  absolutely  quantitative  and 
often  dependant  on  the  quality  of the  high-density  oligonucleotide  ‘chip’.  As 
murine  defensins  have  the  ability  to  modulate  inflammatory  responses  in 
enterocytes  (Lin 2004), there  is  a possibility that HD5  and HD6 may influence 
inflammatory responses in humans, but these assumptions are untested. Deficient 
expression  of  HD5  and  HD6  may  predispose  to  intestinal  infection  and 
inflammation  but  overall,  these  observations  show  that  expression  of  these 
antimicrobial peptides is not lowered, and may be increased.
1.3.4.2  Secretory phospholipase A2 Group IIA (sPLA2) expression
Secretory phospholipase A2 Group IIA (sPLA2) is an antimicrobial enzyme that 
also plays a role in the modulation of inflammatory responses (Nevalainen 1997,
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prominent  cell  types  that  express  sPLA2   mRNA  and  protein  at  the  site  of 
inflammation  although  this  enzyme  is  also  expressed,  albeit  more  weakly,  in 
intestinal columnar cells (Haapamaki  1999). Other immunohistochemical studies 
report similar findings (Minami  1994, Lilja  1995), and sPLA2 enzyme activity is 
increased in Crohn's disease (Olaison 1988, Lilja 1995). More recently, Lawrance 
and  colleagues  (2001),  using  microarray  gene  profiling  of  intestinal  tissue, 
showed increased sPLA2 expression in inflammatory bowel disease.
The role of sPLA2 in the pathogenesis of Crohn's disease is uncertain, given that 
this  enzyme,  which has  antibacterial  properties,  may  prolong  the  inflammatory 
reaction in the intestinal mucosa. In animal studies, sPLA2 activity is increased in 
PAF  or  LPS-induced  small  intestinal  injury  (Rozenfeld  2001).  These  effects, 
however, are mediated by intestinal bacteria, and it is unclear whether increased 
enzyme  activity  reflects  an  appropriate  host  response  to  bacterial  infection  or 
proinflammatory activity. Intriguingly, in dextran sulphate sodium-induced colitis, 
Tomita  and  colleagues  (2003)  have  shown  that  specific  inhibition  of sPLA2  
reduced the size of mucosal erosions and decreased colonic inflammation in vivo, 
suggesting  that  sPLA2   has  a  dominant  pro-inflammatory  role  in  this  model  of 
colitis. Whether inhibition of sPLA2 activity in Crohn's disease reduces intestinal 
inflammation is unclear and requires further investigation.
1.3.4.3  Lysozyme expression
Lysozyme, a bacteriolytic enzyme, is expressed by various cells in inflamed small 
intestinal tissue (Stamp  1992, Cappello  1992, Cunliffe 2002, Fahlgren 2003). By 
in  situ  hybridisation,  however,  Paneth  cells  label  more  intensely  for  lysozyme 
mRNA than other cell types (Stamp 1992), suggesting that Paneth cells contribute 
significantly  to  lysozyme  production  within  the  intestine.  Lysozyme  mRNA  is 
detected  in  other  epithelial  cells  such  as  the  ulceration-associated  cell  lineage 
(UACL)  or  pseudopyloric  metaplastic  cells,  although  the  staining  intensity  in 
these cells is weak (Stamp 1992). In inflamed colonic tissue, lysozyme is detected 
in  metaplastic  Paneth  cells  in  colonic  crypts  (Stamp  1992,  Fahlgren  2003).  In 
leukocytes, lysozyme mRNA is detected in lamina propria mononuclear cells and
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epithelial cells and monocytes, and also shows expression in neutrophils (Stamp 
1992, Cappello  1992, Cunliffe 2002, Fahlgren 2003) and epithelial cells located 
near the villous tip (Cunliffe 2002).
Lysozyme  mRNA  expression,  as  determined by  quantitative  real  time  RT-PCR 
analysis,  is  not  significantly  different  in  small  intestinal  villous  and  crypt 
epithelial  cells  obtained  from  Crohn's  disease-affected  patients  and  controls 
(Fahlgren 2003). In ulcerative colitis, however, lysozyme expression is increased 
in epithelial  cells  (Fahlgren  2003),  confirming  earlier  microarray  gene  profiles 
which  report  enhanced  lysozyme  expression  in  ulcerative  rather  than  Crohn's 
colitis (Lawrance 2001).  It is assumed that metaplastic Paneth cells, which stain 
positively for lysozyme mRNA and protein, account for the increased expression 
in  colonic  epithelium.  Taken  together,  these  results  suggest  that  Paneth  cell 
lysozyme  expression  is  not  significantly  altered  in  Crohn's  ileitis,  and  the 
increased expression seen in ulcerative  colitis is  likely to be  due to Paneth cell 
metaplasia.
1.3.4.4  Tumour necrosis factor alpha (TNFa) expression
TNFa is a potent pro-inflammatory cytokine that is postulated to play a key role 
in  the  pathogenesis  of  Crohn’s  disease  (Beutler  1999).  TNFa  production  is 
thought to be increased in patients with Crohn's disease and anti-TNFa therapy is 
used  successfully  to  treat  relapses  in  Crohn's  disease-affected  patients  (van 
Dullemen 1995, Stack 1997, Ghosh 2004). Keshav and colleagues (1990) showed 
that TNFa mRNA is very prominent in Paneth cells, as well as in lamina propria 
leukocytes,  in  murine  small  intestinal  tissue.  Tan  and  colleagues  (1993)  have 
shown that Paneth cells  express  TNFa  mRNA  in necrotising  enterocolitis.  Beil 
and  colleagues  (1995),  using  electron  microscopy  to  identify 
immunohistochemical  localisation  of  TNFa  protein,  have  shown  that  TNFa 
protein localises  to  metaplastic Paneth cell  granules  in  Crohn's  disease-affected 
colonic tissue. TNFa protein also localised to several types of leukocytes, such as 
macrophages  and  eosinophils,  and  colonic  epithelial  cells  (Beil  1995).  In  this 
study, the intensity of staining was highest in leukocytes and lowest in epithelial
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protein  in  control  and  inflamed  intestinal  tissue  using  more  conventional 
immunohistochemical techniques.
Conflicting  results  have  been  reported  in  studies  that  have  quantitated  TNFa 
mRNA  expression  in  intestinal  tissue  by  RT-PCR.  In  paediatric  IBD  patients, 
Dionne  and  colleagues  (1997)  have  shown  that  TNFa  mRNA  expression  is 
increased  in Crohn's  colitis  compared to  controls  although  other  studies  do  not 
show an increase  in TNFa  production  in  intestinal  samples  from  patients  with 
IBD  (Stevens  1992,  Isaacs  1992).  It  is  postulated  that  local  overproduction  of 
TNFa  by  Paneth  cells,  which  constitutively  express  this  cytokine,  may  initiate 
intestinal inflammation. The cellular sources of TNFa protein, however, have not 
been  identified  as  yet  and  it remains  uncertain whether Paneth  cells  contribute 
significantly to TNFa production in intestinal inflammation.
Overall, these results suggest that the expression of Paneth cell products may be 
regulated in inflammatory disease,  although the functional consequences  of this 
are  unknown.  In  Crohn’s  disease,  Paneth  cells  numbers  are  increased  and 
metaplastic  Paneth  cells  are  a  feature  of Crohn's  colitis.  There  is  evidence  to 
suggest that lysozyme  and TNFa expression is regulated in IBD,  although it is 
unclear if expression of these products is specifically regulated in Paneth cells. In 
Crohn's  disease,  current  data  suggests  that  there  is  increased  expression  of 
defensin and 5PLA2, which are antimicrobial peptides predominantly expressed by 
Paneth cells.  The increased expression of these antimicrobial peptides in Paneth 
cells most likely occurs in response to bacterial infection that may be present in 
Crohn's disease although some of these secreted antimicrobial peptides may play a 
role in inflammation.
491.4  Study aims and Hypothesis
Crohn’s  disease  can  affect the  entire  gastrointestinal  tract,  but  most  commonly 
affects the  terminal  ileum  and colon.  Mutations  in the  newly  described NOD2 
gene  predispose  patients  to  Crohn’s  disease  although  these  patients  usually 
develop  inflammation  of the  terminal  ileum  or  ileitis.  The  reasons  for this  are 
unknown as NOD2 is expressed in circulating monocytes, which are ubiquitously 
distributed  in  the  body.  The  NOD2  gene  encodes  for  a  protein  that  mediates 
cellular  activation  in  response  to  stimulation  with  muramyl  dipeptide  (MDP). 
Paneth  cells,  on the  other hand,  are  most  numerous  in the  terminal  ileum  and 
secrete antibacterial peptides in response to bacterial antigens, including MDP. In 
addition,  Paneth  cells  may  also  play  a  role  in  the  development  of  intestinal 
inflammation. I therefore hypothesised that Paneth cells, which are specialised for 
intestinal  defence,  express  the NOD2  gene  and that  mutations  of NOD2  affect 
Paneth  cell  function  which  predisposes  to  the  development  of  intestinal 
inflammation.
The aims of this study are:
1.  To  analyse  the  expression  of NOD2  in  normal  and  Crohn’s  disease- 
affected intestinal tissue.
2.  To  quantitate NOD2  gene  expression in intestinal  epithelial  cells  and to 
identify  factors  that  regulates  NOD2  gene  expression  in  intestinal 
epithelial cells and monocytes.
3.  To  analyse  Paneth  cell  antimicrobial  gene  expression  in  patients  with 
NOD2-related Crohn’s disease.
4.  To analyse NOD2 and Paneth cell antimicrobial gene expression in other 
intestinal inflammatory conditions such as necrotizing enterocolitis.
1.  To determine whether intestinal epithelial cell lines can be used to assess 
Paneth cell function.
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2. Materials and Methods
2.1 Materials
A list of reagents and suppliers is attached as Appendix C.
2.2 Molecular biology Techniques 
2.2.1. Bacterial Growth media
2.2.1.1 2X YT Medium
16 g tryptone, 10 g yeast extract and 5 g sodium chloride (NaCl) were dissolved in 
900 mL distilled water. The pH of this solution was adjusted to 7.0 using sodium 
hydroxide  (NaOH) pellets, and the volume of the solution adjusted to  1000 mL 
using distilled water. This solution was sterilised by autoclaving for 20 minutes at 
15 psi (1.05 kg/cm ) on liquid cycle.
2.2.1.2 LB Medium (Luria-Bertani Medium)
10 g tryptone, 5 g yeast extract and 10 g NaCl were dissolved in 900 mL distilled 
water.  The pH of this  solution was adjusted to  7.0 using NaOH pellets, and the 
volume of the  solution adjusted to  1000 mL using distilled water.  This solution 
was  sterilised  by  autoclaving  for 20  minutes  at  15  psi  (1.05  kg/cm2)  on  liquid 
cycle.
2.2.1.3 Preparation of solid medium plates
Bacto-agar (Difco) was added to 2X YT media so that the final solution contained 
1.5%  agar.  This  solution was  autoclaved and then cooled to  42.0°C  in  a water 
bath. Using aseptic technique, approximately 15 mL of medium were poured into 
sterile, 90 mm bacterial culture plates. After allowing for the medium to solidify, 
the plates (with theirs lids slightly ajar) were incubated in a warm room to reduce 
condensation.  Thereafter,  the  plates  were  wrapped  in  plastic  and  stored,  in  an 
inverted position, at 4.0°C.
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medium,  using  aseptic  technique, just  before  the  medium  was  poured  into  the 
plates. The final concentration of ampicillin in the agar plates was 100 pg/ mL.
2.2.1.4  Preparation  of IPTG (isopropylthio-P-D-galactoside) and X-gal 
(5-bromo-4-chloro-3-indoyl-P-D-galactoside)
IPTG: A 20% (w/v) solution of IPTG (0.8M) was prepared by dissolving IPTG in 
distilled  water.  The  solution  was  sterilised  by  passing  it  through  a  0.22  pm 
disposable filter. The solution was dispensed in aliquots and stored at -20°C.
X-gal:  A  2%  (w/v)  solution  of  X-gal  was  prepared  by  dissolving  X-gal  in 
dimethyl formamide in a glass tube. The glass tube containing the solution was 
wrapped with aluminium foil and stored at -20.0°C.
100 pL of the IPTG and X-gal solutions were pipetted on the centre of the agar 
plates  and  spread  using  a  sterile  spreader.  The  plates  were  then  incubated  at 
37.0°C until the solutions were absorbed into the agar.
2.2.2  Preparation of competent cells
Reagents:
1.  Escherichia coli DH5alpha bacteria
2.  2XYT media
3.  CaCl2  solution  [60mM  calcium  chloride  (CaCl2),  15%  glycerol,  lOmM 
PIPES buffer pH 7)
Method:
Frozen stocks of the bacterial Escherichia coli strain DH5alpha (a gift from Dr G 
MacColl,  Royal  Free  and  University  College  Medical  School,  London)  were 
revived by streaking a sample of the stock on 2X YT solid medium plates which 
were  then  incubated  at  37.0°C  for  16  hours.  A  single  bacterial  colony,  picked 
from the plate with a sterile toothpick, was propagated in 50 mL 2X YT medium 
that was agitated at 37.0°C for 16 hours. 200 mL of pre-warmed (to 37°C) 2X YT
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of the overnight E.  coli DH5a culture and agitated at 37.0°C  for 2  hours.  The 
optical density of this culture, checked at a wavelength of 590 nm, was 0.670.
This  culture  was  aliquoted  into  chilled polypropylene  centrifuge  tubes  (50  mL 
capacity),  which  were  cooled  on  ice  for  15  minutes.  Thereafter,  the  bacterial 
culture was centrifuged at 1600g at 4.0°C for 7 minutes. After centrifugation, the 
culture supernatant was carefully aspirated and discarded, and the bacterial pellet 
gently resuspended in 10 mL pre-chilled CaCb solution. The resuspended pellets 
were chilled on ice for a further 30 minutes, and centrifuged at 1  lOOg at 4.0°C for 
5 minutes.  After centrifugation, the supernatant was discarded, and the bacterial 
pellet was gently, but thoroughly, resuspended in 2 mL pre-chilled CaC^ solution. 
These cells were aliquoted into pre-chilled microfuge tubes, frozen on dry ice, and 
stored at -80.0°C.
The transformation efficiency was tested by transfecting the competent cells with 
pUC18  plasmid  DNA  (Fermentas).  The  transformation  efficiency  of  the 
competent cells was 9.25 x 106 transformed colonies per pg plasmid DNA.
2.2.3  Transformation of competent cells
Reagents:
1.  Competent cells
2.  2XYT media
3.  Ampicillin-containing 2X YT agar plates
4.  X-gal
5.  IPTG
Method:
Competent  cells  were  thawed  on  ice  and  aliquoted  into  pre-chilled,  sterile 
microfuge tubes  so that each tube contained  50  pL  competent cells.  One  pL of 
plasmid DNA  (either recombinant or control  pUC18  plasmids),  containing  less 
than 50 ng of DNA, were added to the competent cells. As a control, no DNA was
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contents and stored on ice for 30 minutes. The tubes were transferred to a non­
shaking heating block,  preheated to  42.0°C,  and heated  for 90  seconds  exactly 
(‘heat-shock’ treatment). Immediately thereafter, the tubes were cooled on ice for 
2 minutes. 450 pL of pre-warmed (37.0°C) 2X YT media were added to the tubes, 
which  were  incubated  at  37.0°C  for  60  minutes  in  a  shaking  heating  block. 
Thereafter,  either  20  pL  or  200  pL  of the  transformed  competent  cells  were 
spread  on  ampicillin-containing  2X  YT  agar  that  were  plated  with  X-gal  and 
IPTG 30 minutes beforehand. These plates were incubated at 37.0°C for 16 hours, 
and thereafter stored at 4.0°C for 4 hours to permit blue colour development.
Using a sterile toothpick, white colonies, containing recombinant plasmids, were 
picked from the agar plates, and inoculated into  fresh 2X YT media containing 
ampicillin.  Blue  colonies  were  picked  from  plates  containing  competent  cells 
transfected with control pUC18 plasmids. There was no growth on the agar plates 
that contained competent cells without plasmid DNA.
2.2.4  Preparation of bacterial stocks
Reagents:
60% glycerol (sterilised)
Method:
1.35 mL of bacterial culture was added to sterile storage tube containing 450 pL 
sterile  60%  glycerol  [sterilised  by  autoclaving  for  20  minutes  at  15  psi  (1.05 
kg/cm ) on liquid cycle]. This solution was mixed, using a vortex mixer, to evenly 
disperse the glycerol, and the culture was frozen in dry ice or liquid nitrogen, and 
stored at -80.0°C. Bacteria were recovered by scraping the frozen surface of the 
culture with a sterile inoculating loop which was streaked across an LB or 2X YT 
agar plate containing the appropriate antibiotic. The plate was incubated overnight 
at 37.0°C.
542.2.5  Phenol  extraction  and  ethanol  precipitation  of  nucleic 
acids
Phenol  extraction was  performed to  remove  contaminating proteins  from  DNA 
and RNA preparations.
Reagents:
1.  Solvent resistant 1.5 mL microfuge tubes
2.  Phenol  [CeLLO]:  Chloroform  [CHCI3]:  Isoamyl  Alcohol
[(CLL^CHCLLCLLOH] 25:24:1 saturated with 10 mM Tris, pH 8.0, 1  mM 
EDTA
3.  Chloroform: isoamyl alcohol (24:1)
4.  100% ethanol (CH3CH2OH), chilled on ice.
5.  70% ethanol, chilled on ice.
6.  3 M sodium acetate (C2H3Na0 2) (pH 5.2)
7.  Dry ice
Method:
DNA  or  RNA  preparations,  in  a  300  pL  volume,  were  transferred  to  a  sterile 
polypropylene  tube  containing  300  pL  phenol:  chloroform:  isoamyl  alcohol. 
Using  a vortex  mixer,  the  contents  of the  tube  were  mixed  until  an  emulsion 
formed.  The  microfuge  tube  was  centrifuged  at  13  000  rpm  (16  100  g)  for  5 
minutes at room temperature. Following centrifugation to enact phase separation, 
the upper aqueous layer was carefully aspirated, avoiding the protein and phenol 
interface.  To further purify DNA, the aqueous phase was transferred to a sterile 
polypropylene tube containing 300 pL phenol: chloroform:  isoamyl alcohol. The 
contents were mixed using a vortex mixer. The microfuge tube was centrifuged at 
13 000 rpm (16 100 g) for 5 minutes at room temperature. At this stage, no protein 
was visible at the interface of the aqueous and organic phases,  and the aqueous 
phase was transferred to a fresh tube containing 300 pL chloroform. After mixing 
the contents, the tube was centrifuged at 13 000 rpm (16  100 g) for 5 minutes at 
room  temperature.  Following  centrifugation,  the  aqueous  phase  (300  pL)  was 
transferred to a fresh tube where the nucleic acids were concentrated by ethanol 
precipitation.
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mixed using a vortex shaker. Next, 750 pL of ice-cold 100% ethanol was added to 
the tube,  and the  contents were  mixed using a vortex  mixer.  The  nucleic  acids 
were precipitated at -80°C for 60 minutes. Following precipitation, the microfuge 
tube  was  centrifuged  at  13  000  rpm  (16  100  g)  for  10  minutes  at  4°C.  The 
supernatant  was  carefully  removed  by  aspiration  and  the  nucleic  acid  pellet 
washed with 750  pL 70% ice-cold ethanol. The tube was centrifuged at  13  000 
rpm  (16  100  g)  for  10  minutes  at  4°C  and,  after  carefully  discarding  the 
supernatant, the nucleic pellet suspended in 50 pL nuclease-free water and stored 
at -20°C.
2.2.6  Preparation of plasmid  DNA by alkaline lysis with sodium 
dodecyl sulphate (SDS): Minipreparation
Plasmid DNA was  isolated from bacterial cultures  by treatment with alkali and 
SDS,  and the  resulting  DNA  preparations  analysed  by  restriction  endonuclease 
digestion and electrophoresis.
Reagents:
1.  2X YT medium
2.  Ampicillin (100 mg/mL)
3.  STE Buffer:  10 mM Tris-Cl (pH 8.0), 0.1 M NaCl,  1  mM EDTA (pH  8.0).
Solution was sterilised by autoclaving and stored at  4.0°C
4.  Lysis  Buffer:  25  mM  Tris  (pH  8.0),  10  mM  EDTA  (pH  8.0),  50  mM
glucose. Solution was filter sterilised and stored at 4.0°C
5.  0.2 M NaOH, 1% SDS. This solution was freshly prepared before use.
6.  3M sodium acetate solution (C2HsNa0 2) (pH 5.2)
7.  Isopropanol [(CH3)2CHOH]
8.  70% ethanol
9.  10 mM Tris-HCl (pH 7.4)
10. RNase A (10 mg/mL)
11. Phenol: chloroform: isoamyl alcohol (50:49:1)
12. Chloroform: isoamyl alcohol (49:1)
5613. 100% ethanol
14. Nuclease free water
Method:
A single bacterial colony, transformed with plasmid vectors, was picked from an 
agar plate with a sterile toothpick and cultured at 37.0°C for 16 hours in a sterile 
container containing  10 mL of 2X YT culture medium and ampicillin (100  pg/ 
mL). Following overnight culture, the culture medium was transferred to a 50 mL- 
centrifuge tube and centrifuged at 2000 ref (836 g) for  10 minutes at 4°C. After 
discarding the supernatant, the bacterial pellet was washed in ice-cold 1   mL STE 
buffer to remove any residual culture medium; this suspension was transferred to 
a microfuge tube and centrifuged at 13 000 rpm (16 100 g) for 2 minutes at room 
temperature. After discarding the supernatant, the bacterial pellet was suspended 
in  150  pL  lysis  buffer by vigorous  shaking.  200  pL  of freshly prepared  0.2  M 
NaOH,  1%  SDS  solution  was  added  to  the  microfuge  tube,  which  was 
immediately inverted several times to gently mix the contents, and the microfuge 
tube  was  placed  in  ice  for  10  minutes.  300  pL  ice-cold  3M  sodium  acetate 
solution  (pH  5.2)  was  added  to  the  microfuge  tube,  which  was  immediately 
inverted several times to gently mix the contents. Next, the tube was placed in ice 
for a further 30 minutes. The microfuge tube was centrifuged at  13  000 rpm (16 
100 g) for  10 minutes  at room temperature, and the  supernatant (approximately 
700 pL) transferred to a fresh microfuge tube and centrifuged at 13 000 rpm (16 
100 g) for 10 minutes at room temperature. The supernatant was transferred to a 
fresh microfuge tube containing 700 pL isopropanol, and the contents mixed by 
inverting the  tube.  The  tube  was  stored at -80.0°C  for  15  minutes to  allow for 
precipitation of DNA and centrifuged at 13 000 rpm (16  100 g) for 10 minutes at 
room temperature. After discarding the supernatant, the DNA pellet was washed 
in 1  mL 70% ethanol and the microfuge tube centrifuged at 13 000 rpm (16 100 g) 
for 10 minutes at room temperature. After removing the supernatant by aspiration, 
the pellet was dissolved in 300 pL 10 mM Tris-HCl (pH 7.4). RNA was removed 
from the preparation by  adding 5  pL RNase A (10 mg/mL)  and incubating the 
microfuge  tube  at  37.0  °C  for  60  minutes  in  a  heating  block.  Following 
incubation,  300  pL phenol:  chloroform:  isoamyl alcohol (50:49:1) was added to
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centrifuged  at  13  000  rpm  (16  100  g)  for  5  minutes.  The  supernatant 
(approximately 300 pL) was carefully aspirated from the tube and transferred to a 
fresh tube containing 300 pL phenol: chloroform: isoamyl alcohol (50:49:1); after 
mixing the  contents,  the  tube  was  centrifuged  at  13  000  rpm  (16  100 g)  for  5 
minutes.  The  supernatant  (approximately  300  pL)  was  carefully  aspirated  from 
the tube and transferred to a fresh tube containing 300  pL chloroform:  isoamyl 
alcohol (49:1). After mixing the contents, the microfuge tube was centrifuged at 
13 000 rpm (16 100 g) for 5 minutes and the supernatant (approximately 300 pL) 
was carefully aspirated and transferred to a fresh tube. 30 pL 3M sodium acetate 
and 750 pL  100% ethanol were added to the solution, which was shaken to mix 
the  contents,  and  the  tube  stored  at  -80.0°C  for  15  minutes  to  allow  for 
precipitation of DNA. A DNA pellet was obtained by centrifuging the tube at 13 
000 rpm (16  100 g) for  10 minutes.  After discarding the  supernatant, the pellet 
was washed in  1   mL 70% ethanol. The tube was centrifuged at  13  000 rpm (16 
100 g) for  10 minutes and, after discarding the supernatant, the DNA pellet was 
dissolved in 200 pL nuclease free water and stored at -20.0°C.
The yield from this minipreparation was approximately 30 pg plasmid DNA.
2.2.7  DNA minipreparation with QIAprep® Spin Miniprep kit
QIAprep®  Spin  Miniprep  kits  use  silica-gel-membrane  technology  to  obtain 
plasmid  DNA.  Following  alkaline  lysis  of  bacterial  cells,  plasmid  DNA  is 
selectively adsorped  onto  silica in the presence  of high  salts,  and  eluted  into  a 
low-salt buffer. The silica-gel-membrane adsorps DNA, while RNA and cellular 
proteins are not retained by the membrane. The procedure consists of three main 
steps: preparation and clearing of a bacterial lysate, adsorption of DNA onto the 
QIAprep membrane, and washing and elution of plasmid DNA.
Reagents:
1.  QIAprep® Spin Miniprep kit
2.  1 0 0% ethanol
3.  Nuclease-free water
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Alkaline  lysis of bacteria:  Bacteria are  lysed under alkaline  conditions,  and the 
lysate neutralised and adjusted to high-salt binding conditions in one step.
A bacterial pellet was obtained by centrifuging 7.5 mL of liquid bacterial culture 
at 4000 rpm (345 g) for 15 minutes at 4°C. This pellet was resuspended in 250 pL 
of Buffer PI (containing RNase A) and transferred to a microfuge tube. 250 pL of 
Buffer P2 (containing NaOH) was added to the tube, which was gently inverted 
five times to  mix the contents.  After 5  minutes,  350  pL  Buffer N3  (containing 
guanidine hydrochloride and acetic acid) was added to the tube, which was gently 
inverted to mix the contents.
Lysate clearing: Lysates were cleared by centrifugation at 13 000 rpm (16  100 g) 
for  10  minutes  at room  temperature,  and  the  supernatants  were  applied  to  the 
QIAprep® spin columns.
DNA  adsorption  to  the  QIAprep  membrane:  The  QIAprep®  spin  column  was 
centrifuged  at  13  000  rpm  (16  100  g)  for  60  seconds,  and  the  flow-through 
discarded.
Washing and elution of plasmid DNA: The membrane was washed with 500 pL 
Buffer PB, which was removed by centrifuging the spin column at 13 000 rpm (16 
100 g) for 60 seconds. Next, the membrane was washed with 750 pL Buffer PE, 
which was removed by centrifuging the spin column at 13 000 rpm (16 100 g) for 
60  seconds.  After  discarding  the  flow-through,  the  residual  wash  buffer  was 
removed  by  centrifuging  the  spin  column  at  13  000  rpm  (16  100  g)  for  60 
seconds. After washing, the QIAprep® column was placed in a clean microfuge 
tube, and 50 pL of nuclease-free water was added to the centre of the membrane. 
Following  a  short  incubation  lasting  1   minute,  the  DNA  was  collected  by 
centrifugation at 13 000 rpm (16 100 g) for 1  minute. The eluted DNA was stored 
at -20°C.
592.2.8  Digestion of DNA by restriction endonucleases
Reagents:
1.  Restriction enzymes and buffers (see Table 2.1)
2.  Nuclease-free water
Table 2.1. Restriction endonucleases and buffers
Enzyme
Buffer (Supplied as lOx 
concentration)
Supplier
Eel 13611 Buffer Eel 136II Fermentas
EcoRI React 3 Invitrogen
Hindlll React 2 Invitrogen
PstI React 2 Invitrogen
PvuII React 4 Invitrogen
Smal React 4 Invitrogen
SstI React 2 Invitrogen
The following buffers were used for DNA digestion using two restriction
endonucleases:
Enzymes Buffer
Eel 13 611 and EcoRI React 2
EcoRI and Hindlll React 2
PstI and Hindlll React 2
SstI and Hind III React 2
Restriction enzyme digestion of DNA was performed in sterile  1.5 mL microfuge 
tubes  using  commercially  available  restriction enzymes  and  appropriate  buffers 
(Table  2.1).  Analytic  digests  were performed in  a 20  pL  reaction volume,  and 
preparative digests were performed in a 50 pL volume. All buffers were supplied 
in lOx concentration, and the enzymes stocks contained  10 U of enzyme in each 
pL: One unit of enzyme is defined as the amount needed to digest 1   pg of DNA to 
completion  in  1  hour,  in  the  recommended  buffer,  and  at  the  recommended 
temperature in a 20 pL reaction volume.
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sterile microfuge tube according to the following protocol:
DNA (0.5-1.0 pg) x pL*
lOx buffer 2 pL
Nuclease-free water x pL*
Restriction enzyme 1   pL
Reaction volume 20 pL
*The volume  of DNA  and nuclease-free  water was  adjusted  so  that the 
total reaction volume was 20 pL.
For preparative digests, the following recipe was used to digest 10 pg to 20 pg of 
DNA (in a sterile microfuge tube) for 2 hours at 37.0°C:
DNA (10-20 pg) x pL*
lOx buffer 5 pL
Nuclease-free water x pL*
Restriction enzyme 5 pL
Reaction volume 50 pL
*The volume  of DNA  and nuclease-free  water  was  adjusted  so  that the 
total reaction volume was 50 pL.
After completion of the reaction, the digested DNA fragments were visualised by 
agarose  gel  electrophoresis  and  ethidium  bromide  staining.  The  digested  DNA 
fragments  from  preparative  reactions  were  purified  by  phenol  extraction  and 
ethanol precipitation.
612.2.9  Reverse  Transciptase  Polymerase  Chain  Reaction  (RT- 
PCR)
2.1.9.1  Primers
All oligonucleotide DNA primers were synthesised and purified by reverse-phase 
High  Pressure  Liquid  Chromatography  (HPLC)  by  Thermo  Electron  GmbH, 
Germany. Primers were synthesised to a scale of 0.02 pmoles, and shipped in a 
dry  or  lyophilised  form.  The  oligonucleotide  primers  were  reconstituted  in 
nuclease-free  water  to  100  pM  concentration,  and  stored  at  -20  °C.  These 
oligonucleotide primers were diluted to a final concentration of 10 pM for use in 
PCR amplification reactions,  and all primers were  designed to  anneal  at 60  °C 
during  PCR  amplification.  I  designed the  primers  after visually  examining  the 
nucleotide  sequences that are  accessible on PubMed,  a service provided  by the 
United  States  National  Library  of  Medicine
(http://www.ncbi.nlm.nih.gov/entrez/query.fcgi).  Primer  lengths  were  usually 20 
nucleotide  bases  in length.  All primer pairs were  designed to  span an intron to 
distinguish mRNA from contaminating genomic DNA amplicons. Table 2.2 lists 
the  oligonucleotide  primers  used  in RT-PCR,  nested  RT-PCR  and  quantitative 
RT-PCR reactions.
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Primer 5’ - 3’sequence
Expected size 
(base pairs)
Accession
number
IL-8 2878F CTT TCT GAT GGA AGA GAG CTC RNA 676 
DNA 1090
M28130
IL-8 3968R GT CCT CAC AAC ATC ACT GTG
HD5(i) 1454F CTG AGT CAC TCC AGG AAA G RNA 204 
DNA 1196
M97925
HD5(i) 2636R GGC CAC TGA TTT CAC ACA C
HD5(e) 1412F CCA TCC TTG CTG CCA TTC TC RNA 268 
DNA 1247 HD5(e) 2658R CGA CAG CAG AGT CTG TAG AG
HD6(i) 1493F CAC TGC AGG CAA AAG CTT ATG RNA 241 
DNA 1151
U33317
HD6(i) 2644R CTC TCT GTT CTC ATC CCT C
HD6(e) 147 IF CCA CTC CAA GCT GAG GAT G RNA 314 
DNA 1226 HD6(e) 2697R TAG GAC ACA CGA CAG TTT CC
NOD2 115520F (e) GCG CGA TAA CAA TAT CTC AGA RNA 402 
DNA 6794
AJ303140
NOD2 122313R (e) CAG AGT TCT TCT AGC ATG ACG
NOD2 115545F (i) GGC ATC TGC AAG CTC ATT G RNA 336 
DNA 6714 NOD2 122258R (i) CCA CAC TGC CAA TGT TGT TC
GAPDH 3608F (i) CTT CAC CAC CAT GGA GAA G RNA 488 
DNA 863
J04038
GAPDH 4470R (i) GC TTC ACC ACC TTC TTG ATG
GAPDH 3543F (e) CGA GAT CCC TCC AAA ATC AAG RNA 693 
DNA 1068 GAPDH 461 OR (e) G AGC TTG ACA AAG TGG TCG
Lysozyme 4353F (e) GCT GCA AGA TAA CAT CGC TG RNA 210 
DNA 1060
X14008
Lysozyme 5417R (e) ACC TTT CAC TTA ATT CCT ACT CCC
sPLA2  1422F GCT GTG TCA CTC ATG ACT G RNA 188 
DNA 2348
M22431
J04704 sPLA2  3770R GTA GGT CGT CTT GTT TCT AGC
TLR4 8055F GCC CTA AAC CAC ACA GAA G RNA 270 
DNA 526
AF177765
TLR4 8580R CT GGA TAA ATC CAG CAC CTG
TNFa 1814F GAG TGA CAA GCC TGT AGC CC RNA 265 
DNA 566
AY066019
TNFa 2380R TGG CAG AGA GGA GGT TGA CC
F: forward primer;  R:  reverse primer.  All primers pairs were designed to span 
introns,  and the expected genomic DNA  and mRNA  sizes  (number of nucleotide 
base pairs)  is indicated,  (i) indicates the internal and (e)  the external primer set 
used for nested RT-PCR reactions. All numbers  indicate  the starting nucleotide 
position of the primer, listed according to the GenBank accession number.
63Reagents:
1.  10  pM  sense  and  anti-sense  primers  (Primers  synthesised  by  Thermo 
Electron GmbH, Germany)
2 .  25 mM MgCl2
3.  10  mM  deoxynucleotide  triphosphate  (dNTP)  mix  (containing  10  mM 
dATP, 10 mM dTTP, 10 mM dCTP and 10 mM dGTP)
4.  10X  Qiagen  PCR  Buffer  (Contains  Tris-Cl,  KC1,  (NH^SC^,  15  mM 
MgCb;  pH  8.7.  Manufacturer  does  not  disclose  information  regarding 
concentrations)
5.  5X  Q-Solution  (Qiagen;  manufacturer  does  not  disclose  details  of 
composition)
6 .  Taq polymerase (5U/ pL; Qiagen)
7.  DEPC-treated water
Method:
PCR was performed using the Eppendorf Mastercycler®  Gradient thermocycler 
(Eppendorf Scientific). Each 20 pi PCR reaction contained 2 pi of cDNA,  1   pM 
of sense and anti-sense primer, 1.5 mM MgCk, 5 mM each of dATP, dTTP, dCTP 
and dGTP, 2pl PCR buffer (Qiagen,  Crawley, UK), 4pl  of Q-solution (Qiagen) 
and 0.25U Taq polymerase (Qiagen).  Intron-spanning primer pairs were used to 
amplify  each  cDNA.  RT-PCR  was  performed,  in  a  20  pL  reaction  volume, 
according to the following protocol:
cDNA 2 pL
10 pM primers (sense + anti-sense) 2 pL
25 mM MgCl 1.5 pL
10 mM d NTP mix 1  pL
Taq polymerase (5U/ pL) 0.25 pL
PCR Buffer solution 2 pL
5X Q-Solution 4 pL
DEPC-treated water 7.25 pL
Reaction volume 20.0 pL
64RT-PCR  was  performed  using  the  Eppendorf  Mastercycler®  Gradient 
thermocycler (Eppendorf Scientific). Synthesised cDNA was initially denatured at 
94  °C  for  3  minutes,  and  amplified  using  40  cycles  of denaturation  at  94  °C, 
annealing at 60  °C  for 30 seconds, and extension at 72  °C  for 60  seconds.  The 
amplified  products  were  visualised  on  1.2%  agarose  gel  stained  with  ethidium 
bromide and photographed under UV light.
2.2.9.2 Nested RT-PCR
Nested  RT-PCR  was  used  to  amplify  cDNA  synthesised  from  laser  capture 
microdissection (LCM)-acquired cells. The genes of interest, as well as non-DNA 
control  templates,  were  amplified  by  two  rounds  of  PCR.  The  first-stage 
amplification  was  performed  as  described  above.  Afterwards,  2  pL  of  PCR 
product and non-template control were amplified in the second-stage PCR using 
the same cycling conditions.
NOD2,  HD6  and  GAPDH  mRNA  expression  in  LCM-derived  tissue  were 
determined  by  nested  RT-PCR  using  the  following  internal  intron-spanning 
primer sets for the second-stage PCR: NOD2: 5’-GGCATCTGCAAGCTCATTG- 
3’  and  5,-CACACTGCCAATGTTGTTC-3’;  HD6 :  5’-
CACTGCAGGCAAAAGCTTATG-3’  and  5’-CTCTCTGTTCTCATCCCTC-3’; 
and  GAPDH:  5’-CTTCACCACCATGGAGAAG-3’  and  5’-
GCTTC  ACCACCTTCTTGATG-3 ’.
2.2.9.3 Quantitative RT-PCR: creation of standards
Quantitative  real-time  PCR  was  performed  using  the  Rotor-Gene  amplification 
system  (Biogene,  Kimbolton,  UK).  Each  20pl  PCR  reaction  contained  2pl  of 
cDNA, lpM of sense and anti-sense primer,  1.5mM MgC12, 5mM each of dATP, 
dTTP,  dCTP  and  dGTP,  1   pL  SYBR  green  (Biogene;  final  concentration  1:60 
000),  2pl  PCR buffer  (Qiagen,  Crawley,  UK),  4pl  of Q-solution  (Qiagen)  and
0.25U  Taq  polymerase  (Qiagen).  Intron-spanning  primer  pairs  were  used  to 
amplify each cDNA.
65Relative levels of GAPDH, N0D2, and defensin 6 PCR products were calculated 
according to  the  threshold  cycle  (Ct)  value,  normalized using the  value  of the 
sample with the lowest level of each product, and the data expressed as the ratio 
of NOD2 to GAPDH. Specificity of the desired PCR products was determined by 
melting curve analysis and confirmed by agarose gel electrophoresis and ethidium 
bromide staining.
The threshold cycle (Ct) was defined as the cycle number at which fluorescence 
emission exceeds the fixed threshold.  At the end of each reaction, the recorded 
fluorescence  intensity (Rn)  is used for the following  calculations  by the  Rotor- 
Gene  thermocycler  software:  Rn+  is  the  Rn  value  of a  reaction  containing  all 
components  (the  sample  of  interest);  Rn'  is  the  Rn  value  detected  in  NTC 
(baseline value).  ARn is  the  difference  between Rn+  and  Rn',  and indicates the 
magnitude of the signal generated by the PCR. ARn plotted against cycle numbers 
produces the amplification curves from which the Ct values are derived.
The size of all PCR products was verified by agarose gel electrophoresis and UV 
transillumination.  To  further  confirm  the  specificity  of the  real-time  RT-PCR 
reaction,  the  PCR products  were  screened by melt  curve  analysis.  The  melting 
point of a DNA fragment depends on its individual length and guanine-cytosine 
(G/C) content. Thus, the determination of the individual melting temperature for a 
DNA fragment can be used to characterize the amplification products. The melt 
curve  is  derived  by  plotting  the  first  negative  derivative  (-dF/dT)  against  the 
temperature.  Typically,  small amplitude peaks,  corresponding to primer dimers, 
melt at a lower temperature due to their shorter length, whereas peaks from the 
specific amplification product are of larger amplitude and occur at higher melting 
temperatures.
2.2.9.4  The comparative CT  method (AACT ) for relative quantitation of 
gene expression
Gene expression was quantitated by comparing the Ct values of the samples of 
interest with a control sample, using the comparative Ct method. The CT  values of
66both  the  control  and  samples  of  interest  were  normalised  to  an  endogenous 
housekeeping gene, glyceraldehyde-3-phosphate dehydrogenase (GAPDH).
The comparative Ct method is also known as the 2'A A C T  method, where 
AACt=ACt, sample -  ACt, reference 
Here,  ACt,  sample  is  the  Ct  for  any  sample  normalised  to  the  endogenous 
housekeeping gene (GAPDH) and ACt, reference is the CT value for the control 
also normalised to the endogenous housekeeping gene (GAPDH).
The amplification efficiencies of the endogenous reference and target genes were 
approximately equal, thus ensuring that the AACt calculations were valid. Using 
serial dilutions of GAPDH and NOD2  cDNA, the amplification efficiencies  for 
GAPDH and NOD2 were 99% and 96% respectively.
2.2.10  Quantification  of  NOD2  RNA  by  quantitative  real-time 
PCR
An absolute standard curve method, using serial dilutions of NOD2, was used to 
determine  the  sensitivity  of NOD2  detection  by  PCR.  Using  RT-PCR,  NOD2 
cDNA sequences were  amplified from PBMC-derived cDNA.  These  sequences, 
visualised by  ethidium  bromide  staining after agarose  gel  electrophoresis,  were 
extracted  from  the  gel  using  a  commercial  kit  and  then  quantitated  by 
fluorometry.
2.2.10.1  NOD2 DNA quantitation by fluorometry
DNA concentrations  were  determined by fluorometry using the  fluorescent dye 
bisBenzimide  (Hoechst  33258).  This  dye  binds  to  AT  sequences  in  double 
stranded DNA, and is specific for the quantitation of nanogram amounts of DNA 
(range  10 ng/mL -  10 pg/mL). When excited with 360 nm light, the fluorescence 
emission of the dye at 460 nm increases significantly in the presence of DNA. A 
DNA standard calibration curve was constructed after measuring known amounts 
of calf DNA dissolved in a solution containing bisBenzimide.  The least squares
67regression  equation  derived  from this  standard  curve  was  used  to  calculate  the 
concentration of NOD2 cDNA.
Reagents:
1.  DNA standard (product number D48100) containing  1   mg/mL solution of 
calf thymus DNA in 10 mM Tris HC1, 1  mM EDTA, pH 7.4
2.  bisBenzimide  (Hoechst  33258;  product  number  B1302)  containing  1  
mg/mL bisBenzimide in deionised water
3.  10X Fluorescent Assay Buffer  (product number F7171)  comprising  100 
mM Tris HC1, 10 mM EDTA, 2M NaCl, pH 7.4
Method:
The  bisBenzimide  and  Fluorescent  Assay  Buffer  were  dissolved  in  deionised 
water to prepare a solution containing 2 pg/mL bisBenzimide, 10 mM Tris HC1, 1  
mM  EDTA  and  200  mM  NaCl,  pH  7.4.  DNA  standards  were  prepared  by 
thoroughly dissolving 10, 20, 50,  100, 200, 500 and 1000 ng calf thymus DNA in 
200  pL  freshly prepared  bisBenzimide  solution.  These  solutions,  including  one 
not containing DNA  (‘blank’),  were  added to  separate wells  in a 96-well plate, 
which  was  placed  in  a  fluorometer  with  the  following  settings:  excitation 
wavelength 360 nm and emission wavelength 460 nm. The emissions were read at 
ambient temperature,  and a calibration curve was drawn by plotting total  DNA 
concentration versus relative fluorescent units (RFU) (Figure 2.1).
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Figure  2.1.  Standard  curve  to  determine  DNA  concentrations  using 
fluorometry.
The  least  squares  regression  equation  for  the  line  generated  by  the  standard 
samples  was y  =  13,53^-148.96  where y  is  the  emission  expressed  in  relative 
fluorescent units  (RFU)  and x is the DNA concentration.  The  emission reading 
from 5 pi of NOD2 PCR product dissolved in 200 pL bisBenzimide solution was 
2077 RFU; this meant that each pL of the undiluted NOD2 PCR product solution 
contained approximately 32.92 ng or 8.10 x  101 0  molecules. Next, these NOD2 
molecules were diluted in 100 pL aliquots; the initial aliquot contained  10 pL of 
the undiluted NOD2 PCR product solution and 90 pL water. This and subsequent 
aliquots were diluted ten-fold,  so that 8.10 x  103  NOD2  cDNA molecules were 
present in 100 pL of solution diluted by a factor of 108.
692.3 Collection of cells and tissues for RNA extraction
2.3.1 Collection of intestinal tissue and PBMC
Intestinal tissue and PBMC were collected from patients undergoing treatment at 
the Royal  Free Hospital,  London.  Crohn’s disease-affected tissue  was  collected 
from  patients  undergoing  surgical  resection,  and  normal  small  intestinal  tissue 
was obtained from the surgical resection margins of specimens from patients with 
intestinal  carcinoma  or  benign  intestinal  obstruction,  and  no  clinical  or 
histological  evidence  of  IBD.  Intestinal  tissues  were  placed  in  containers 
containing  ice-cold PBS,  which were  placed in a container  filled with  ice,  and 
transported to the laboratory. PBMC were harvested, using Ficoll density gradient 
centrifugation,  from peripheral blood obtained from healthy volunteers,  or from 
otherwise healthy patients with polycythaemia undergoing venesection (described 
on page  102).  The  project was  approved by the joint Ethics  Committee  of the 
Royal  Free  Hampstead  NHS  Trust  and  Royal  Free  and  University  College 
Medical School (London, UK).
Intestinal  tissue  sections,  from  infants  that  were  treated  for  necrotizing 
enterocolitis  and  intestinal  atresia  at  the  Chris  Hani-Baragwanath  Hospital, 
Johannesburg,  South Africa, were obtained from archived wax-embedded tissue 
blocks. Ethical permission for this study was obtained from the Ethics Committee 
of the University of the Witwatersrand, Johannesburg.
2.3.2 Isolation of crypt and villus epithelial cells
The mucosa was dissected from surgically resected segments of terminal ileum, 
rinsed in lOmM dithiothreitol in PBS for 10 minutes and then incubated in 30mM 
EDTA  for  10  minutes  at room  temperature  to  detach  the  epithelium  from  the 
basement  membrane.  Mucosal  segments  were  pinned  onto  a  corkboard  and 
attached to  a mechanical  shaker, and shaken in aliquots  of ice-cold PBS  for  1- 
minute  periods.  Shaking  initially  detached  epithelial  cells  from  the  villi,  and 
subsequently  from  crypts,  with  intervening  fractions  containing  mixed 
populations, and the composition of each fraction was evaluated microscopically. 
Relative  expression of defensin  6  mRNA,  determined  by  quantitative  real-time 
RT-PCR, was subsequently used to confirm that the villus-derived fractions did
70not contain Paneth cells, while crypt-derived fractions were greatly enriched for 
this  marker.  Epithelial  cells  were  collected  by  centrifugation  at  400g  for  5 
minutes, and lysed in Trizol reagent to extract cellular RNA.
2.3.3 Laser capture microdissection
Terminal  ileal  tissue  was  embedded  in  OCT  compound  (Tissue-Tek,  Sakura 
Finetechnical,  Tokyo,  Japan)  and  stored  at  -70°C.  8pm-thick  sections  were 
mounted  on  uncoated  and  uncharged  slides,  then  fixed  in  70%  ethanol  for  5 
minutes, rinsed in water, and stained with haematoxylin and eosin. Sections were 
dehydrated  in  graded  ethanol  baths  followed by xylene,  and  allowed to  air-dry 
completely. Approximately 250 Paneth cells and villus epithelial cells, separately 
microdissected from the same section, were captured on LCM Transfer Film caps 
(Arcturus  Engineering,  Mountain  View,  California,  USA)  using  the  PixCell  II 
LCM system (Arcturus Engineering). The dissected cells were treated with tissue 
lysis  solution  (20mM  Tris-HCl  pH  8.0,  20  mM  EDTA,  2%  sodium  dodecyl 
sulphate) for 2 minutes, and lysed in Trizol reagent (Life Technologies) to extract 
cellular RNA.
2.3.4 RNA extraction
Reagents:
1.  Trizol® reagent
2.  Isopropanol
3.  70% ethanol
4.  Nuclease-free water 
Method:
RNA extraction from human intestinal tissue, intestinal epithelial cells, peripheral 
blood mononuclear  cells  (PBMC)  and  hepatic  leukocytes  was  performed  using 
Trizol® reagent.  Surgically resected intestinal tissue samples were transferred in 
sterile tubes,  chilled on ice,  from the operating theatre to the  laboratory,  where 
samples were  stored at -80°C.  For RNA extraction, these tissues were removed 
from  storage  and crushed using a pestle  and mortar filled with liquid nitrogen.
71Alternatively, the frozen tissue was homogenised using a power homogeniser.  100 
mg of crushed or homogenised tissue was lysed using 1  mL Trizol reagent.
For  RNA  extraction  from  intestinal  epithelial  cells  grown  in  monolayer,  the 
culture  medium was  removed from the  culture  flasks,  and the  cells  were twice 
washed  with  PBS.  After  removing  the  PBS,  the  cells  were  lysed  with  Trizol 
reagent:  1  mL Trizol was added per 10cm  surface area of the culture dish. As an 
example, for intestinal epithelial cells cultured in 6-well plates (surface area 9.6 
cm  per  well),  1   mL  Trizol  was  added  to  each  well.  The  Trizol-filled  culture 
dishes were  left on ice for  1   minute, to allow for cell  lysis,  and the  lysate was 
transferred to clean microfuge tubes, and stored at -20°C.
For RNA extraction from PBMC  cultured in 6-well plates,  the  culture  medium 
containing  non-adherent  lymphocytes  was  transferred  to  clean  microfuge  tubes 
and centrifuged at 13 000 rpm (16  100 g) for 5 minutes at 4°C. After discarding 
the supernatant, the lymphocyte pellet was lysed using 400 pL Trizol reagent. The 
remaining  adherent  mononuclear  cells  in  the  6-well  culture  plates  were  lysed 
using  600  pL  Trizol,  and  this  solution  was  transferred  to  the  microfuge  tubes 
containing the lysed lymphocytes so that the entire cell lysate was present in 1  mL 
Trizol reagent.
For RNA extraction, microfuge tubes containing cell and tissue samples, in 1   mL 
Trizol  reagent,  were  incubated  at  room  temperature  (typically  22  °C)  for  5 
minutes.  Next,  400  pL  chloroform  was  added to  each  tube,  and  mixed  for  15 
seconds  using  a  vortex  mixer.  The  samples  were  then  incubated  at  room 
temperature  for  2  minutes,  and  centrifuged  at  14  000  rpm  (20  817  g)  for  10 
minutes  at  4  °C  to  allow  for phase  separation.  The  upper  or  RNA-containing 
aqueous phase was removed by careful aspiration, taking care to avoid the protein 
interface,  and  transferred  to  fresh  tubes  containing  600  pL  isopropanol.  After 
mixing  the  contents,  the  sample  was  incubated  at  room  temperature  for  10 
minutes to allow for RNA precipitation. Next, the tubes  were  centrifuged at  14 
000  rpm  (20  817  g)  for  10  minutes  at  4  °C  to  collect  the  RNA  pellet.  After 
discarding the supernatant, the RNA pellet was washed in 750  pL  70% ethanol
72and the tubes were centrifuged at 14 000 rpm (20 817 g) for 10 minutes at 4 °C. 
After discarding the supernatant, the RNA pellet was air dried and resuspended in 
22 pL nuclease-free water. 20 pL of RNA solution was used for cDNA synthesis, 
and  2  pL  of  solution  used  to  quantify  and  assess  RNA  integrity  by 
spectrophotometry and agarose gel electrophoresis.
2.3.5 Synthesis of cDNA
Reagents:
1.  OHgo(dT)i2-i8 primer (0.5 pg/pL; Invitrogen Life Technologies)
2.  lOmMdNTP
3.  5X First Strand Buffer [250 mM Tris-HCl (pH 8.30, 375 mM KC1, 15 mM 
MgCh; Invitrogen Life Technologies]
4.  Moloney  Murine  Leukemia  Virus  Reverse  Transcriptase  (M-MLV  RT) 
(200 units/pL; Invitrogen Life Technologies)
5.  Nuclease-free water 
Method:
For cDNA synthesis, 2 pg of total RNA, in 20 pi of nuclease-free water, and 0.5 
pg oligo(dT) primer (Life Technologies Ltd), were heated to 65° C for 5 minutes 
and rapidly cooled on ice. Reverse transcription was performed at 37.0°C  for 2 
hours, in a 50 pi volume comprising 50 mM Tris-HCl pH 8.3, 75 mM KC1, 3 mM 
MgCl2,  0.5  mM  each  of dATP,  dTTP,  dCTP  and  dGTP,  and  800  U  Moloney 
murine leukemia virus reverse transcriptase (MMLV-RT; Life Technologies Ltd). 
cDNA  synthesis  was  performed,  in a 50  pL  reaction volume,  according  to  the 
following protocol:
RNA (2 pg) 20 pL
Oligo(dT) primer 1  pL
10 mM dNTP 2.5 pL
5X First Strand buffer 10 pL
MMLV-RT 4 pL
Nuclease-free water 12.5 uL
Reaction volume 50.0 pL
Synthesised cDNA was stored at -20°C.
732.3.6. In situ hybridisation
2.3.6.1  Ligation of cDNA into plasmid vectors
Reagents:
T4 DNA Ligase (5 U/ pL; Fermentas)
10X Ligation buffer: 400 mM Tris-HCl,  100 mM MgCl2,  100 mM DTT,  5 mM 
ATP (pH 7.8)
Method:
A  234  base  pair  sequence  of the  human TNFa  gene,  obtained  by  digestion of 
human  TNFa  cDNA  sequence  with  the  restriction  enzyme  PvuII  (nucleotide 
position  452  to  6 8 6;  NCBI  accession  number  Ml0988),  was  ligated  into  the 
multiple  cloning  site  of the  pPCR  Script Amp  SK(+)  vector  (Stratagene).  The 
TNFa cDNA sequence was obtained from Dr.  Satish Keshav. The pPCR Script 
Amp vector was initially linearised by digestion with the restriction endonuclease, 
Smal.  Both  plasmid  and  TNFa  DNA  were  purified  by  phenol  extraction  and 
ethanol precipitation prior to use in the ligation reactions.
The  ligation reactions  were  performed  in a  10  pL  reaction volume  comprising 
lOng pPCR-Script Amp plasmid DNA (pre-digested with Smal), 20 ng 234 base 
pair-TNFa cDNA, 40 mM Tris-HCl,  10 mM MgCl2,  10 mM DTT, 0.5 mM ATP, 
5 U T4 DNA ligase. The reaction mixture was incubated at 16.0°C for 16 hours, 
and the ligation products transformed into competent cells.
HD-5 and HD-6 cDNA sequences were synthesised by RT-PCR amplification of 
terminal  ileal  RNA.  Restriction  sites  for  the  enzymes  Hindlll  and  PstI  were 
incorporated into the oligonucleotide primer designs. The following primers were 
used for HD-5  amplification:  5’-GAAG AAGCTT  CTG AGT CAC TCC AGG 
AAA G-3’  (sense strand primer) and 5’-GAAG CTGCAG GGC CAC TGA TTT 
CAC ACA C-3’  (anti-sense strand primer). The following primers were used for 
HD-6 amplification: 5’- GAAG AAGCTT CCA CTC CAA GCT GAG GAT G-3’ 
(sense strand primer) and 5’- GAAG CTGCAG GGA CAC ACG ACA GTT TCC 
TT-3’ (anti-sense strand primer).
74After  amplification  of HD-5  and HD-6  cDNA  by  RT-PCR,  the  PCR  products 
were  extracted  from  agarose  gels  and  purified.  The  HD-5  and  HD-6  cDNA 
sequences  were  digested  with  restriction  enzymes  Hindlll  and  Pst,  and  then 
purified. 30 ng of HD-5 and HD-6 cDNA and 10 ng of pPCR-Script Amp plasmid 
DNA  (pre-digested with Hindlll  and PstI,  and purified)  were  used  for  ligation 
reactions (described above).
DH5a  competent  cells  were  transformed  with  ligation  products,  and  plasmid 
containing-strains were selected for ampicillin sensitivity and X-gal/ IPTG colour 
selection.  DNA  minipreparations  of  plasmid  DNA  was  performed,  and  the 
identity of the cloned DNA sequences verified by restriction mapping and DNA 
sequencing.
The following vectors were previously constructed by my supervisor, Dr Satish 
Keshav:  the  plasmid  vector,  pGEM-3  (Promega),  containing  the  subcloned 
lysozyme sequence (Chung  1988, Keshav  1991); the plasmid vector, pBluescript 
II KS + (Stratagene), containing the subcloned secretory phospholipase A2 Group 
IIA (5PLA2) sequence (Keshav  1997). The NOD2  sequence was cloned into the 
pPCR-Script Amp (Stratagene) vector.
Plasmids, containing the subcloned sequences in the multiple cloning sites, were 
linearised by restriction enzyme digestion. Restriction nucleases were chosen to 
cleave  DNA  so  that  subcloned  sequences  remained  in  continuity  with  RNA 
polymerase  transcription  start sites.  The  linearised plasmids  were  visualised  by 
agarose gel electrophoresis and UV transillumination to verify complete digestion 
by  restriction  nucleases.  The  linearised  plasmids  were  purified  by  phenol: 
chloroform extraction and ethanol precipitation. A list of restriction nucleases and 
corresponding  RNA  polymerases  used  initiate  transcription,  is  shown  in  Table 
2.3.
75Table 2.3. Vector constructs for in vitro riboprobe transcription
Construct 
(Parent vector/ 
subcloned cDNA 
sequence)
Probe Length (base pairs)
Restriction
endonuclease
RNA
polymerase
pGEM-LYZ 
(pGEM-3/ Lysozyme)
738 (corresponding to nucleotide 
positions 1  to 738; NCBI 
accession number J03801)
EcoRI Sp6
Hindlll T7
pBS-PLA2 IIA 
(pBluescript IIKS +/ 
sPLA2 IIA)
402 (corresponding to nucleotide 
positions 525 to 927; NCBI 
accession number NM  000300)
SstI T3
Hindlll T7
pPCR-TNFa 
(pPCR-Script Amp/ 
TNFa)
234 (corresponding to nucleotide 
positions 452 to 686; NCBI 
accession number Ml0988)
Eel 13611 T7
EcoRI T3
pPCR-NOD2 
(pPCR-Script Amp 
/NOD2)
220 (corresponding to nucleotide 
positions 4117 to 4337; NCBI 
accession number NM  022162)
Eel 13611 T7
EcoRI T3
pPCR-HD-5 
(pPCR-Script Amp /HD- 
5)
204 (corresponding to nucleotide 
positions 94 to 997; NCBI 
accession number BC069690)
PstI T7
Hindlll T3
pPCR-HD-6 
(pPCR-Script Amp /HD- 
6)
278 (corresponding to nucleotide 
positions 136 to 413; NCBI 
accession number BC069728)
PstI T7
Hindlll T3
7623.6.2  Transcription of digoxigenin-labelled riboprobes
Reagents:
1.  DIG RNA labelling Kit (Roche) comprising:
a.  10X  labelling  mix  (Roche):  10  mM  ATP,  10  mM  CTP,  10  mM 
GTP,  6.5  mM UTP,  3.5  mM digoxigenin-1 l-2'-deoxy-uridine-5'- 
triphosphate (DIG-11-UTP); pH 7.5
b.  10X  transcription  buffer  (Roche):  400  mM  Tris-HCl  pH  8.0;  60 
mM MgC12, 100 mM DTT, 20 mM spermidine
c.  RNA polymerases (Sp6, T3 and T7)
2.  Nuclease-free water
3.  DNase 1  (10 U/pL; RNase-free)
4.  0.2 M EDTA (pH 8.0)
5.  3M sodium acetate (pH 5.2)
6.  1 0 0% ethanol
Method:
Digoxigenin-labelled  riboprobes  were  transcribed  in  a  50  pL  reaction  volume 
containing  1   to 5 pg linearised DNA,  1   mM ATP,  1   mM CTP,  1   mM GTP, 0.65 
mM UTP, 0.35  mM DIG-11-UTP, 40 mM Tris-HCl (pH 8.0),  6 mM MgCl2,  10 
mM DTT, 2 mM spermidine, and 40 U RNA polymerase (either Sp6, T3, or T7). 
The following protocol was used for in vitro transcription of digoxigenin-labelled 
riboprobes:
Linearised plasmid DNA (1 -5 pg) pL*
Nuclease-free water pL*
10X labelling mix 5 pL
10X transcription buffer 5 pL
Sp6/ T3/ T7 (20 U/ pL) 2 pL
Final volume 50 pL
* Adjusted to ensure a final reaction volume of 50 pL
The reaction mixture was set-up in a nuclease-free microfuge tube placed in ice, 
and then incubated at 37 °C. After 60 minutes of incubation, 20U of polymerase
77(1  pL) was added to the reaction mixture, and reaction mixture  incubated for a 
further  60  minutes.  After  removing  2  pL  of sample  volume  for  analysis  (to 
visualise the DNA template), the DNA template  was removed by  adding 20  U 
DNase 1  (10 U/pL; RNase-free) to the reaction volume, which was then incubated 
at 37°C for 15 minutes. A further 4 pL of the reaction volume was removed (2 pL 
to assess probe integrity using gel electrophoresis and UV transillumination; 2 pL 
for dot-blot quantitation). Thereafter, 2 pL of 0.2M EDTA was added to the tube 
to  stop  the  reaction.  The  contents  of  the  tube  were  collected  by  brief 
centrifugation and 51  pL of nuclease-free water was added to the reaction mixture 
to  adjust  the  volume  to  100  pL.  The  riboprobes  were  stored,  as  an  ethanol 
precipitate, at -20°C after adding 10 pL 3M sodium acetate (pH 5.2) and 250 pL 
100% ethanol to the reaction mixture. Riboprobes were stably stored at -20 °C for 
12  months.  For  in  situ  hybridization,  the  riboprobes  were  re-suspended  in 
nuclease-free water and then added to the hybridization mixture.
2.3.6.3  Quantitation of digoxigenin-labelled riboprobes
Following  transcription,  the  integrity  of the  riboprobes  and  the  DNA  template 
(before and after DNase I digestion) was verified by agarose gel electrophoresis, 
and the digoxigenin-labelled riboprobes were quantified by ‘dot-blot’ analysis, an 
immunologic  detection  of riboprobes  blotted  onto  a  neutral  nylon  membrane 
(Hybond™-NX, Amersham). The concentration of the transcribed riboprobes was 
also estimated by agarose gel electrophoresis.
Reagents:
1.  Neutral nylon membrane (Hybond™-NX, Amersham)
2.  RNA standards (100 ng/ mL; Roche)
3.  Washing buffer (pH  7.5):  0.1  M Maleic  acid,  0.15  M NaCl,  0.3%  (v/v) 
Tween 20; pH 7.5. pH adjusted with NaOH pellets and solution stored at 
room temperature.
4.  Maleic acid buffer: 0.1 M Maleic acid, 0.15 M NaCl; pH 7.5. pH adjusted 
with NaOH pellets and solution stored at room temperature.
785.  Detection buffer:  0.1M Tris-HCl,  0.1M NaCl;  pH 9.5.  pH  adjusted with 
NaOH pellets and solution stored at room temperature.
6.  10X  Blocking  solution:  Blocking  reagent  (Roche;  composition  not 
disclosed by manufacturer) was dissolved in maleic acid buffer to a final 
concentration  of 10%  (w/v).  This  solution was  autoclaved  and  stored at 
4°C.  IX Blocking solution was freshly prepared by diluting 10X blocking 
reagent ten-fold in maleic acid buffer.
7.  Antibody solution: An antibody solution was freshly prepared by diluting 
an alkaline phosphatase conjugated anti-digoxigenin antibody (150 U/ 200 
pL;  Roche)  5  000-fold  in blocking  solution to  achieve  a  final  antibody 
concentration of 150 mU/mL.
8.  Colour substrate solution:  This solution, which was protected from light, 
was freshly prepared by dissolving 200pL of NBT/BCIP stock solution in 
lOmL  of  detection  buffer.  NBT/BCIP  stock  solution  (Roche)  contains 
18.75 mg/mL NBT (Nitro blue tetrazolium chloride) and 9.4 mg/mL BCIP 
(5-Bromo-4-chloro-3-indolyl  phosphate,  toludine  salt)  in  67%  DMSO 
(v/v).
Procedure:
Known  concentrations  of RNA  solutions,  or RNA  standards,  ranging  from  1.5 
pg/pL to 1  ng/pL, were prepared by dissolving control RNA (100 ng/mL; Roche) 
in DEPC-treated water.  Similar dilution series were prepared for the transcribed 
riboprobes and RNA standards, and are shown in Table 2.4.
79Table 2.4. Riboprobe dilution series for dot-blot quantitation
Aliquot
number
Dilution factor
RNA concentration
i 1:100 1  ng/mL
A 1 :1000 100 pg/mL
B 1:2000 50 pg/mL
C 1:4000 25 pg/mL
D 1:8000 12.5 pg/mL
E 1:16000 6.25 pg/mL
F 1:32000 3.13 pg/mL
G 1:64000 1.56 pg/mL
One  pL  from each dilution sample was blotted onto  a neutral nylon membrane 
and  allowed  to  dry.  The  RNA  was  cross-linked  to  the  membrane  by  UV 
irradiation at 245 nm for 2 minutes at 1.5 J/cm .
Using a plastic box and shaking platform, the nylon membrane  (8  cm by  8 cm) 
was  twice  rinsed  with  washing  buffer  for 2  minutes.  The  membrane  was  then 
incubated with 20  mL  blocking  solution for 30  minutes,  and  then with 20  mL 
antibody solution for 30 minutes. The membrane was then twice washed with 50 
mL  washing  buffer  and  left  to  soak  in  20  mL  detection  buffer  for  5  minutes. 
Finally, the membrane was covered with 10 mL colour substrate solution and the 
plastic  box  was  removed  from  the  shaking  platform  and  covered  with  foil  to 
protect the membrane from light.  The membrane was incubated with the colour 
substrate  solution  for  16  hours  and  the  reaction  was  stopped  by  rinsing  the 
membrane in distilled water.
The  quantity  of  transcribed  riboprobe  was  estimated  by  visual  colorimetric 
analysis, and an example is shown below (Figure 2.2):
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Figure  2.2.  Dot  blot  quantitation  of digoxigenin-labelled  riboprobes. A  dot
blot  used  for  the  quantitation  of  digoxigenin-labelled  riboprobes  shows 
decreasing  intensity  of staining  of standard quantities  of digoxigenin-labelled 
RNA in the top row.  The concentration of transcribed riboprobes is determined by 
matching the  intensity of staining of the  transcribed riboprobes to  the staining 
intensity of the standards, and adjusting  for the dilution  factor.
812.3.6.4  In situ hybridisation
Reagents:
1.  10% neutral buffered formalin
2.  Poly-l-lysine-coated slides
3.  Xylene
4.  100% ethanol; also diluted with DEPC-treated water to prepare 95%, 80%, 
70%, 60%, 40%, and 20% ethanol solutions
5.  4% paraformaldehyde in phosphate buffered saline (PBS)
6.  Phosphate buffered saline (PBS)
7.  0.2 M hydrochloric acid (HC1)
8.  Proteinase K buffer: lOOmM Tris-HCl pH 7.4, 5mM EDTA
9.  Proteinase K
10. Deionised formamide
11. 50% dextran sulphate (Amersham Biosciences, Little Chalfont, UK))
12. 5 M NaCl
13. 1  M Tris-HCl pH 7.2
14. 1  M sodium phosphate buffer pH 6.8 
15.500 mM EDTA pH 8.0
16. 50X Denhardt’s solution:
17.  1  M dithiothreitol (DTT)
18. 10 mg/mL tRNA (Roche Diagnostics)
19. 20X saline-sodium citrate (SSC) solution:  175.3g NaCl and 88.2g Sodium 
Citrate were dissolved in distilled water, and the  solution pH adjusted to 
7.0 with NaOH.  The final volume was adjusted to  1   L,  and the  solution 
sterilised by autoclaving
20. NTE solution: 500 mM NaCl, 1  mM EDTA, 10 mM Tris-HCl pH 7.4
21. 20 mg/ mL RNase A
22. Human, horse and rabbit serum
23. Mouse anti-digoxigenin monoclonal antibody (Roche Diagnostics)
24. Biotinylated anti-mouse antibody (Vector Laboratories, Burlingame,  CA, 
USA)
25. avidin-biotin peroxidase complex (ABC) reagent (Vector Laboratories)
82Method:
Preparation of slides and fixation of material:
Resected surgical tissues were fixed overnight in  10% neutral buffered formalin, 
and embedded  in paraffin wax  blocks.  Tissue  sections,  of 8  micron thickness, 
were cut using a microtome, and placed on Poly-L-Lysine coated slides (VWR). 
These slides were either dried at 37°C for 4-8 hours or air-dried for  16 hours at 
room temperature, and stored at room temperature until further use.
Pre-treatments of materials on slides:
Tissue  sections  were  dewaxed  with  fresh  xylene  by  placing  the  slides  in  a 
Schieferdecker jar that filled with xylene. Three washes, with fresh xylene, lasting 
20  minutes  each,  were  performed  using  a rocking platform.  The  sections  were 
then rehydrated to water through graded ethanol baths by twice washing them in 
100% ethanol for 5 minutes, in 95% ethanol for 5 minutes, in 70% ethanol for 5 
minutes,  and  finally,  twice  in  DEPC-treated  water  for  5  minutes.  The  tissue 
sections  were  fixed  using  4%  paraformaldehyde  in  phosphate  buffered  saline 
(PBS) for 20 minutes at room temperature. The sections were twice rinsed in PBS 
for 5 minutes, treated with 0.2M HC1 for 20 minutes and rinsed in DEPC-treated 
water.  The  sections  were  soaked  in  lOOmM  Tris-HCl  pH  7.4,  5mM  EDTA 
(Proteinase K buffer) for 5 minutes, and treated with Proteinase K (40pg/ml) in 
the same solution at 37°C for 15 minutes precisely. The sections were rinsed with 
Proteinase K buffer, and twice washed in PBS for 5 minutes. Next, tissue sections 
were  dehydrated  through  a  series  of graded  ethanol  baths  by  washing,  for  2 
minutes each, in 20%, 40%, 60%, 80% and 100% ethanol solutions.
In situ hybridisation:
The slides were removed from the Schieferdecker jar, allowed to air dry briefly, 
and placed in an airtight, humidified incubation box. Each section was coated with 
50-150 pL of hybridisation mixture, depending on the size of the tissue section. 
Hybridization  mixture  containing  eitherNOD2  (1.0  ng/pl),  TNFa  (2.0  ng/pl), 
lysozyme (1.4 ng/pl),  5PLA2 (0.7 ng/pL), HD5  (1.0 ng/pl), or HD6 (1.0 ng/pl), 
riboprobes  were  pipetted  directly  onto  the  sections.  Both  anti-sense  and  sense 
(control)  strand  riboprobes  were  used  for  hybridisation.  These  probe
83concentrations  were  determined  empirically  beforehand.  The  hybridization 
mixture comprised 50% deionised formamide,  10% dextran sulphate (Amersham 
Biosciences),  300mM NaCl,  lOmM Tris-HCl pH  7.2,  lOmM  sodium phosphate 
buffer pH 6.8, 5mM EDTA pH 8.0,  IX Denhardt’s solution, 50mM dithiothreitol 
and  1  mg/mL tRNA (Roche Diagnostics).  Slides were hybridized at 42°C for  16 
hours in an airtight, humidified container.
Post-hybridisation washes:
Following hybridisation,  the  slides  were  removed  from  the  incubation box  and 
placed in a Schieferdecker jar. These hybridized sections were twice washed, with 
constant agitation for  15  minutes  in a shaking water bath,  in 2X  saline-sodium 
citrate (SSC) solution and rinsed in 500mM NaCl,  lOmM Tris-HCl pH 7.4,  ImM 
EDTA  (NTE  solution)  at 37°C.  The  sections were then treated with 20  pg/mL 
RNase  A  in NTE  solution  for  30  minutes  at  37°C,  and  rinsed  in NTE  buffer. 
Stringency washes were performed by rinsing the sections, with constant agitation 
in a shaking water bath,  in 0.2X SSC at 37°C  for 30 minutes, followed by two 
washes in 0.2X SSC at 42°C for 30 minutes.
Immunohistochemistry:
Following  the  stringency  washes,  the  sections  were  washed  in  PBS  for  10 
minutes.  The  slides were removed from the  Schieferdecker jar and mounted on 
Sequenza  Coverplates™  that  were  placed  in  Sequenza  slide  racks  (Thermo 
Electron, Hemel Hempstead, United Kingdom).  Sections were covered with  1% 
human and  1%  horse  serum  in PBS  (blocking  solution)  for  30  minutes,  rinsed 
with PBS and then incubated with a mouse anti-digoxigenin monoclonal antibody 
(Roche  Diagnostics)  for  90  minutes  at  room  temperature.  Sections  were  then 
rinsed in PBS, covered with blocking solution for 30 minutes, and rinsed again in 
PBS  before  incubation  with  a  biotinylated  anti-mouse  antibody  (Vector 
Laboratories, Burlingame, CA, USA) for 30 minutes.  Sections were then rinsed 
PBS, and covered with blocking solution for 30 minutes, rinsed again in PBS and 
incubated  with  the  avidin-biotin  peroxidase  complex  (ABC)  reagent  (Vector 
Laboratories) for 30 minutes, and then rinsed in PBS.  The  slides were removed 
from  the  Sequenza  Coverplates  and the  sections  were  covered  with  a  solution
84containing  0.7mg/ml  diaminobenzidine  (DAB)  and  0.02%  hydrogen  peroxide. 
The  sections  were  periodically  examined under  the  microscope  to  monitor the 
development of the brown precipitate. The reaction was terminated at the  same 
time for all slides in a single experiment, by rinsing the  slides in PBS.  Sections 
were  counterstained  with  haematoxylin  for  5  seconds  and  mounted  under 
coverslips with DPX.
All  glassware  used  for  in  situ  hybridization  was  baked  at  200°C  for  14  hours 
beforehand,  and  RNase-ffee  chemicals  were  obtained  from  Sigma  Chemical 
Company, Poole, UK, except where otherwise indicated. All water used in these 
experiments  was  treated  with  diethyl-pyrocarbonate  to  eliminate  RNase 
contamination.
852.3.7 Northern blotting/ hybridisation
Northern  hybridisation  is  used  to  measure  the  amount  and  size  of  RNA’s 
transcribed from eukaryotic genes and to estimate their abundance.
Reagents:
1.  50X  Denhardt’s  solution:  2  g  Ficoll  400  (Sigma),  2  g  polyvinyl 
pyrrolidone,  and  2  g  bovine  serum  albumin  were  dissolved  in  200  mL 
DEPC-treated  water  using  a  heat-sterilised  magnetic  stirrer-bar.  The 
solution was filter-sterilised and stored in aliquots at -20.0°C.
2.  Ethidium bromide (200 pg/ml)
3.  37 % Formaldehyde
4.  Formamide
5.  10X  Formaldehyde  gel-loading  dye:  50%  glycerol,  10  mM  EDTA  (pH 
8.0), 0.25% (w/v) bromophenol blue, and 0.25% (w/v) xylene cyanol FF. 
The following protocol was used to prepare  1   mL of 10X formaldehyde 
gel-loading buffer:
Glycerol  500 pL
0.5M EDTA (pH8.0)  20 pL
2.5% (w/v) bromophenol blue 100 pL 
2.5% (w/v) xylene cyanol  100 pL
Nuclease-free water  280 uL
Final volume  1000 pL
6.  10X MOPS electrophoresis buffer: 0.2 M MOPS (pH 7.0), 20 mM sodium 
acetate,  10  mM  EDTA  (pH  8.0).  10X  MOPS  buffer  was  prepared  by 
dissolving  41.8  g  of MOPS  in  700  mL  DEPC-treated  water,  and  the 
solution pH adjusted to 7.0 with 2N NaOH. 20 mL 1M sodium acetate and 
20  mL  0.5M EDTA  (pH  8.0)  were  added to  the  solution,  and the  final 
volume adjusted to  1000 mL with DEPC-treated water. The solution was 
passed through a 0.45 pm filter, and stored at room temperature protected 
from light.
7.  0.05 M NaOH
8.  0.5 M Tris (pH 7.4)
869.  DEPC-treated water
10. Neutral nylon membrane (Hybond™-NX; Amersham Biosciences)
11. 20X, 6X and 2X SSC buffer
2.3.7.1  Separation of RNA through a denaturing gel
A 1.5% agarose gel, containing 2.0 M formaldehyde, was prepared by dissolving
1.5 g agarose in 85 mL water. This solution was heated, using a microwave oven 
(for 3  minutes using the  low power setting), and cooled to  50  °C.  10 mL  10X 
MOPS buffer and 5.4 mL formaldehyde (37%) was added to the solution, which 
was cast in a horizontal electrophoresis box that was  specifically used for RNA 
analysis. The gel was allowed to set at room temperature and, once polymerised, 
was covered with IX MOPS solution to a depth of 5 mm. The gel was run for 5 
minutes at 65 V (5 V/ cm) prior to loading the RNA samples.
The  RNA  samples  were  denatured  in  nuclease-free  microfuge  tubes  in  the 
following manner. 40 pg RNA, dissolved in 8 pL nuclease-free water, was added 
to  a  nuclease-free  microfuge  tube  containing  6  pL  10X  MOPS  buffer,  10  pL 
formaldehyde and 30 pL formamide (37%). This mixture was heated to 65 °C for 
5 minutes and briefly cooled on ice. After brief centrifugation (16  100 g for  15 
seconds) to collect the contents, 6 pL of 10X formaldehyde gel-loading dye was 
added to the reaction mixture. Next, 30 pL (containing 20 pg total RNA) of the 
reaction mixture was loaded into each well. The gel was run at 65 V (5 V/ cm) for 
five  hours,  at  which  stage  the  dye  front  had  migrated  approximately  10  cm. 
Electrophoresis  was  stopped  and  the  gel  rinsed  in  DEPC-treated  water  for  5 
minutes. Next, the gel was denatured in 0.05 M NaOH for 30 minutes, and then 
washed in DEPC-treated water for 5 minutes. The gel was then neutralised in 0.5 
M Tris (pH  7.4)  for  1   minute, washed briefly in DEPC-treated water,  and then 
soaked in 2X SSC for 30 minutes. The gel was briefly illuminated under UV light 
to visualise the RNA.
872.3.7.2  Transfer of RNA to a solid support
A neutral nylon membrane (Hybond™-NX), cut to match the size of the gel, was 
briefly rinsed in DEPC-treated water and soaked in 2X SSC buffer for 5 minutes. 
The RNA was transferred from the gel to the nylon membrane using an upward 
capillary transfer system, which was  assembled as  described below.  Absorbent, 
but firm, sponge sheets were placed in a glass reservoir containing 20X SSC. The 
gel was placed on filter paper sheets, pre-wet with 2X SSC solution, which were 
placed on the sponge supports. The nylon membrane was carefully aligned over 
the gel, and filter paper sheets, pre-wet with 2X SSC solution, were placed on the 
gel. Next, dry paper towels were placed over the sheets of filter paper, and a glass 
plate,  supporting  a  weight,  was  placed  over  the  dry  paper  towels.  The  nylon 
membrane, filter sheets and paper towels were all cut to match the size of the gel, 
and no air bubbles were present between the  sheets of filter paper, between the 
filter paper and the gel, and between the gel and nylon membrane. The assembly 
was carefully constructed to ensure the filter paper and dry towels placed on top 
of the gel did not droop over the edges of the gel and touch the  solution in the 
glass  reservoir.  The  assembly  schema  for  upward  capillary  transfer  system  is 
shown in Figure 2.3.
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Figure 2.3. Assembly schema for upward capillary transfer system.
88The RNA was transferred (for 16 hours) from the gel to the membrane by upward 
capillary transfer using SSC as a transfer buffer.
2.3.7.3  Fixation of RNA to the solid matrix
After transfer, the capillary assembly was disassembled, and the nylon membrane 
was rinsed  in 6X  SSC  buffer for  5  minutes.  The RNA  was  cross-linked to the 
membrane  by  UV  irradiation  at  245  nm  for  2  minutes  at  1.5  J/cm .  The 
formaldehyde  gel  was  visualised  under  UV  light  to  verify  that  the  RNA  had 
transferred from the gel.
892.3.7.4  Hybridisation  of  the  immobilized  RNA  to  probes 
complementary to the sequence of interest
Reagents:
1.  5X OLB  Buffer:  5  mM dATP,  5  mM dTTP,  5  mM dGTP,  1M HEPES, 
250 mM Tris HC1 (pH 8.0), 25 mM MgCl2, 100 mM NaCl, 10 mM DTT
2.  32P  dCTP  (10 mCi/mL)  (Redivue deoxycylidine  5’  [a  32P]  triphosphate, 
triethylammonium salt; 1  lTBq/mmol, -3000 Ci/mmol)
3.  BSA (10 mg/mL; Sigma)
4.  Klenow Fragment of DNA polymerase (2 U/pL)
5.  Random hexamers (132 ng/pL)
6.  Nuclease free water
7.  tRNA (10 mg/mL)
8.  5M ammonium acetate (CH3COONH4)
9.  100% ethanol
10. TE buffer (pH 7.6)
11. Pre-hybridisation  solution:  50%  deionised  formamide,  1M NaCl,  0.02% 
(v/v) SDS, 5X Denhardt’s solution, 8 mg salmon sperm DNA,  10% (w/v) 
dextran sulphate. The pre-hybridisation buffer was mixed by boiling, and 
then cooled on ice. The following protocol was used to prepare 40 mLs of
pre-hybridisation buffer:
NaCl  2.34 g
5OX Denhardt’s solution  4 mL
Formamide  20 mL
50% Dextran sulphate  8 mL
10% SDS  400 pL
Salmon sperm DNA (10 mg/mL)  600 pL
DEPC-treated water  7 mL
12.  2X SSC, 0.1% SDS and 0.2X SSC, 0.1% SDS solutions 
Methods:
The nylon membranes were hybridised with probes to locate GAPDH and NOD2 
RNA.  The  32P-labelled  DNA  probes  were  prepared  in  a  dedicated  laboratory
90reserved  for  the  handling  of radioactive  reagents,  and  appropriate  precautions 
were taken when handling  P.
GAPDH and NOD2 PCR products, gel-extracted and purified, were used as DNA 
templates for random primed DNA labelling. A microfuge tube, containing 50 ng 
of DNA and 1  pL random hexamers (132 ng/ pL, Invitrogen) dissolved in 13.5 pL 
nuclease-free water, was heated at 95°C for 5 minutes and then rapidly cooled on 
ice. Next, 32P-labelled GAPDH and NOD2 DNA probes were  synthesised in 25 
pL  reaction  volume  containing  10  pg  bovine  serum  albumin,  5  pL  5X  OLB 
buffer,  2  U Klenow fragment and 25  pCi  32P-dCTP  (1.3  x  108   cpm/  pg)  were 
synthesised using random hexamers. The reaction mixture was incubated at room 
temperature  for  16  hours.  The  following  protocol  was  used  to  synthesise  the 
probes:
Random hexamers  1   pL (132 ng/pL)
DNA (50 ng)  x pL*
Nuclease free water  x pL*
BSA (10 mg/mL)  1   pL
5X OLB Buffer  5 pL
Klenow (2 U/ pL)  1  pL
32P dCTP (10 mCi/mL)  2.5 uL
Final volume  25 pL
* Adjusted to 25 pL final reaction volume.
Following random priming, transfer RNA was added to the reaction mixture, and 
the labelled probes were precipitated using ammonium acetate. 6 pL transfer RNA 
(10 mg/mL)  and 269  pL  nuclease-free water were  added to the microfuge tube 
which was gently shaken to mix the contents. Next, 30 pL 5 M ammonium acetate 
and  750  pL  100%  ethanol  were  added  to  the  microfuge  tube  and  probe  was 
precipitated on dry ice for 60 minutes. The microfuge tube was centrifuged at 13 
000 rpm (16  100 g) for 10 minutes, and the supernatant carefully transferred to a 
separate microfuge tube. The pellet was washed in 500 pL 70% ethanol, and the 
microfuge tube was centrifuged at  13  000 rpm (16  100 g) for  10 minutes. After
91carefully  aspirating  the  supernatant,  the  pellet  was  briefly  air-dried  and  re­
suspended in 100 pL TE buffer (pH 7.6).
Using a  scintillation  counter,  the  radioactivity  counts  of the  probe  and  ethanol 
wash supernatants  were  measured,  and approximately  35-60%  of the  P  dCTP 
were incorporated into the probes.
2.3.7.5  Northern hybridisation
Using a commercial rotating wheel, the nylon membrane was incubated with pre-
29 hybridisation  solution  for  5  hours  at  50.0°C.  The  P-labelled  probe  was 
denaturated by heating at 95°C for 5 minutes, and then rapidly chilled on ice. The 
probe was added the hybridisation solution so that the final concentration of probe 
in the  hybridisation  solution was  5  X  105   cpm/mL.  The  nylon  membrane  was 
incubated with the probe-containing hybridisation solution at 42°C for 16 hours.
After  hybridisation,  the  membrane  was  removed  from  the  rotating  wheel  and 
placed in a plastic box containing  1000 mL pre-warmed  (42°C) 2X  SSC,  0.1% 
SDS.  The membrane  washed for  10  minutes  in a shaking water bath heated to 
42°C. After refilling the plastic box with fresh 2X SSC, 0.1% SDS  solution, the 
membrane was washed in this manner two more times. Next, the membrane was 
washed with  1000 mL 0.2X  SSC,  0.1%  SDS  solution for 30 minutes  at 60  °C. 
After  refilling  the  plastic  box  with  fresh  0.2X  SSC,  0.1%  SDS  solution,  the 
membrane was washed in this manner two more times.
Following the stringency washes, the membrane was dried and wrapped in cling 
film. An autoradiograph was established by exposing the membrane to X-ray film 
(Kodak) at -70°C for 24 hours.
922.4  Protein detection and expression
2.4.1  Protein immunoblot (Western Blot Procedure)
Reagents:
The  following  solutions  were  prepared  for  use  in  SDS  polyacrylamide  gel 
electrophoresis (SDS-PAGE):
1.  Acrylamide: 30% acrylamide/ bis solution
2.  10% SDS (w/v): lOg SDS was dissolved in 100 mL distilled water
3.  Separating  buffer:  27.23  g  Tris  base  was  dissolved  in  80  mL  distilled 
water, and adjusted to pH 8.8 with 6 M HC1. Distilled water was added to 
adjust the final volume of the solution to 150 mL.
4.  Stacking Buffer: 6 g Tris base was dissolved in 60 mL distilled water, and 
adjusted to pH 6.8 with 6 M HC1. Distilled water was added to adjust the 
final volume of the solution to 100 mL.
5.  Sample buffer: 0.06 M Tris-HCl (pH 6.8), 25% glycerol, 2% SDS, 0.01% 
(w/v)  bromophenol  blue,  and  5%  (v/v)  p-mercaptoethanol.  10  mLs  of 
sample buffer was prepared by adding 3.55  mL  distilled water,  1.25  mL 
0.5  M  Tris-HCl  (pH  6.8),  2.5  mL  glycerol,  2.0  mL  10%  SDS,  0.2  mL 
0.5%  (w/v)  bromophenol  blue  (0.001 g/0.2  mL),  and  0.5  mL  P- 
mercaptoethanol.
6.  10X running buffer:  6.06  g Tris base,  72  g  glycine,  and  5  g  SDS  were 
dissolved in 500 mL distilled water and stored at 4°C. For electrophoresis, 
the running buffer was used at  IX concentration by adding  50 mL  10X 
running buffer to 450 mL distilled water.
7.  10%  Ammonium  Persulfate  (APS)  Solution:  100  mg  ammonium 
persulfate dissolved in 1  mL distilled water; solutions were stored at 4 °C 
for no longer than 7 days.
8.  Lysis Buffer: 0.5% SDS, 10 mM Tris, pH 7.4, and 0.1% Protease inhibitor 
(Sigma)
9.  Coomassie Stain solution: Prepared by mixing 0.5 g Coomassie Blue, 200 
mL distilled water, 50 mL acetic acid, and 250 mL methanol
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acetic acid, and 250 mL methanol
An  8%,  10 mL-volume,  separating gel was prepared according to the following 
protocol:
Distilled water 4.7 mL
Acrylamide 2.7 mL
Separating buffer 2.5 mL
10% SDS 0.1 mL
10% APS (fresh)* 50 pL
TEMED* 5 pL
Final volume 10.06 mL
An  8%,  5  mL-volume,  stacking  gel  was  prepared  according  to  the  following 
protocol:
Distilled water 2.35 mL
Acrylamide 1.35 mL
Separating buffer 1.25 mL
10% SDS 50 pL
10% APS (fresh)* 25 pL
TEMED* 2.5 uL
Final volume 5.03 mL
* These reagents were added last into the mixtures.
2.4.2  Preparation of samples
2.4.2.1  Lysis of cells
PBMC  (1  x  10s  cells),  and  Caco-2  (2  x  107  cells)  and  HT29  (6  x  107  cells) 
intestinal epithelial cells (cultured to 90-100% confluence) were concentrated by 
centrifugation in microfuge tubes, thoroughly resuspended in 1   mL ice-cold lysis 
buffer  and  kept  on  ice  for  1   hour.  Frozen  intestinal  tissue  samples  (100  mg), 
which were  obtained  from  macroscopically normal  regions  of resected  surgical 
tissue,  were  crushed,  under  liquid  nitrogen,  using  a  mortar  and  pestle  and 
transferred to pre-chilled microfuge tubes. Lysis buffer (1  mL) was added to the
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microfuge  tubes.  The  lysate  was  further homogenised  using  a 22G  needle  and 
syringe and kept on ice for a further 60 minutes. All lysates were then centrifuged 
at  14000  rpm  (20  817  g)  for  5  minutes  at  4°C.  Following  centrifugation,  the 
protein-rich supernatant was transferred to sterile pre-chilled microfuge tubes and 
stored at -20°C.
2.4.2.2  Quantification of protein
Extracted proteins were quantitated using a Coomassie® Protein Assay Reagent 
Kit  (Pierce  Biotechnology,  Perbio  Science  UK  Ltd,  Tattenhall,  UK).  Protein 
standards and test samples were diluted 5-fold using lysis buffer solution (diluted 
5-fold) as the diluent.  The dilute lysis buffer solution was prepared by a 5-fold 
dilution: these dilutions were necessary as high SDS concentrations interfere with 
the assay. Five pL of lysis buffer diluent (‘blank’), BSA protein standards and test 
samples were pipetted into individual wells (in a 96-well microplate) containing 
250 pL Coomassie reagent and mixed by shaking for 30 seconds. The plate was 
incubated at room temperature for  10 minutes, and the absorbance of the diluent, 
BSA standards and samples measured at 595 nm. A standard curve was derived 
by  plotting  the  absorbance  readings  obtained  from  BSA  standards  against 
absorbance  at  595  nm  (Figure  2.4),  which  was  used  to  determine  the  protein 
concentrations in the test samples.
950.6
0.5
0.4
U )
CT> IO
0.3
0.2
y = 0.0004x 
R2 = 0.9961
400  600  800  1000  1200
Protein concentration in micrograms per mL
200 1600 1400
Figure  2.4.  Standard  curve  to  determine  protein  concentrations  using 
spectrophotometry.
2.4.2.3  Preparation of the gels
The sample proteins were resolved using SDS-polyacrylamide (SDS-PAGE) gel 
electrophoresis,  according to the  method described by Laemmli  (1970).  Protein 
electrophoresis was performed using the Mini-PROTEAN® 3  Cell tank (BioRad 
Laboratories Ltd, Hemel Hempstead, UK). After assembling a glass cassette in the 
casting stand, an 8% separating gel was cast to a level approximately  1  cm below 
the  comb  teeth.  250  pL  of  isopropanol  was  carefully  poured  on  top  of  the 
separating gel to degas and level the top edge of the gel. After the separating gel 
had set, the isopropanol was removed from the glass cassette and the area above 
the polymerised gel was thoroughly washed with distilled water and dried using 
tissue paper. An 8% stacking gel was cast above the separating gel and allowed to 
set with  a moulding  comb  in place.  After  gently removing  the  comb  from the 
polymerised gel, the wells were washed with running buffer.  The  glass cassette 
was removed  from the  casting  stand and placed  in the  electrode  assembly; this 
assembly was then placed into the clamping frame thus forming the inner chamber 
assembly.  The  inner  chamber  was  filled  with  125  mL  running  buffer  and 
transferred to a tank that was prefilled with 200 mL running buffer. At this stage, 
the protein  samples,  each containing  15  pg protein,  were  mixed  with  an  equal
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and allowed to cool to room temperature. The protein samples were then carefully 
loaded into the wells using a pipette. Electrophoretic separation was performed at 
100  V  for  approximately  90  minutes,  or when the  protein  standard  ladder  dye 
front was visible near the bottom of the resolving gel.
After completion of the electrophoretic separation, the gel was carefully removed 
from the glass cassette and equilibrated in blotting buffer for 10 minutes. A piece 
of  polyvinylidene  difluoride  (PVDF)  membrane  (Hybond™  P  membrane, 
Amersham Biosciences UK Limited, Little Chalfont, UK), cut to match the size of 
the gel, was briefly soaked in  100% methanol for  10 seconds, and then soaked in 
distilled water for 5 minutes, and equilibrated in blotting buffer for  10 minutes. 
Protein transfer from the gel to the PVDF membrane was performed using a semi­
dry electrophorectic transfer cell (Trans-Blot®  SD blotter,  BioRad Laboratories 
Ltd,  Hemel  Hempstead,  UK).  The  gel  and  PVDF  membrane  were  sandwiched 
between saturated sheets of buffer-soaked filter paper (also cut to match the size 
of the gel and PVDF membrane) in the following way. Pre-soaked filter paper was 
gently layered onto the platinum anode.  The PVDF membrane was placed over 
the filter papers and rolled with a glass rod to extrude air bubbles.  The gel was 
placed on top of the PVDF membrane, and a glass rod was rolled over the surface 
of the gel to extrude air bubbles. Pre-soaked filter paper was carefully layer onto 
the gel, and rolled with a glass rod to extrude air bubbles. The cathode plate was 
placed over the gel- PVDF membrane-filter paper assembly and the protein was 
transferred from the gel to the membrane at 20 V for 90 minutes.
Following transfer of protein, the membrane was carefully removed from the gel 
and soaked overnight,  at 4°C, in blocking buffer (5% w/v non-fat dried milk in 
TPBS).  The  gel  was  Coomassie-stained  to  confirm  that  protein  transfer  had 
occurred.
The membrane  was then washed,  three times,  in PBS-Tween  solution (0.01%). 
The  membrane  was  incubated  in  a  solution  containing  the  primary  antibody 
(either Polyclonal Rabbit Anti-Human Lysozyme or NOD2) in 10% goat serum in
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concentrations of the primary antibodies were as follows:  lysozyme 35.5  pg/mL, 
NOD2 2.15  pg/mL.  Thereafter the membrane was thrice washed in PBS-Tween 
solution and incubated for 60 minutes in  15 mL  10% goat serum in PBS-Tween 
containing  the  secondary  antibody  at  1:10  000  dilution.  For  the  lysozyme 
immunoblotting,  a peroxidase  labelled anti-rabbit  antibody  was  used whereas  a 
peroxidase  labelled  anti-mouse  antibody  was  used  for  NOD2  immunoblotting. 
The membrane  was  thrice washed  in PBS-Tween and placed  on  filter paper to 
remove the excess PBS-Tween. Next, the entire membrane  surface was covered 
with 2 mL of ECL reagent, which was left on the membrane for  1   minute. The 
excess  ECL  fluid  was  drained  from  the  membrane  using  filter  paper,  and the 
membrane  was  wrapped  in  Clingfilm  and  placed  in  an  X-ray  cassette.  The 
membrane  was  exposed  to  Kodak  ®  Biomax  XAR  Scientific  Imaging  film 
(Anachem) for 20 seconds and developed.
982.4.3  Immunohistochemistry
Reagents:
1.  Xylene
2.  Ethanol (100%, 95%, and 70% solutions)
3.  DEPC-treated water
4.  PBS
5.  0.3% H2O2 in methanol
6.  Blocking solution: 20% goat or horse serum in PBS
7.  Biotinylated anti-rabbit and anti-mouse immunoglobulin antibody
8.  ABC reagent
9.  DAB/ 0.02% hydrogen peroxide
10. DPX mountant
Method:
Tissue  sections,  8  microns  thick,  were  cut  from  wax-embedded  tissue  blocks 
using a microtome. These sections were placed on clean glass slides, and allowed 
to air dry for 16 hours. To dewax the sections, the slides were thrice washed for 
20  minutes  in  fresh  xylene.  The  sections  were  rehydrated  through  a  series  of 
graded ethanol baths: twice in 100% ethanol for 5 minutes, then 95% ethanol for 5 
minutes, then 70% ethanol for 5 minutes, and finally in DEPC-treated water for 5 
minutes. After soaking the sections in PBS for 10 minutes, the slides were placed 
in 0.3% H2O2  in methanol  for 30  minutes  and rinsed  in  PBS.  The  slides  were 
removed  from  the  Schieferdecker jar  and  mounted  on  Shandon  Coverplates™ 
(Thermo Electron),  and placed in  Sequenza slide racks  (Thermo Electron).  The 
sections were rinsed with PBS, and covered with 20% goat or horse serum in PBS 
(blocking solution) for 30 minutes. After rinsing in PBS, sections were incubated 
for  90  minutes  with  the  primary  antibody.  The  concentrations  of  primary 
antibodies are listed in Table 2.5. Sections were rinsed with PBS, incubated with a 
biotinylated  anti-rabbit  or  anti-mouse  immunoglobulin  antibody  (Vector 
Laboratories) in PBS containing 1% goat or horse serum, for 30 minutes, and then 
rinsed  with  PBS.  Sections  were  incubated  with  ABC  reagent  for  30  minutes, 
rinsed with PBS, covered with a solution containing 0.7 mg/ml DAB and 0.02% 
hydrogen  peroxide,  and  monitored  for  the  development  of brown  precipitate.
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haematoxylin,  and  mounted  under  coverslips  with  DPX.  Separate  controls 
sections  were  incubated  without  the  primary  antibody  and  with  an  unrelated 
primary antibody.
2.4.4 Cytospins for CD68 immunocytochemistry
Reagents:
Shandon pre-made cuvettes Cat n° 5991040 (box of 50).
Method:
For  immunocytochemistry,  cytospin  cell  preparation  was  used  to  create  a 
monolayer of PBMC  on poly-l-lysine-coated glass  slides.  PBMC,  5  x  104  cells 
suspended  in  100  pL  HBSS,  were  loaded  into  Shandon  pre-made  cuvettes 
(Thermo Electron) attached to glass slides. The cuvettes were spun at  1000 rpm 
for 3  minutes  in  a  Shandon  Cytospin  3  cytocentrifuge  (Thermo  Electron).  The 
glass slides, which were carefully separated from the cuvettes, were air dried for  1  
minute, and fixed in 95% ethanol for 5 minutes at room temperature. The slides 
were  stored  at  -20  °C.  For  immunocytochemistry,  the  slides  were  placed  in  a 
Schieferdecker jar and briefly warmed to room temperature for  10 minutes. The 
slides were fixed in acetone for  10 minutes, washed in PBS  for 5  minutes, and 
incubated in PBS containing 0.3% H2O2 for 30 minutes. The slides were washed 
in PBS for 5 minutes, and mounted on Shandon Coverplates™ (Thermo Electron) 
and placed in Sequenza slide racks (Thermo Electron). The PBMC monolayer was 
rinsed with PBS, and covered with 20% horse serum in PBS (blocking solution) 
for 30 minutes. After rinsing in PBS, the PBMC monolayer was incubated for 90 
minutes with monoclonal anti-human CD68 antibody. The slides were rinsed with 
PBS, incubated with a biotinylated anti-mouse immunoglobulin antibody (Vector 
Laboratories) in PBS containing 1% horse serum, for 30 minutes, and then rinsed 
with PBS. Sections were incubated with ABC reagent for 30 minutes, rinsed with 
PBS,  covered with a solution containing 0.7  mg/ml  DAB  and  0.02% hydrogen 
peroxide,  and  monitored  for  the  development  of brown  precipitate.  Developed 
slides were rinsed in PBS to stop the reaction, counterstained with hematoxylin, 
and  mounted  under  coverslips  with  DPX.  Separate  controls  sections  were 
incubated without the primary antibody.
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Primary antibody Secondary antibody
Description and supplier Final concentration Description Final concentration
NOD2 (108 pg/ mL); 
anti-human rabbit 
polyclonal,
Dr Gabriel Nunez, 
University of Michigan, 
USA
2.15 pg/mL in PBS 
containing 1% goat 
serum
Biotinylated anti­
rabbit antibody (1.5 
mg anti-IgG + 0.5 mg 
anti-IgM/ mL), made 
in goat
10 pg/ mL (7.5 pg mL anti- 
IgG + 2.5 pg anti-IgM/ mL) 
in PBS containing 1% goat 
serum
NOD2 (2D9;  100 pg/ 
mL); monoclonal anti­
human NOD2, Dr 
Gabriel Nunez, 
University of Michigan, 
USA
2 pg/ mL in PBS 
containing 1 % horse 
serum
Biotinylated anti­
mouse antibody (1.5 
mg anti-IgG + 0.5 mg 
anti-IgM/ mL), made 
in horse
10 pg/ mL (7.5 pg mL anti- 
IgG + 2.5 pg anti-IgM/ mL) 
in PBS containing 1% horse 
serum
monoclonal anti-human 
CD68 antibody (15.5 mg/ 
mL)
(Clone PG-M1; 
DakoCytomation, Ely, 
Cambridgeshire, UK)
62 pg/ mL in PBS 
containing  1% horse 
serum in.
Biotinylated anti­
mouse antibody (1.5 
mg anti-IgG + 0.5 mg 
anti-IgM/ mL), made 
in horse
10 pg/ mL (7.5 pg mL anti- 
IgG + 2.5 pg anti-IgM/ mL) 
in PBS containing 1% horse 
serum
Lysozyme (7.1  mg/ mL); 
anti-human rabbit 
polyclonal antibody, 
DakoCytomation, Ely, 
Cambridgeshire, UK)
35.5 pg/ mL in PBS 
containing 1  % goat 
serum
Biotinylated anti­
rabbit antibody (1.5 
mg anti-IgG + 0.5 mg 
anti-IgM/ mL), made 
in goat
10 pg/ mL (7.5 pg mL anti- 
IgG + 2.5 pg anti-IgM/ mL) 
in PBS containing 1% goat 
serum
sPLA2 (2.5 mg/ mL); 
anti-human rabbit 
polyclonal antibody 
(Dr T Nevalainen, 
Department of Pathology, 
University of Turku, 
Finland)
25 pg/ mL in PBS 
containing 1  % goat 
serum
Biotinylated anti­
rabbit antibody (1.5 
mg anti-IgG + 0.5 mg 
anti-IgM/ mL), made 
in goat
10 pg/ mL (7.5 pg mL anti- 
IgG + 2.5 pg anti-IgM/ mL) 
in PBS containing 1% goat 
serum
1012.5  Cell culture
2.5.1  Isolation of peripheral blood mononuclear cells (PBMC)
Reagents:
1.  Histopaque®  1077:  A  solution  containing  polysucrose  and  sodium 
diatrizoate, adjusted to a density of 1.077 g/mL.
2.  Hanks’ balanced salt solutions (HBSS)
3.  Roswell Park Memorial Institute (RPMI)-1640 Medium
4.  10% pooled human AB serum
5.  Phytohaemagglutinin PHA-P (Lectin from Phaseolus vulgaris)
Method:
Blood  was  collected  from  human  healthy  volunteers  or  from  patients  with 
polycythaemia,  who  were  otherwise  well,  into  anti-coagulant  tubes  containing 
K3EDTA  (BD  Diagnostics).  25  mL  whole blood was  carefully  layered onto  15 
mL Histopaque®  1077 in a 50 mL-centrifuge tube, and centrifuged at  1400 rpm 
(409  g)  for  20  minutes  at  room  temperature.  Following  centrifugation, 
mononuclear cells form a distinct layer at the plasma- Histopaque® interface, and 
neutrophils  and  red  blood  cells  form  a  pellet  at  the  tube  base.  The  layer  of 
mononuclear cells was carefully aspirated and placed in fresh 50 mL-centrifuge 
tubes.  HBSS  was  added  to  adjust  the  final  volume  to  40  mL,  and  the  tubes 
centrifuged  at  1400  rpm  (409  g)  for  7  minutes  at  room  temperature.  After 
discarding the  supernatant containing contaminating  platelets,  the  PBMC  pellet 
was  suspended  in  30  mL  HBSS,  and  centrifuged  at  1200  rpm  (301  g)  for  7 
minutes  at  room  temperature.  This  wash  was  repeated,  twice  more,  to  remove 
contaminating platelets. Following the final wash, the PBMC were suspended in 
RPMI-1640 medium and counted using an improved Neubauer counting chamber. 
The  monocytes  were  seeded  in  T25  culture  flasks,  at  a  concentration  of  105  
cells/cm2, and maintained in RPMI 1640 medium supplemented with 10% pooled 
human AB serum, lOOU/ml penicillin and 1  mg/ml streptomycin, at 37°C in a 95% 
air/ 5% C02 atmosphere.
To  determine  the  effect  of in  vitro  culture  on NOD2  expression,  PBMC  were 
incubated for 24, 48  and 72 hours,  and recovered by aspiration and mechanical
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PBMC and cultured cells were cytocentrifuged onto slides, air-dried, fixed in 95% 
ethanol for 5 minutes, and stored at -20°C. Before immunodetection, slides were 
warmed to room temperature, fixed in acetone for 10 minutes, rinsed in PBS and 
placed in 0.3% H202 in methanol for 30 minutes, and rinsed again in PBS. Slides 
were stained with a monoclonal anti-human CD68 antibody (DakoCytomation), as 
described above. For RNA extraction, the recovered PBMC were lysed in Trizol® 
reagent.
2.5.2 Lymphokine preparation and cell stimulation
A  lymphokine  (soluble  cytokines  secreted  by  lymphocytes)  preparation  was 
obtained  by  stimulating  PBMC  with  phytohaemagglutinin  (PHA).  PBMC,  in 
RPMI  1640 medium supplemented with 10% pooled human AB serum,  lOOU/ml 
penicillin and  1  mg/ml  streptomycin (Sigma),  were  seeded at a concentration of 
105 cells/cm2 in T25 culture flasks and incubated at 37°C in a 95% air/ 5% C02 
atmosphere  for  1   hour.  The  cells  were  stimulated  with  PHA  (5  pg/ml)  for  48 
hours,  and  lymphocyte  clumping was noted during microscopic  examination of 
the  cells.  Thereafter,  the  supernatant was  collected  from  the  culture  flasks  and 
placed  in  sterile  centrifuge  tubes  which  were  centrifuged  at  1400  rpm  for  5 
minutes at 4  °C.  The  cell-free  supernatant,  containing lymphokine, was used to 
stimulate Caco-2 and HT-29 intestinal epithelial cells (at 50% confluence) in vitro 
for 48 hours.  DMEM culture medium containing  50% lymphokine  solution was 
used to stimulate the intestinal epithelial cells for 48 hours at 37 °C.
2.5.3 Cell culture
Reagents:
1.  lOOx  Antibiotic  antimycotic  solution:  10  000  U  penicillin,  10  mg 
streptomycin, and 25 pg amphotericin B per mL)
2.  lOx Trypsin-EDTA solution:  5.0 g porcine trypsin, 2.0 g EDTA-4 Na in
0.9% NaCl; cell culture tested
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PBS
4.  Dulbecco PBS
5.  Dulbecco’s modified Eagle medium (DMEM)
6.  DMEM/F12 medium
7.  10% foetal calf serum
8.  200 mM L-Glutamine
9.  Caco-2 intestinal epithelial cells (ATCC Number HTB-37)
10. HT-29 intestinal epithelial cells (ATCC Number HTB-38)
11. SW480 intestinal epithelial cells (ATCC Number CCL-228)
Caco-2 and HT29  intestinal epithelial cells were  obtained from Dr.  K.  Srai and 
Dr.  C.  Osborne  (Departments  of Medicine  and  Biochemistry,  Royal  Free  and 
University College Medical  School, London). These investigators had originally 
purchased the cells from LCG Promochem, the European distribution partner for 
American  Type  Culture  Collection  (ATCC)  products.  SW480  cells  were 
purchased directly from LCG Promochem.
2.5.3.1  Propagation of intestinal epithelial cell lines
Human  colon  cancer  cell  lines  Caco-2  and  HT29  (American  Type  Culture 
Collection, Manassas, USA) were cultured in Dulbecco’s modified Eagle medium 
(DMEM) supplemented with 10% foetal calf serum, 2mM L-Glutamine,  1   U/mL 
penicillin,  1   pg/mL  streptomycin  and 2.5  ng/mL  amphotericin  B,  at  37°C  in  a 
95% air/ 5% C02 atmosphere. SW480 cells were cultured in DMEM/F 12 medium 
supplemented  with  10%  foetal  calf  serum,  1   U/mL  penicillin,  1   pg/ml 
streptomycin  and  2.5  ng/mL  amphotericin  B,  at  37°C  in  a  95%  air/  5%  C02 
atmosphere.  All  reagents  used  for  cell  culture  were  purchased  from  Sigma 
Chemical Company, Poole, UK.
Cell  lines  were  propagated  after  reaching  80-90%  confluence  in  T75  flasks 
(usually  after  one  week  of culture).  The  growth  medium  was  poured  from the 
flask, and the cells were twice washed with 10 mL Dulbecco PBS. After pouring 
out the  PBS,  5  mL  of trypsin solution was  added to the  flask.  After  1   minute,
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flask was incubated at 37.0°C for 12 to  15 minutes.  Following trypinisation, the 
cells were  visualised under an inverted microscope  to  confirm  cell  detachment 
from the plastic walls of the flask. The detached cells were thoroughly suspended 
in 8 mL of appropriate culture medium. After calculating the cell count, using an 
improved Neubauer counting chamber, cells were  seeded into fresh T75  culture 
flasks according to the following concentrations: 2-4 x  104 cells/ cm2 for Caco-2 
and HT-29 cells, and  104 cells/ cm2 for SW480 cells. Fresh culture medium was 
added to the T75  flask so that cells were allowed to propagate in  10 mL growth 
medium; the  growth medium was replenished twice weekly.  All cell lines were 
checked and found to be free from mycoplasma infection by Ms Demetra Mavri 
(Research  assistant,  Centre  for Hepatology,  Royal  Free  and  University  College 
Medical School, London).
Table 2.6. Seeding concentrations used to propagate intestinal epithelial cells.
Cell type Seeding concentration 
(cells/ cm2)
Cell yield from trypsin- 
treated confluent cells 
cultured in T75 flasks
Caco-2 2-4 x 104 1-2 x 10'
HT-29 2-4 x 104 2-3 x 10'
SW480 1 x  104 2-3 x 10;
1052.6  Secretory Phospholipase Assay
Caco-2 intestinal epithelial cells express secretory phospholipase  A2  Group IIA 
(5PLA2), an antibacterial enzyme secreted by Paneth cells. There were no suitable 
commercially available antibodies to detect secreted 5PLA2 protein, and this assay 
was  performed  to  detect  5PLA2  enzymatic  activity  in  Caco-2  cell  culture 
supernatants.
2.6.1  Enzymes
Porcine  pancreas  PLA2  (Group  IB)  was  obtained  from  the  Sigma  Chemical 
Company,  Poole,  UK.  Human  pancreatic  PLA2  is  not  commercially  available, 
although the porcine enzyme is virtually identical in structure and activity (Kudo 
1993).  Duodenal  secretions  containing  pancreatic  PLA2  were  obtained  from 
patients undergoing oesophagogastroduodenoscopy.  Secretions  were  centrifuged 
to remove cellular debris and food particles, and the supernatants stored at -20°C. 
Ethical approval for the collection of duodenal secretions had been obtained from 
the Royal Free Hampstead NHS Trust local ethics committee.
Bee venom PLA2 was obtained from Sigma Chemical Company. This enzyme is 
closely  related  to  human  pro-inflammatory  5PLA2,  which  is  not  available 
commercially and cannot be readily isolated from human clinical  material.  The 
circulating  5PLA2  in  rabbit  serum  is  also  virtually  identical  to  human  pro- 
inflammatory 5PLA2, and was also used in the assays.
2.6.2 Enzyme assay
Pancreatic 5PLA2 (Group IB) preferentially hydrolyses phosphatidylethanolamine 
and  phosphatidylserine  (Kudo  2002),  however,  it  also  hydrolyses 
phosphatidylcholine  in the presence  of low concentrations  of detergent  such as 
deoxycholate  (Hanasaki  1999,  Kudo  1993).  Furthermore,  the  digestion  of 
phospholipids in the diet by pancreatic 5PLA2 (Group IB) occurs in the presence 
of bile acids in the digestive tract. I therefore performed the control enzyme assay 
using  phosphatidylcholine  micelles  suspended  in  a  solution  containing 
deoxycholate.
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substrates  incorporated into bacterial cell membranes,  although it is  also active 
against micellar and vesicular substrates. It has no acyl-chain or polar head group 
preference.
Reagents:
1.  Dipalmitoyl phosphatidylcholine stock solution: 120 mM dipalmitoyl L-a- 
phosphatidylcholine  (1,  2-dipalmitoyl-sn-glycero-3-phosphocholine),
[dissolved in chloroform: methanol 9:l(v/v)].
2.  l-palmitoyl-2-[l-14C]palmitoyl  L-3-phosphaditylcholine  (925  kBq/ml, 
1.85-2.29 GBq/mmol)
3.  Chloroform: methanol 3:1 (v/v)
4.  Glycine buffer: 20 mM glycine, pH 8.0; 6 mM sodium deoxycholate; 0.1% 
Triton X-100
5.  200 mM CaCl2
6.  20 mM EDTA
7.  Lipid extraction solution [Chloroform: methanol 1:1 (v/v)]
8.  Hexane: diethyl ether: acetic acid 90:20:10 (v/v/v)
9.  Ecoscint A scintillation fluid
2.6.2.1  Preparation  of  the  dipalmitoyl  phosphatidylcholine  substrate 
solution
6  pmoles dipalmitoyl L-a-phosphatidylcholine  (final  concentration  12mM),  and 
10 nmoles l-palmitoyl-2-[l-14C]palmitoyl L-3-phosphaditylcholine was dissolved 
in chloroform:  methanol 3:1. Dipalmitoyl phosphatidylcholine  substrate solution 
was prepared as follows:
50 pi dipalmitoyl phosphatidylcholine stock solution 
22 pi l-palmitoyl-2-[l-14C] palmitoyl phosphatidylcholine 
438 pi chloroform: methanol 3:1
107Substrate solutions were dried at 40°C under a stream of nitrogen, and the residue 
reconstituted in 1000 pi glycine buffer, heated to 60°C for 2 minutes and cooled. 
After cooling,  20  pi CaCb  (200 mM) was  added to the  reconstituted substrate, 
until a clear solution was obtained.
2.6.2.2 Enzymatic hydrolysis of substrate
50  pi  of the  enzyme  solution  (duodenal  juice/serum/commercial  enzyme/cell 
culture supernatant) was added to 100 pi substrate solution and incubated at 37°C 
for 1  hour. The enzyme reaction was stopped by adding 150 pi EDTA (20 mM) to 
the  reaction  mixture.  Commercial  enzyme  solutions  contained  400  U/ml  bee 
venom 5PLA2 and 1330 U/ml porcine pancreas 5PLA2.
2.6.2.3 Extraction of hydrolysis products
300 pi of the enzyme reaction mixture was added to 4ml  chloroform:  methanol 
1:1 (v/v) in flat-bottomed glass tubes. Thereafter 1.2 ml distilled water was added 
to  the  lipid  extraction  solution  and  mixed  well.  After  phase  separation  by 
centrifugation,  1   ml  of the  organic phase  was  dried  at 40°C  under a stream  of 
nitrogen, redissolved in 30 pi chloroform and placed on glass-backed TLC plates.
2.6.2.4 Thin Layer Chromatography (TLC)
Glass-backed  TLC  plates  were  placed  in  solvent  chambers  containing  hexane: 
diethyl ether:  acetic  acid 90:20:10 (v/v/v). Relevant fractions  scrapped from the 
TLC plates were placed in scintillation vials containing 8 ml Ecoscint A fluid and 
radioactivity counts measured in an automated scintillation counter.
2.7  Statistical analysis
Values in the text and figures are expressed as the mean ± S.E.M. (Standard error 
of  the  mean).  Statistical  differences  between  means  were  determined  using 
Student’s t-test and considered significant if P<0.05. All analyses were performed 
using GraphPad Prism version 3.02 (25 April 2000).
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3. Localisation of NOD2 gene expression in Crohn’s 
disease
3.1  Introduction
Crohn's  disease  is  a  chronic  inflammatory  disease  that  can  affect  the  entire 
gastrointestinal  tract  although the terminal  ileum,  colon  or  anorectum  are  most 
commonly affected. Many studies, however, have shown that in NOD2-associated 
Crohn's disease, the terminal  ileum  is most commonly affected region although 
the reason  for this  association  is  unclear (Ahmad 2002,  Cuthbert 2002, Lesage 
2002).
NOD2,  an  intracellular  protein  that  is  postulated  to  function  as  a  pathogen 
recognition  receptor  (PAMP)  and  play  a  role  in  innate  defences,  is  mainly 
expressed  in  circulating  monocytes  that  are ubiquitously  distributed  throughout 
the  body  (Ogura  2001a).  Monocytes,  which  are  key  elements  of  the  innate 
defences, can respond to pathogens irrespective of the site of infection. There is 
therefore no  satisfactory explanation to  account for the  disease  localisation,  i.e. 
terminal  ileitis  that  is  a  feature  of NOD2-related  Crohn's  disease,  and  NOD2 
expression has not been analysed in intestinal tissue from patients.  It is possible 
therefore,  that NOD2  may  also  be  expressed  in  other  cells  involved  in  innate 
defences, including specialised intestinal epithelial cells, such as Paneth cells.
In mice, Paneth cells secrete antimicrobial peptides in response to stimulation by 
bacterial  antigens,  including  the  bacterial  antigen  muramyl  dipeptide  (MDP) 
(Ayabe 2000).  In addition, these cells are most numerous  in the terminal ileum 
and also express pro-inflammatory molecules such as secretory phospholipase A2 
Group  IIA  (5PLA2)  and  TNFa  and  may  play  a  role  in  intestinal  inflammation 
(Porter 2002).  I  therefore  hypothesised that NOD2  is  also  expressed  in Paneth 
cells, and analysed NOD2 expression in intestinal tissue.
109To  test  this  hypothesis,  I  used  reverse  transcriptase  PCR  (RT-PCR)  and 
immunoblotting to  determine  whether NOD2  mRNA  and  protein  expression  is 
detected  in  intestinal  tissue.  Then,  I  used  in  situ  hybridisation  and 
immunohistochemistry  to  detect  the  cellular  sources  of NOD2  expression  in 
terminal  ileal  tissue  obtained  from  patients  with  Crohn's  disease  and  in 
histologically normal terminal ileal sections obtained from patients with colorectal 
cancer. In addition, I also determined whether metaplastic Paneth cells, which are 
found in inflamed colonic tissue, expressed NOD2.
1103.2 Results
3.2.1  Reverse  transcriptase  polymerase  chain  reaction  (RT- 
PCR)  amplification  of  NOD2  mRNA  in  intestinal  tissue  and 
peripheral blood mononuclear cells
To determine whether NOD2 is expressed in intestinal tissue, I used RT-PCR to 
amplify NOD2  and  human alpha defensin  6  (HD6)  sequences in terminal  ileal 
tissue  and  PBMC.  Using  reverse transcriptase  PCR  (RT-PCR),  NOD2  mRNA 
could  not  be  amplified  in  the  terminal  ileum,  where  Paneth  cells  are  most 
abundantly found although NOD2 mRNA expression was more readily detected 
in  peripheral  blood  mononuclear  cells.  Expression  of a  house-keeping  gene, 
GAPDH, was easily detected in terminal ileal tissue and PMBC, and expression of 
HD6 was detected in terminal ileal tissue (Figure 3 .1).
Figure 3.1. NOD2 and HD6 mRNA expression in terminal ileum and PBMC.
Using RT-PCR,  NOD2  mRNA  is  detected in  PBMC  (Lane  5),  but  not  in  the 
terminal ileum (Lane 6). GAPDH mRNA is amplified in both tissues (Lanes 1 and 
2), and HD-6 mRNA is easily amplified in terminal ileal tissue (Lane 4) but not in 
PBMC (Lane 3). PCR products were separated using agarose gel electrophoresis 
and visualised using ethidium bromide staining.  The expected PCR amplicon size 
(in base pairs)  was used to confirm the identity of the PCR products:  GAPDH 
488; HD6 241; NOD2 402.
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111The  lack of NOD2  expression in intestinal tissue by the RT-PCR assay I used, 
which  is  a  sensitive  method  for  detecting  gene  expression,  was  surprising  as 
terminal  ileal  tissue  sections  contain  tissue  macrophages  and,  most  probably, 
circulating  monocytes  in  the  intestinal  blood  vessels.  RNA  degradation  in  the 
resected  terminal  ileal  tissue  specimens  may  account  for  the  lack  of NOD2 
amplification,  but  GAPDH  and HD6  mRNA were  easily  detected by  RT-PCR. 
These  genes,  however,  are  abundantly  expressed  in  intestinal  tissues  and  it  is 
possible that NOD2  is not abundantly expressed.  I hypothesised, therefore, that 
the dynamic range of the RT-PCR reaction used did not permit detection of low 
copy numbers of NOD2 mRNA. Therefore, I used quantitative real-time RT-PCT 
to determine the minimum number of NOD2 molecules that could be amplified by 
RT-PCR to determine the sensitivity of this technique.
Using  RT-PCR,  NOD2  cDNA  sequences  were  amplified  from  PBMC-derived 
cDNA.  These  sequences, visualised by ethidium bromide  staining  after agarose 
gel electrophoresis, were extracted from the gel using a commercial kit and then 
quantitated by fluorometry.  Serial dilutions of the NOD2 cDNA were prepared, 
which were then amplified by real-time PCR to determine the minimum number 
of NOD2 molecules that could be amplified using the present PCR amplification 
conditions.  In  addition,  the  starting  concentration  of NOD2  cDNA  used  in the 
real-time  PCR  reactions  were  correlated  with  the  cycle  number  where  linear 
amplification  occurred  in  order  to  gauge  the  accuracy  of  real-time  PCR 
quantitation.
DNA concentrations  were  determined by  fluorometry using the  fluorescent dye 
bisBenzimide (Hoechst 33258) as described in section 2.1.10 of Chapter 2. 2 pL 
of each  dilution  solution  were  then  amplified  by  real-time  PCR  in  a  20  pL 
reaction volume, using intron-spanning NOD2 primers. This analysis showed that 
at least 1.62 x  103  NOD2 molecules are required in a 20 pL reaction volume for 
successful  amplification  by  PCR,  so  that  the  amplification  products  could  be 
reliably  identified  by  melt  curve  analysis  and  visualised  by  ethidium  bromide 
staining after electrophoretic separation on an agarose gel (Figure 3.2).
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Figure 3.2. Visualisation of NOD2 amplicons by ethidium bromide staining.
Using quantitative real-time RT-PCR, approximately 1.62 x 10s NOD2 molecules 
(Lane  6) are required to be present in a 20 pL reaction volume for successful 
visualisation  by  ethidium  bromide  staining  on  an  agarose  gel  (arrow).  PCR 
products were separated using agarose gel electrophoresis and visualised using 
ethidium bromide staining.  The expected PCR amplicon size (in base pairs) was 
used to confirm the identity of the PCR products: NOD2 402. (L : ladder)
These PCR reactions were also analysed to assess the accuracy of the real-time 
PCR  reactions  by  comparing  the  starting  concentration  of  NOD2  cDNA 
molecules with the cycle number where linear amplification occurred. This take­
off value, or Ct value, denotes the starting cycle at which product fluorescence is 
detectable and can be directly related to the starting copy number of the sample 
(Figure  3.3).  A  standard  curve,  constructed  by  plotting  the  Ct  values  against 
known concentrations of NOD2 cDNA (Figure 3.3), showed a strong correlation 
between the Ct value and starting concentration of NOD2 cDNA (r=0.99968).
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Figure  3.3.  Real-time  PCR  analysis  of  NOD2  cDNA  standards.  A:
Background-corrected fluorescence data for NOD2 cDNA standards,  ranging in 
concentration from 3.29 x 101  to 3.29 x 10'6 ng/pL,  which show parallel curves 
passing a threshold (arbitrarily set within the exponential growth of  fluorescence 
with respect to cycle number) at equally spaced intervals of approximately 3.5 
cycles/10-fold  change  in  concentration.  B:  Table  showing  the  starting
concentrations of NOD2 cDNA and corresponding Ct values,  colour-matched to 
the fluorescence curves shown in A.
These analyses verified the accuracy of real-time RT-PCR analysis to quantitate 
NOD2  gene  expression,  as  the  Ct  value  strongly  correlated  with  the  starting
114cDNA concentrations (Figure 3.4). The accuracy of real-time PCR analysis using 
other primers, such as GAPDH, was also verified in this way.
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Figure  3.4.  Standard  curve  of  threshold  cycle  number  (Ct)  versus  log 
concentration of NOD2 cDNA.  The line represents a best logarithmic fit to the 
data (cDNA concentration = 10 (-°-282* CT +  2-425); r= 0.99968, r2=0.99936).
For successful NOD2 detection by RT-PCR, at least 4 fg of the targeted NOD2 
cDNA sequences are needed in each microlitre (pL) of the PCR reaction volume 
for successful amplification. This is the equivalent to approximately 81 molecules 
of NOD2 cDNA per pL of the reaction volume. The RT-PCR reaction mixtures 
containing PBMC cDNA contained at least  1.92 x  104 NOD2 cDNA molecules 
per pL, and NOD2 sequences were easily amplified. It is likely that the number of 
NOD2 molecules  in terminal  ileal cDNA preparations  is  considerably  less,  and 
that the lower limit of RT-PCR dynamic range is not sensitive for the detection of 
small copy numbers.
These results did not exclude the possibility that Paneth cells express NOD2, as 
the  cDNA  sequences  synthesised  from  terminal  ileal  mRNA  are  derived  from 
various cellular sources, and as Paneth cells constitute a small fraction of the total 
intestinal cell population. Low copy Paneth cell-mRNA sequences may therefore 
not be easily detected by RT-PCR. Therefore, I next determined whether NOD2 
expression could be analysed using alternative methods such as immunoblotting, 
in situ hybridisation, and immunohistochemistry.
R*0.99988  R2=0.99936  Efficiency=0.92 
M*-0.282  8*2.425
1153.2.2  N0D2  protein  detection  in  the  terminal  ileum  and 
peripheral blood mononuclear cells by immunoblotting
The NOD2  protein was  not  detected  in  cellular  lysates  obtained  from PBMC, 
inflamed  and  non-inflamed  terminal  ileal  tissue,  and  colonic  epithelium  by 
immunoblotting. In contrast, lysozyme, which is abundantly produced by Paneth 
cells and PBMC, was easily detected in these samples by immunoblotting (Figure
3.5).
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Figure  3.5.  Lysozyme  protein  expression  in  PBMC,  intestinal  tissue  and 
epithelial  cell  lines.  Lysozyme protein  (14 kDa)  is easily detected in  cellular 
lysates obtained from PBMC,  inflamed and non-inflamed terminal ileal tissue, 
colonic epithelium and HT29 intestinal cells.  The protein is also detected in the 
standard sample, which contains hen egg lysozyme and the positive control (also 
terminal ileal tissue).
Paneth cell-derived antimicrobial enzymes, such as HD6 and lysozyme, could be 
easily detected by RT-PCR or immunoblotting although NOD2 expression could 
not be  detected.  These  results  suggest that NOD2  is  either  absent  in  intestinal 
tissue or, more likely, expressed at low levels that do not permit detection by these 
techniques. Next, I used in situ hybridisation and immunohistochemistry, which 
are also sensitive techniques to detect mRNA and protein expression, to determine 
whether NOD2 is expressed in Paneth cells.
1163.2.3  Determination  of NOD2  mRNA expression  in  the terminal 
ileum by in situ hybridisation
3.2.3.1  Optimising tissue permeability for in situ hybridisation
In situ hybridisation (ISH) is a method of localising and detecting specific mRNA 
sequences  in  morphologically  preserved  tissues  sections  by  hybridising  the 
complimentary  strand  of a  nucleotide  probe  to  the  sequence  of interest.  The 
sensitivity of the  technique  is  such that threshold  levels  of detection are  in the 
region of 10-20 copies of mRNA per cell (Harper 1986).
Standard hybridisation techniques require the electrophoretic separation of DNA 
or RNA on a gel, and subsequent transfer to membranes that are probed with a 
complimentary  sequence.  On  the  other  hand,  ISH  presents  a  unique  set  of 
problems as the sequence to be detected will be at a lower concentration, may be 
masked  because  of  associated  proteins,  or  protected  within  a  cell  or  cellular 
structure. To overcome this, tissues are treated with a protease, usually Proteinase 
K, to increase tissue permeability and the visibility of the nucleotide sequence to 
the probe  without  destroying  the  structural  integrity  of the  cell  or tissue.  Prior 
tissue fixation is an important factor that governs the amount of digestion needed 
for  adequate  tissue  permeabilisation,  and  initial  experiments,  to  empirically 
determine  the  optimal  Proteinase  K  concentrations,  were  performed  on  frozen 
sections  that  were  fixed  in  paraformaldehyde.  Thereafter,  Proteinase  K 
concentrations  required  for  tissue  permeabilisation  were  optimised  for  wax- 
embedded duodenal biopsies. These biopsies were fixed in formalin overnight, as 
the  archived tissue  blocks  that would be  used  for  subsequent  ISH  experiments 
would most likely have been fixed in this way in our histopathology department.
Previously,  using  ISH  with  radiolabelled  probes,  Chung  (1988)  and  Keshav 
(1991) have demonstrated that Paneth cells express lysozyme mRNA abundantly. 
Based  on  these  observations,  I  determined  the  concentrations  of Proteinase  K 
required for digestion of frozen and wax-embedded tissue  sections that allowed 
lysozyme  mRNA  detection  by  digoxigenin-labelled  probes.  Thereafter, 
subsequent  ISH  would  be  performed  using  Proteinase  K  concentrations  that
117produced  an  intense  lysozyme  hybridisation  signal  whilst  maintaining  the 
integrity of the tissue section.
The following concentrations  of Proteinase K were  used to permeabilise  frozen 
sections: 30, 60 and 90 pg/mL. Wax-embedded sections were treated with 20 and 
40 pg/mL Proteinase K. All tissue sections were treated with Proteinase K for 15 
minutes at 37.0°C.
For frozen  sections  hybridised with the  lysozyme  antisense  riboprobe,  positive 
signal was noted in those sections treated with 30, 60 and 90 pg/mL Proteinase K. 
Lysozyme  mRNA  staining  was  most  intense  in  those  sections  treated  with  60 
pg/mL Proteinase K, compared with those sections treated with 30 and 90 pg/ mL 
Proteinase K. The tissue morphology was preserved in those sections treated with 
30 and 60 pg/mL Proteinase K, although excessive tissue digestion was noted in 
sections  treated  with  90  pg/mL  Proteinase  K  (Figure  3.6).  For  wax-embedded 
sections, lysozyme mRNA staining was most intense in sections treated with 40 
pg/mL Proteinase K, with good preservation of tissue morphology (Figure 3.7). 
For  all  Proteinase  K  concentrations  tested,  parallel  sections  were  treated  with 
control lysozyme  sense-strand riboprobes.  These  sections  did not show positive 
staining, thus confirming the specificity of detection.
118119Figure  3.6.  Lysozyme  mRNA  expression  in  Proteinase  K-treated  frozen 
duodenal sections (page 119).
(Al).  In  situ  hybridisation  demonstrates  positive  lysozyme  mRNA  staining  in 
Paneth cells  (asterisks)  in histologically normal duodenal tissue.  The structural 
morphology of the intestinal crypt (solid line) is preserved in this section treated 
with 30 pg/mL  Proteinase K.  At higher magnification  (A2),  the positive  mRNA 
staining is located in the infranuclear nuclear region of Paneth cells,  where the 
endoplasmic reticulum is located. Numerous apical secretory granules are seen in 
Paneth cells.
(Bl).  In  situ  hybridisation  demonstrates  positive  lysozyme  mRNA  staining  in 
Paneth cells (asterisks),  with structural preservation of the intestinal crypt (solid 
line) in this section treated with 60 pg/mL Proteinase K. At higher magnification 
(B2),  the  lysozyme  mRNA  staining  is  more  intense  compared to  section A  (30 
pg/mL Proteinase K) and section B (90 pg/mL Proteinase K.
(Cl).  In  situ  hybridisation  demonstrates  positive  lysozyme  mRNA  staining  in 
Paneth  cells  (asterisks),  but the structural  integrity  of intestinal crypts  (broken 
lines) are disrupted in this section treated with 90 pg/mL Proteinase K. At higher 
magnification  (C2),  the  lysozyme  mRNA  staining  is  of a  weaker  intensity  than 
section B2.
All  sections  were  hybridised  with  the  digoxigenin-labelled  lysozyme  antisense 
strand riboprobe,  and viewed under the  40x objective  (Al,  Bl  and Cl),  or the 
lOOx objective (A2, B2 and C2).
120121Figure  3.7.  Lysozyme  mRNA  expression  in  Proteinase  K-treated  wax- 
embedded duodenal sections (page 121).
(Al).  In  situ  hybridisation  demonstrates  positive  lysozyme  mRNA  staining  in 
Paneth cells  (asterisks)  in histologically normal duodenal tissue.  The structural 
morphology  of the  intestinal  crypt  is preserved in  this  section  treated with  20 
pg/mL Proteinase K. At higher magnification (A2),  the positive mRNA staining is 
located in the infranuclear nuclear region of Paneth cells, and the overall cellular 
morphology is better preserved compared to frozen sections.
(Bl).  In  situ  hybridisation  demonstrates  positive  lysozyme  mRNA  staining  in 
Paneth cells (asterisks), with structural preservation of the intestinal crypt in this 
section  treated with  40 pg/mL  Proteinase  K.  At higher magnification  (B2),  the 
lysozyme mRNA staining is slightly more intense compared to section A. At lower 
magnification (B3),  lysozyme mRNA staining is most prominent in Paneth cells in 
the  intestinal  crypts  (arrows).  The  brown  staining  on  the  edges  of the  tissue 
section  is an artefact:  this stain,  which  is not intense,  was very distinguishable 
from the intense mRNA staining in Paneth cells.
All  sections  were  hybridised  with  the  digoxigenin-labelled  lysozyme  antisense 
strand riboprobe, and viewed under the lOx objective (B3),  40x objective (Al and 
Bl) or the lOOx objective (A2 and B2).
These results indicate that for tissues fixed in formalin overnight and embedded in 
paraffin-wax,  tissue  permeabilisation  using 40  pg/mL  Proteinase  K  is  likely to 
produce strong intensity mRNA hybridisation signals with preservation of tissue 
morphology. Next, tissue sections from patients with Crohn’s disease and controls 
were  permeabilised  with  40  pg/mL  Proteinase  K  prior  to  hybridisation  using 
digoxigen-labelled riboprobes to detect NOD2 mRNA expression.
3.2.3.2  NOD2  mRNA  is  expressed  by Paneth  cells  and  lamina  propria 
leukocytes
To  analyse  NOD2  expression  in  intestinal  tissue,  I  obtained  archived  tissue 
sections from eight patients with Crohn’s disease and five patients with colorectal 
carcinoma from the Department of Histopathology at the Royal Free Hampstead
122NHS Trust. Ethical permission for the use of this material was obtained from the 
local ethics committee.
In  Crohn’s  disease-affected  terminal  ileum  tissue  sections  hybridised  with  the 
digoxigenin-labelled antisense riboprobes, NOD2 mRNA was clearly detected in 
intestinal epithelial cells and lamina propria leukocytes by in situ hybridisation. 
Specifically, NOD2 mRNA was localised to epithelial cells located at the bases of 
the  crypts  of Lieberkiihn.  These  cells  contained  a  large  number  of secretory 
granules  in their  apical  cytoplasm  and  were  morphologically  typical  of Paneth 
cells  (Figure  3.8).  In adjacent  sections, the NOD2  expressing cells also  stained 
positively  for  secretory  phospholipase  A2  Group  IIA  (5PLA2)  and  lysozyme 
mRNA that are highly restricted markers of Paneth cells  in vivo  (Keshav  1991, 
Keshav  1997), which further confirmed their identity. NOD2 mRNA staining in 
Paneth  cells  was  most  apparent  in  Crohn's  disease-affected  terminal  ileum, 
although  a  weaker  signal  could  be  detected  in  histologically  normal  terminal 
ileum, both from patients with Crohn's disease and those without IBD.
Ulcer  associated  cell  lineages  (UACL)  are  a  feature  of  Crohn's  disease,  and 
represent  newly  regenerated  epithelial  cells.  These  cells  stain  positively  for 
lysozyme mRNA, although NOD2 mRNA staining was not visible in these cells. 
Leukocytes  infiltrating the  lamina propria that stained  for positively  for NOD2 
mRNA contained large bean-shaped nuclei and were morphologically typical of 
monocytes.  These  cells  also  stained  positively  for  the  CD68  antigen  by 
immunostaining, thus confirming their identity as monocytes.
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124Figure  3.8.  NOD2  mRNA  is  expressed  by  Paneth  cells  in  small  intestinal 
crypts  and  lamina  propria  mononuclear  cells  (page  124).  (a)  In  situ 
hybridization  with  the  digoxigenin-labelled NOD2  antisense  strand  riboprobe 
demonstrates positive  brown staining in small intestinal crypts  (arrowheads)  in 
Crohn’ s disease-affected terminal ileum,  (b) Hybridization with the control sense 
strand riboprobe shows no signal,  confirming specificity of detection,  (c)  Within 
crypts, positive staining is present mainly in the  infra-nuclear region of Paneth 
cells (thick arrows),  where mRNA and rough endoplasmic reticulum is localized, 
while the protein-rich granules in the apical cytoplasm (asterisks) are unstained. 
Positive signal is also noted in lamina propria mononuclear cells (thin arrows), 
(d) Sections hybridized with the control sense strand riboprobe show no positive 
staining, (e) NOD2-positive crypt cells are identified as Paneth cells by localizing 
lysozyme  mRNA  in  adjacent  sections  hybridized  with  the  lysozyme  antisense 
strand riboprobe.  (f) Sections hybridized with the control sense strand riboprobe 
show no staining,  (g) Positive NOD2 mRNA staining is seen in scattered lamina 
propria  mononuclear  in  sections  hybridised  with  the  NOD2  antisense  strand 
riboprobe.  (h) Sections hybridized with the control sense strand riboprobe show 
no  staining  in  lamina  propria  cells.  All  sections  were  counterstained  with 
haematoxylin,  and  viewed  under  the  2Ox  objective  (a)  and  (b),  or  the  lOOx 
objective (c) to (h).
Although ISH is not a quantitative technique, NOD2  mRNA staining was more 
intense  in  inflamed  than  histologically  normal  tissue,  suggesting  that  gene 
expression is increased in inflammation. Using an arbitrary scale, NOD2 mRNA 
did not stain as intensely as lysozyme, 5PLA2 or TNFa mRNA within Paneth cells 
in Crohn's disease-affected terminal ileal tissue (Figure 3.10). NOD2 mRNA was 
detected in 7 of 8 patients with Crohn's disease. NOD2 mRNA was not detected in 
a section where staining for lysozyme and 5PLA2 mRNA was also weak, possibly 
indicative of RNA degradation in this tissue section (Figure 3.9).
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Figure 3.9. NOD2, lysozyme, SPLA2, and TNFa mRNA staining intensity in 
Paneth  cells.  Paneth  cell NOD2,  lysozyme,  SPLA2,  and  TNFa mRNA  staining 
intensity  were  determined  in  parallel  sections from  8  patients  with  Crohn's 
disease  and  compared  to  NOD2  mRNA  staining  in  5  control  patients.  The 
intensity  of mRNA  staining  in  Paneth  cells  was  graded  as follows:  +:  weak 
staining - staining confined to the infranuclear region of the cell;  ++: moderate 
staining - staining extending beyond the  infranuclear region of the cell,  but not 
completely surrounding the nucleus;  + ++: strong staining - dense staining that 
completely surrounding the cell nucleus. (Non-In.: Non-inflamed tissue)
1263.2.4  N0D2  protein  is  expressed  by  Paneth  cells  and  lamina 
propria leukocytes
To confirm NOD2  expression in Paneth cells,  I  used  immunohistochemistry to 
detect NOD2 protein.  In terminal ileal sections, the NOD2 protein was detected 
by  immunohistochemical  staining  using  a  purified  rabbit  polyclonal  antibody 
raised against the N-terminal CARD domains of a recombinant NOD2 protein. In 
Crohn's disease-affected terminal ileum sections, positive  immunoreactivity was 
observed  in  Paneth  cells  in  the  crypt  bases  and  in  adjacent  lamina  propria 
mononuclear  cells.  NOD2  protein  was  also  easily  detected  in  Paneth  cells  in 
histologically  normal  small  intestine,  although  expression  in mononuclear cells 
was  observed  in  inflamed  tissue  only.  Within  the  gastrointestinal  tract,  NOD2 
protein was expressed in duodenal, jejunal  and terminal  ileal  sections,  although 
the greatest staining was noted in the terminal ileal crypts where Paneth cells are 
most  numerous.  Immunohistochemistry  with  an  unrelated  rabbit  antibody,  and 
without primary antibody, gave no signal, confirming the specificity of detection 
(Figure 3.10).
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Figure 3.10.  NOD2  protein  is  expressed  by  Paneth  cells  in  small  intestinal 
crypts.  (a)  In  Crohn’ s  disease-affected  terminal  ileum,  positive
immunohistochemical staining,  using a purified rabbit antibody raised against 
recombinant NOD2 protein,  is seen in the basal and apical cytoplasm in Paneth 
cells (thick arrow) and in a monocyte in the lamina propria (thin arrow),  (b-d) 
Positive  immunohistochemical staining of a weaker intensity is seen in Paneth
128cells  (asterisks)  in  histologically  normal  terminal  ileal  (b),  jejunal  (c)  and 
duodenal (d)  tissue,  (e) No staining is seen in Crohn’s disease-affected terminal 
ileal sections incubated with an unrelated rabbit antibody,  (f) No staining is seen 
in  Crohn’ s  disease-affected  terminal  ileal  sections  incubated  without primary 
antibody. All sections were counterstained with haematoxylin,  and viewed under 
the lOOx objective.
In  summary, N0D2  mRNA  and  protein  expression  in Paneth cells  and  lamina 
propria  monocytes  was  detected  by  in  situ  hybridisation  and 
immunohistochemistry.  NOD2  mRNA  was  detected  predominantly  in  Paneth 
cells and not in other intestinal  epithelial  cell types  such as  enterocytes,  goblet 
cells,  stem  cells  or  ulcer-associated  cell  lineages.  Using  a purified  rabbit  anti­
human NOD2  antibody, NOD2 protein expression was  most obvious  in Paneth 
cells. Within Paneth cells, NOD2 mRNA and protein do not stain as intensely as 
other antimicrobial enzymes, such as lysozyme, and the lack NOD2 detection by 
RT-PCR and immunoblotting suggest that this protein is not abundantly expressed 
in intestinal tissue.
3.2.5  NOD2  expression  by  metaplastic  Paneth  cells  in 
Inflammatory Bowel Disease-affected colonic mucosa
Paneth  cells  are  generally  absent  from  the  colon  in  health;  however,  colonic 
Paneth  cell  metaplasia  occurs  in  IBD,  in  which  it  is  thought  to  represent  a 
response  to  chronic  injury  (Porter  2002,  Haapamaki  1997).  These  metaplastic 
cells are unlikely to initiate inflammation because they appear later in the disease 
process,  although they  may play  a role  in chronic  inflammation  (Porter 2002). 
Using  ISH  with  digoxigenin-labelled  antisense  mRNA  probes,  I  determined 
whether NOD2 was also expressed in metaplastic Paneth cells. I localised NOD2 
mRNA  to  metaplastic  Paneth  cells  in  Crohn’s  disease-affected  colonic  crypt 
epithelium, as well as in ulcerative colitis-affected colon. The positive NOD2 ISH 
signal  co-localised  in  adjacent  sections  with  lysozyme  mRNA,  confirming  the 
identity  of  metaplastic  Paneth  cells.  The  intensity  of  staining  of  metaplastic 
Paneth cells  was  comparable with that of Paneth cells  in the  inflamed terminal
129ileum, although there were fewer Paneth cells in each crypt, and most crypts did 
not contain any detectable NOD2 mRNA or protein.
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Figure  3.11.  NOD2  mRNA  is  expressed  by  metaplastic  Paneth  cells  in 
Crohn’s  disease-affected  colonic  mucosa,  (a)  In  situ  hybridization  with  the 
digoxigenin-labelled  NOD  2  anti  sense  strand  riboprobe  demonstrates positive 
brown staining in metaplastic Paneth cells  (thick arrows) present in  the  crypt 
epithelium in Crohn’ s disease-affected colon, and a positive signal is also seen in 
lamina propria mononuclear cells (thin arrows),  (b) Sections hybridized with the 
control  sense  strand riboprobe  show  no  staining,  (c)  NOD2-positive  colonic 
epithelial  cells  are  identified  as  metaplastic  Paneth  cells  (thick  arrows)  by 
localizing  lysozyme  mRNA  in  adjacent  sections  hybridized with  the  lysozyme 
cmtisense strand riboprobe.  (d) Sections hybridized with the control sense strand 
riboprobe show no staining. Lysozyme mRNA is more abundantly expressed than 
NOD2 mRNA,  and lysozyme mRNA staining is more intense.  All sections were 
counterstained with haematoxylin, and viewed under the 40x objective.
1303.2.6  N0D2  protein  expression  in  Crohn's  disease-affected 
patients carrying the NOD2 mutations
The  NOD2  genotype  status  of the  cases  that  I  used  to  demonstrate  NOD2 
expression in Paneth cells could not be established. Therefore, it was important to 
determine whether NOD2 genotype had an effect on NOD2 expression in Paneth 
cells.  To  analyse  NOD2  expression  in  patients  with  NOD2-related  Crohn’s 
disease, I worked in collaboration with Dr Yasunori Ogura and Professor Gabriel 
Nunez at the University of Michigan, USA.
Dr Ogura generated a monoclonal antibody, named 2D9 that was raised against 
the CARD domain of the NOD2 protein (Ogura 2003a). This antibody localised 
the NOD2 protein in close proximity to the secretory granules in Paneth cells. We 
analysed expression in a total  of 52 patients  of whom  26  were  diagnosed with 
Crohn's  disease,  10  with  ulcerative  colitis,  10  with  non-IBD  gastrointestinal 
disease and 6 patients with Crohn's disease who were either homozygous for the 
frameshift mutation or compound heterozygotes.
This work confirmed my observations that Paneth cells, located in the normal and 
inflamed regions of terminal ileum, as well as metaplastic Paneth cells present in 
the colonic mucosa in patients with IBD express the NOD2 protein (Figure 3.12). 
NOD2 was expressed in Paneth cells irrespective of the NOD2 genotype. NOD2 
expression in mononuclear cells was seen in inflamed tissue only.
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Figure  3.12.  NOD2  protein  expression  in  Crohn’s  disease.  (A)  Using  the 
monoclonal 2D9 antibody,  NOD2  is protein  is detected in Paneth  cells in  the 
intestinal crypts in Crohn’ s disease-affected terminal ileal section (arrows).  (B) 
No staining is seen in Crohn's disease-affected terminal ileal sections incubated 
with no primary antibody.  (C) NOD2 protein staining is prominent in the apical 
region  of  Paneth  cells.  (D)  NOD2  protein  is  also  detected  by 
immunohistochemical  staining  within  the  cytoplasm  of  lamina  propria 
mononuclear  leukocytes  (yellow  arrow).  All  sections  are  counter  stained with 
haematoxylin, and viewed under the 2Ox objective (A and B) or lOOx objective (C 
andD).3.2.7  Paneth cells express TNFa mRNA in Crohn’s disease
While  the  role  of  Paneth  cells  in  antibacterial  host  defence  is  increasingly 
recognized,  it  is  also  possible  that  these  cells  play  a  role  in  intestinal 
inflammation.  Paneth cells  express TNFa constitutively in mice,  in response to 
hypoxia-reperfusion  injury  in  rats,  and  in  necrotizing  enterocolitis  in  humans. 
Despite the clinical success of anti-TNF treatment for Crohn’s disease, the cellular 
sources of TNFa in Crohn’s disease-affected tissue have so far remained poorly 
defined,  partly  due  to  the  lack  of  suitable  reagents  for  immunohistochemical 
detection. Using in situ hybridization, I therefore determined whether Paneth cells 
express TNFa in Crohn’s ileitis. I could not detect TNFa mRNA in histologically 
normal terminal ileum (Figure 3.14), although lysozyme and  5PLA2 were easily 
detected in parallel sections. However, in Crohn’s disease-affected terminal ileum, 
I readily demonstrated TNFa mRNA expression in Paneth cells and in infiltrating 
leukocytes  (Figure  3.13).  These  results  suggest  that  Paneth  cells  do  not 
constitutively express high levels of TNFa mRNA in humans, in contrast to mice, 
but  can  be  induced  to  do  so  under pathological  conditions  and  play  a  role  in 
intestinal inflammation.
133134Figure 3.13.  TNFa  mRNA is  strongly expressed  in Paneth  cells  in  Crohn’s 
ileitis (page  134).  (a)  In situ hybridization with the digoxigenin-labelled TNFa 
antisense strand riboprobe demonstrates no positive staining in Paneth cells  in 
histologically  normal  terminal  ileum,  (b)  Parallel  sections  hybridized with  the 
control sense strand riboprobe show no positive staining,  (c) In situ hybridization 
with  the  TNFa  antisense  strand  riboprobe  demonstrates  positive  staining  in 
Paneth  cells  (arrowed)  in  Crohn’ s  disease-affected  terminal  ileum,  (d) 
Hybridization  with  the  control  sense  strand  riboprobe  shows  no  signal, 
confirming the specificity of detection,  (e)  In situ  hybridization  with  the  TNFa 
antisense  strand  riboprobe  demonstrates  positive  signal  in  lamina  propria 
monocytes  in  Crohn’s  disease-affected terminal  ileum,  (f)  No positive  signal  is 
detected  in  sections  hybridized  with  the  control  sense  strand  riboprobe.  All 
sections  were  counterstained  with  haematoxylin,  and  viewed  under  the  lOOx 
objective.
1353.3 Discussion
These results confirm my hypothesis, and show that Paneth cells,  located at the 
base  of  the  intestinal  crypt,  express  NOD2.  NOD2  expression  was  also 
demonstrated  in  mononuclear  cells.  I  was  able  to  demonstrate  expression  of 
NOD2  mRNA,  using  in  situ  hybridisation,  and  protein,  using 
immunohistochemistry  with  both  a purified  rabbit  polyclonal  antibody  and the 
2D9 monoclonal antibody, in Paneth cells. In addition, metaplastic Paneth cells, 
present in IBD-affected colonic mucosa, also expressed NOD2.
My results also show that Paneth cells also express the pro-inflammatory cytokine 
TNFa,  which  is  implicated  in  the  pathogenesis  of  Crohn's  disease.  There  is 
increasing  evidence  that  Paneth  cells  are  involved  in  intestinal  inflammation. 
Paneth cell  hyperplasia  occurs  in response  to  signals  derived  from  activated  T 
cells  in  models  of  enteric  infection  (Kamal  2001),  and  in  IBD,  Paneth  cell 
metaplasia is seen in the colon. In mice, Paneth cells constitutively express TNFa 
mRNA  that  is  apparently  not  translated  into  protein,  probably  because  of 
regulation by the AU-rich element in the 3’ untranslated region of the TNFa gene 
(Keshav 1990). Interestingly, deletion of this regulatory region in transgenic mice 
causes terminal ileitis, but not generalized intestinal inflammation, suggesting that 
local  overproduction  of  TNFa,  potentially  in  Paneth  cells,  is  important 
(Kontoyiannis 1999).
These results, which analysed NOD2 expression in intestinal tissue is important as 
they have identified, for the first time, specific cells in the intestine that express 
NOD2. It is likely, therefore, that understanding the physiological role of NOD2 
in  these  cells  may  yield  insights  into  the  pathophysiology  of NOD2-related 
Crohn’s disease. These results do not indicate the level of expression in these cells 
types  as  in  situ  hybridisation  and  immunohistochemistry  are  not  quantitative 
techniques. Nonetheless, my results show that NOD2 mRNA and protein stains 
most intensely in Paneth cells, which may indicate a prominent role for these cells 
in the pathophysiology of Crohn’s disease.
136Berrebi  and  colleagues  (2003),  using  immunohistochemistry  and  in  situ 
hybridisation,  also  show  that  NOD2  is  expressed  in  mononuclear  cells  and 
epithelial cells in inflamed colonic mucosa in patients with Crohn’s disease. These 
investigators, however, did not analyse NOD2 expression in terminal ileal tissue, 
which is most commonly affected in patients with NOD2-related Crohn’s disease. 
It  is  possible  that  the  NOD2-expressing  epithelial  cells  identified  by  these 
investigators may, speculatively, represent metaplastic Paneth cells (J-P Cezard, 
personal communication).
Although  NOD2  expression  in  Paneth  cells  could  be  detected  by  in  situ 
hybridisation and immunohistochemistry, I was surprised that NOD2 expression 
in terminal ileal tissue could not be detected by RT-PCR. A possible explanation 
for this discrepancy is that the dynamic ranges of PCR reactions are insensitive 
for the detection of low copy numbers of NOD2 mRNA molecules. The mRNA 
sequences that are extracted from terminal ileal tissue are derived from a variety 
of cellular  sources,  and  as  Paneth  cells  constitute  a  small  fraction  of the  total 
intestinal  cellular  population,  Paneth  cell-mRNA  sequences  will  be  present  in 
small  quantities  in  terminal  ileum-RNA  extracts.  Furthermore,  RNA  extracted 
from surgically resected tissue showed RNA degradation, as determined by UV 
transillumination  of  ethidium  bromide-stained  agarose  gels,  which  may  also 
account for the poor detection of NOD2 by PCR.
As far as I am aware, RT-PCR amplification of NOD2 in intestinal epithelial cells 
has only been demonstrated in intestinal epithelial cell lines (Gutierrez 2002) or in 
mechanically isolated epithelial cells (Hisamatsu 2003). In addition, NOD2 is not 
easily  detected  in  terminal  ileal  tissue  by  immunoblotting.  Rosenstiel  and 
colleagues  (2003)  have  successfully  detected  the  NOD2  protein  in  intestinal 
biopsies by immunoblotting, and this experiment was technically very difficult to 
perform  (Philip  Rosenstiel,  personal  communication).  Most  other  investigators 
have not detected NOD2 protein in intestinal tissue by immunoblotting and we, in 
collaboration with Professor G Nunez, could not detect NOD2 protein in isolated 
intestinal crypts, which are enriched with Paneth cells.  Even after concentrating 
the crypt proteins by immunoprecipitation,  I have been unable to detect NOD2 
using  either  purified  rabbit  polyclonal  or  monoclonal  2D9  antibodies  (Gabriel
137Nunez, personal communication). Overall, these observations suggest that NOD2 
is expressed at low levels in Paneth cells and its expression is difficult to detect in 
intestinal tissue.
Although conventional  methods  of mRNA  and protein expression i.e.  RT-PCR 
and immunoblotting suggest that NOD2 is not abundantly expressed in intestinal 
tissue,  my  results  identify  Paneth  cells  and  mononuclear  cells  as  the  most 
prominent NOD2-expressing cells in intestinal tissue. These results may therefore 
indicate  that  Paneth  cells  and  monocytes  play  an  important  role  in  the 
pathophysiology of NOD2 related-Crohn’s disease.
In the next section,  I determined the level of NOD2  gene expression in Paneth 
cells and peripheral blood mononuclear cells. Presently, there is no Paneth cell­
like  cell  line  and  I  therefore  determined  whether  intestinal  epithelial  cell  lines 
express NOD2 and also investigated whether NOD2 expression can be regulated 
in cell lines and PBMC.
138Chapter four
4.  Regulation  of  NOD2  gene  expression  by 
microbial and pro-inflammatory mediators
4.1  Introduction
Previously,  in intestinal  sections  obtained  from patients  with Crohn's  disease,  I 
have shown that Paneth cells and lamina propria mononuclear cells express the 
NOD2  gene  product.  NOD2  expression  was  not  only  confined to  Paneth  cells 
present in the terminal ileum, where they are most numerous, but was also evident 
in metaplastic Paneth cells that are found in IBD-affected colonic tissue.  Using 
non-quantitative  techniques  such  as  in  situ  hybridisation  and 
immunohistochemistry,  my  observations  extend  the  work  of other  studies  that 
describe  NOD2  expression  in  monocytes  and  myelomonocytic  cells  (Ogura 
2001a, Gutierrez 2002). The purpose of this chapter was to investigate further the 
expression  of NOD2  in  Paneth  cells  and  peripheral  blood  mononuclear  cells 
(PBMC). Therefore, I quantitated NOD2 gene expression in Paneth cells that were 
obtained by laser capture microdissection from terminal  ileal tissue  sections.  In 
addition,  I  quantitated  NOD2  expression  in  intestinal  epithelial  cells  obtained 
from surgically resected terminal ileal segments.
Within primary cells, NOD2 is most abundantly expressed in PBMC (Gutierrez 
2002)  although  there  are  no  reports  quantitating  NOD2  mRNA  expression  in 
primary epithelial cells. As NOD2 is most likely to be functionally important in 
those  cells  that  express  the  gene  at  the  highest  levels,  I  therefore  determined 
whether Paneth cells express the NOD2 gene at levels comparable to mononuclear 
cells. It is likely that NOD2 is likely to be expressed at low levels by epithelial 
cells  and monocytes  as  expression in intestinal tissue  is  not easily detected by 
conventional techniques, such as RT-PCR and immunoblotting - NOD2 mRNA 
molecules are likely to be classified as scarce or intermediate, i.e. less than 300 
molecules per cell (Alberts 1994). To facilitate quantitation, I isolated Paneth cells 
from terminal ileal tissue sections by laser capture microdissection, and intestinal 
crypts from terminal ileal tissue by mechanical dissociation and compared NOD2
139mRNA expression, using real-time RT-PCR, in crypt and villus epithelial cells, 
and PBMC.
In haematopoietic cells, I determined if NOD2 expression was regulated in PBMC 
as NOD2 expression increases as precursor cells of the myelomonocytic lineage 
differentiate into mature monocytes (Gutierrez 2002). To determine whether there 
are further changes  in NOD2 expression as mononuclear cells differentiate into 
tissue  macrophages,  I  analysed NOD2  expression in tissue  granulomata,  which 
contain  mature  macrophages  and  newly  recruited  mononuclear  cells  and 
determined  NOD2  expression  in  PBMC  as  monocytes  differentiate  into 
macrophages in vitro.
Previously, using in situ hybridisation, I showed that NOD2 RNA stained more 
intensely in Paneth cells  in inflamed terminal  ileal tissue  sections  compared to 
controls, suggesting that NOD2 expression may be regulated in Crohn’s disease. 
Ideally, I would assess NOD2 regulation in primary cells obtained from patients 
with  NOD2-related  Crohn’s  disease  and  controls.  However,  this  was  not 
practically  feasible  as  it  would  take  a  considerable  length  of time  to  identify 
patients with the NOD2 mutations by genotyping.  Furthermore,  intestinal tissue 
could only  be  obtained  from  patients  undergoing  surgical  treatment.  For these 
reasons, I used intestinal epithelial cells and PBMC to analyse NOD2 expression.
In inflammatory bowel disease, intestinal epithelial cells  are exposed to various 
inflammatory  mediators  that  are  produced  by  activated  leukocytes,  and  I 
speculated that these mediators may also regulate NOD2 expression in these cells. 
T helper 1  (ThI) lymphocytes, which produce pro-inflammatory cytokines such as 
IFNy and TNFa, are thought to mediate mucosal inflammation in Crohn's disease, 
and mucosal T-cells that are isolated from patients with Crohn's disease  secrete 
increased amounts of IFNy (Bouma 2003). I therefore determined whether NOD2 
expression  could  be  regulated  in  intestinal  epithelial  cells  by  lymphokine- 
containing  medium.  Thereafter,  I  determined  whether  the  pro-inflammatory 
cytokines  TNFa  and  IFNy  specifically  regulate  NOD2  expression  in  intestinal 
epithelial cells and PBMC.
140In animal models of IBD, the presence of bacteria is essential for the development 
of intestinal inflammation (Bouma 2003). As it is postulated that NOD2 mediates 
cellular  inflammation  after  interacting  with  bacteria  or  bacterial  products,  I 
determined  whether  bacterial  products  could  regulate  NOD2  expression  and 
cellular inflammation in intestinal epithelial cells.
1414.2 Results
4.2.1 N0D2 quantitation in Paneth cells and PBMC
To quantitate NOD2 expression, I isolated Paneth cells and villus epithelial cells 
by laser capture microdissection from tissue sections. In surgically resected small 
intestinal tissue, I isolated intestinal crypts and villus epithelial cells by detaching 
the  epithelium  from  the  basement  membrane  using  calcium  chelation  and 
mechanical shaking.
4.2.1.1 Laser capture microdissection
Laser capture microdissection (LCM) is a technique that allows specific cells to 
be isolated from a tissue section, which is usually stained with haematoxylin and 
eosin and mounted on adhesive-free glass slides. In LCM, targeted cells adhere to 
a thermoplastic membrane that has been activated by a low energy infrared laser 
pulse.  The  thermoplastic  membrane,  made  of  ethylene  vinyl  acetate,  has  a 
diameter of 6 mm and is mounted on an optically clear cap, which fits on standard 
0.5 mL microfuge tubes, thus facilitating the transfer of cellular contents from the 
adherent  cells  to  microfuge  tubes  containing  appropriate  buffer  solutions.  The 
analysis of mRNA expression in microdissected cells, using reverse transcription 
PCR (RT-PCR), is a relatively newly described technique, which I used to analyse 
NOD2 expression in LCM-acquired Paneth cells.
Gene  profiling  and  quantitation  has  been  successfully  performed  in  LCM- 
acquired cells although there are several factors that may limit gene expression in 
LCM-acquired Paneth cells.  Firstly,  in archived human sections,  approximately 
200-300 Paneth cells can be extracted by LCM from  a section of terminal ileal 
tissue.  In  general,  several  thousand  LCM-acquired  cells  are  required  for  gene 
quantitation  or profiling  (Stappenbeck  2002a),  and  gene  quantitation  in human 
tissue  may  be  limited  by  the  small  number  of  LCM-acquired  Paneth  cells. 
Secondly, cells from frozen tissue sections, which yield better quality RNA, are 
more difficult to dissect by LCM as ethanol, which is used as a tissue fixative, 
increases the adherence of the tissue to glass slides.  Thirdly, eosin inhibits PCR 
reactions  (Fend 2000,  Eltoum 2002) and the mRNA molecules  in Paneth cells,
142which contain numerous intensely-staining apical eosinophilic granules, may not 
amplify easily by RT-PCR. Finally, small amounts of non-dissected cells adhere 
non-specifically  to  thermoplastic  membrane,  contaminating  LCM-acquired  cell 
preparations.  Although  gene  quantitation  in  Paneth  cells  present  in  archived 
human tissue may be technically difficult, this technique nonetheless provides an 
independent method to confirm that Paneth cells express the NOD2 gene.
To determine whether Paneth cell-derived mRNA could be amplified by RT-PCR, 
I  extracted  total  cellular  RNA  from  haematoxylin  and  eosin-stained  frozen 
terminal ileal sections that were fixed on glass slides with ethanol. Frozen sections 
were  manually  scraped  off the  glass  slide,  using  a  sterile  surgical  blade,  and 
collected  in  microfuge  tubes.  Similarly,  haematoxylin  and  eosin-stained  wax 
sections  were  manually  scrapped  off glass  slides,  and  collected  in  microfuge 
tubes.  After  using  xylene  washes  to  de-wax  the  paraffin-embedded  sections,  I 
used oligodT primers to synthesise cDNA from total cellular RNA extracted from 
both  frozen  and  wax  sections.  These  cDNA  sequences  were  subsequently 
amplified  by PCR,  so  that  a  single  40-cycle  PCR  amplification  reaction  could 
amplify GAPDH and defensin 6 mRNA in frozen but not wax sections (Figure
4.1). NOD2 mRNA, however, could not be amplified in frozen sections by this 
method. These results suggested that NOD2 quantitation in LCM acquired cells 
would be difficult, considering that each tissue section contained approximately 
2500 Paneth cells -  10-times as many that are likely to be acquired by LCM.
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Figure 4.1.  GAPDH  and  defensin  6  mRNA expression  in  a frozen  terminal 
ileal section.  Using RT-PCR,  GAPDH (Lane 1) and HD6 mRNA  (Lane 3) were 
amplified from a single frozen section of terminal ileal tissue.  Prior staining of 
this section with haematoxylin and eosin did not  inhibit  PCR  amplification  of 
GAPDH and HD6 mRNA, which is abundantly expressed in Paneth cells. NOD2 
mRNA  can be amplified from PBMC (Lane  7)  but not from  this frozen section 
(Lane 5).  PCR products were separated using agarose gel electrophoresis and 
visualised using ethidium bromide staining.  The expected PCR amplicon size (in 
base pairs) was used to confirm the identity of the PCR products: GAPDH 693; 
HD6 241; NOD2 402. (L: ladder; F: frozen section; W: water; P: PBMC)
In LCM-acquired cells, I was unable to analyse gene expression using RT-PCR. 
After a 40-cycle PCR reaction, I could detect expression of a gene that is highly 
expressed  in  Paneth  cells,  such  as  lysozyme,  but  these  results  could  not  be 
consistently  replicated.  I used  a number of different  strategies to optimise RT- 
PCR  amplification  of  mRNA  obtained  from  LCM-acquired  Paneth  cells, 
including pooling LCM-acquired cells from many sections, but could not amplify
144Paneth cell-mRNA using a 40-cycle PCR reaction (see Discussion).  I therefore 
used  nested  RT-PCR  to  analyse  NOD2  mRNA  expression  in  LCM-acquired 
Paneth cells.
4.2.1.2  NOD2 and alpha defensin 6 (HD6) mRNA expression in LCM- 
acquired Paneth cells
Using  laser-capture  microdissection,  I  obtained  relatively  pure  populations  of 
Paneth cells and villus epithelial cells from terminal ileal tissue sections (Figure
4.2). Using nested RT-PCR, I confirmed that human alpha defensin 6 (HD6) and 
NOD2 mRNA were most abundantly expressed in the Paneth cell fraction. Some 
HD6 mRNA is amplified in the villus epithelial cell fraction (Figure 4.2), and this 
apparently aberrant expression is probably caused by contamination of the villus 
epithelial  cell  samples  with  Paneth  cell-fragments  during  laser-capture 
microdissection.  Greater NOD2 and HD6 mRNA expression were demonstrated 
in Paneth cells obtained from both frozen and wax-embedded sections, although 
gene expression could not quantified by real-time RT-PCR.
To eliminate the possibility of false positive results using nested PCR, which is an 
extremely  sensitive  technique,  I  used  nuclease-free  water  as  a  non-template 
negative  control  that  was  also  re-amplified  in the  second  stage  PCR  reaction. 
Nested  PCR  reactions  are  extremely  sensitive  for  the  detection  of  low  copy 
numbers  of cDNA,  which  undergo  two  cycles  of amplification.  As  the  PCR 
amplification efficiency of small numbers of cDNA molecules is variable, minor 
differences in amplification efficiency are therefore artificially exaggerated in the 
second round of amplification using nested PCT. Although I could not quantitate 
NOD2 gene expression using nested PCR, the results obtained using this method 
are very specific, and support the previous findings, which show that Paneth cells 
specifically express the NOD2 gene.
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146Figure 4.2. Expression of NOD2 mRNA in microdissected Paneth cells (page 
146). Sections of small intestine before and after laser-capture microdissection of 
Paneth  cells  (a)  and  villus  epithelial  cells  (b)  are  shown  stained  with 
haematoxylin  and eosin  and viewed under the  lOx  objective.  The  upper panels 
show  Paneth  cells  and  the  lower panels  show  villus  epithelial  cells,  before 
microdissection  (left-most  panels)  and  after  microdissection  (middle  panels). 
Microdissected cells captured on membranes are shown in the right-most panels, 
(c)  NOD2,  HD6  and GAPDH mRNA  were  analyzed by  nested RT-PCR  using 
intron-spanning primer pairs, in samples of LCM-acquired Paneth cells and villus 
epithelial cells.  For samples with equivalent GAPDH expression,  NOD2 mRNA 
expression  is  readily  detected in  crypt Paneth  cells  but  not  in  villus  epithelial 
cells.  HD6 is detected in both Paneth cells and villus epithelial cells,  with much 
lower  levels  in  the  villus  epithelial fraction.  PCR products  were  separated by 
agarose  gel  electrophoresis  and visualized  by  ethidium  bromide  staining.  The 
expected PCR amplicon size (base pairs) was used to confirm the identity of the 
PCR products: GAPDH 693; HD6 314; NOD2 402.
4.2.1.3  Quantification  of NOD2  mRNA  expression  in  villus  and  crypt 
epithelial cells
To  quantify  NOD2  gene  expression  in  epithelial  cells,  I  extracted  RNA  from 
larger  numbers  of epithelial  cells  that  were  obtained  from  surgically  resected 
terminal ileal tissue.  Large numbers of cells were obtained by calcium chelation 
and mechanical shaking of fresh ileal tissue, which separates epithelial cells from 
the  underlying  basement  membrane.  Using  this  technique,  I  collected  cells 
comprising mainly of villous epithelial cells after the initial periods of mechanical 
shaking,  and  collected  mainly  crypt  epithelial  cells  after  further  periods  of 
mechanical  shaking (Figure 4.3).  This technique,  which allowed me to obtain a 
purer population of Paneth cells,  optimised the  detection of NOD2  in intestinal 
epithelial cells by RT-PCR. In addition, I extracted RNA from a larger number of 
cells (in aliquots containing either >90% villus epithelial cells or >90% intestinal 
crypts) which allowed me to obtain sufficient numbers of intact sheets of villus- 
epithelium  and  intestinal  crypts  to  perform  quantitative  real-time  RT-PCR, 
without the need for nested PCR cycles.
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Figure  4.3.  Villus  and  crypts  isolated  from  surgically  resected  intestinal 
tissue.  Whole villi and crypts containing Paneth cells (arrows) were obtained by 
calcium  chelation  and  mechanical  shaking  of mucosal  tissue  dissected from 
surgically resected small intestinal segments, and viewed under the 20x objective 
in an inverted phase microscope.
By  real-time  RT-PCR  analysis,  NOD2  mRNA  expression  is  approximately  85 
fold  enriched  in  crypt  epithelial  cells  as  compared  to  villous  epithelial  cells 
(Figure 4.4). The current technique used to separate epithelial cells does not yield 
exclusive  crypt  and  villous  epithelial  cells  populations,  and  a  minor  level  of 
NOD2 mRNA expression seen in the villus epithelial cell fraction.  This is most 
likely due to the presence of a  small  percentage of crypt epithelial  cells  in the 
villous cell fraction, or may reflect a lower level of NOD2 expression in villous 
epithelial cells, which is less likely to be the case.  HD6 mRNA, which is much 
more  abundantly  expressed  than  NOD2  in  Paneth  cells,  was  enriched 
approximately  100 fold in crypts, confirming the successful separation of crypts 
and villi (Figure 4.4).
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cells  and PBMC  (page  149).  Quantitative  real-time  RT-PCR  analysis  of crypt 
and  villus  epithelium  shows  enrichment  of  (a)  NOD2  and  (b)  HD6  mRNA 
expression  in  crypts  compared  to  villi.  For  comparison,  NOD2  expression  in 
freshly isolated peripheral blood mononuclear cells (PBMC)  is also shown,  and 
this is approximately 2.7-fold greater than  in crypts.  The  relative  expression of 
NOD2,  HD6 and GAPDH mRNA  were determined by real-time RT-PCR,  using 
intron-spanning primers,  and  the  NOD2:  GAPDH  and  HD6:  GAPDH  ratios 
calculated for  each  sample.  Results  are  shown  as  the  relative  expression 
compared to the level in crypts.  The data are representative of three experiments. 
PCR products were separated using agarose gel electrophoresis and visualised 
using ethidium bromide staining.  The expected PCR amplicon sizes  (base pairs) 
were used to confirm the identity of the PCR products:  GAPDH 693; HD6 241; 
NOD2 402.
To determine the  significance  of NOD2  expression in Paneth cells,  I  compared 
NOD2  mRNA  expression in crypt and villous  epithelial  cells  and PBMC.  This 
quantitative  analysis  of NOD2  mRNA  expression  showed  that  expression  was 
highest  in  freshly  isolated  PBMC  and  that  Paneth  cells  expressed  NOD2  at 
approximately  30-40%  of  the  levels  in  PBMC.  As  Paneth  cells  comprise 
approximately  10%  of the  crypt cell number,  and monocytes  comprise  10%  of 
PBMC, NOD2  mRNA levels in Paneth cells are calculated to be approximately 
30%-40% of the level in monocytes (Figure 4.4).
To confirm that NOD2 is mainly expressed by Paneth cells in the small intestinal 
epithelium, I isolated intestinal crypts and villus epithelial cells from ileal tissue, 
and  isolated  colonic  crypts,  which  normally  do  not  contain  Paneth  cells,  from 
patients  without  IBD.  Real-time  RT-PCR  quantitation  confirmed  that  NOD2 
mRNA  is  predominantly  expressed  in  small  intestinal  crypts,  which  contain 
Paneth cells. In contrast, minimal NOD2 mRNA expression could be detected in 
villus epithelial cells or colonic crypts (Figure 4.5).
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Figure  4.5.  Expression  of NOD2  mRNA  in  crypt  and  villus  epithelial  cells 
isolated from ileal tissue.  Quantitative real-time RT-PCR analysis of crypt and 
villus epithelium shows enrichment of lysozyme and NOD2 mRNA  expression in 
crypts.  Lysozyme  expression  is  enriched  approximately  40-fold  in  crypts  and 
NOD2  expression  is  enriched  approximately  20-fold  crypts  from  the  ileum 
compared to villi or colonic crypts.  Relative expression of NOD2 and lysozyme 
mRNA was determined by real-time RT-PCR,  using intron-spanning primers, and 
the NOD2:  GAPDH and lysozyme:  GAPDH ratios calculated for each sample. 
Results  are  shown  as  the  relative  expression  compared  to  the  level  in  small 
intestinal crypts.  The data are representative of three experiments.
Overall, these results show that NOD2 is most prominently expressed by Paneth 
cells  in  intestinal  epithelial  tissue,  and  that  the  level  of  expression  is 
approximately 30% of the level of expression in PBMC.
1514.2.2  Regulation  of  NOD2  expression  in  PBMC  and  intestinal
epithelial cells
4.2.2.1 NOD2 expression in mononuclear cells in Crohn's disease
There  is  a  prominent  inflammatory  infiltrate  composed  of  monocytes, 
macrophages,  and  lymphocytes  within  the  lamina  propria  of Crohn’s  disease- 
affected tissue.  Although NOD2  is most abundantly expressed in PBMC,  I was 
surprised to find that, by in situ hybridisation and immunohistochemistry, NOD2 
expression is not prominent in tissue macrophages. NOD2 RNA and protein were 
readily  detected  in  scattered  mononuclear  cells,  which  were  characterised  by 
indented  nuclei  and  moderate  amounts  of  cytoplasm.  These  cells  with  these 
typical  morphologic  characteristics  also  expressed  the  CD68  antigen,  thereby 
confirming  their  identity  as  monocytes  (Figure  4.6).  I  did  not  observe  NOD2 
expression  in  the  majority  of resident  tissue  macrophages,  which  also  express 
CD68. In Crohn’s disease-affected tissue, most cells strongly expressed the CD68 
marker  for  mononuclear  phagocytes  in  granulomata.  NOD2-positive  cells, 
however,  were  found  on  the  periphery  of  granulomas  whereas  mature 
macrophages  at the  centre did not express NOD2  RNA or protein (Figure 4.6). 
Overall,  these  observations  suggest  that  NOD2  expression  by  mononuclear 
phagocytes  is most abundant in circulating monocytes,  and in tissues,  in newly 
recruited monocytes, rather than in mature macrophages.
152Figure  4.6.  NOD2  expression  in  mononuclear  cells  in  inflamed  intestinal 
tissue,  (a)  In situ  hybridization  with  the  digoxigenin-labelled NOD2  antisense 
strand  riboprobe  demonstrates  NOD2  RNA  in  newly  recruited  monocytes 
(arrows)  located on the periphery of a granuloma,  and not in centrally located 
histiocytes  and  epitheloid macrophages  (asterisk)  in  Crohn's  disease-affected 
terminal ileum,  (b) Hybridization with the control sense strand riboprobe shows 
no signal,  confirming specificity of detection.  The asterisk indicates the central 
region of the granuloma,  (c) Immunohistochemical staining using an anti-CD68 
antibody positively identifies newly recruited monocytes (arrows) located on the 
periphery  of a  granuloma,  and  mature  macrophages  (open  arrows)  located 
centrally within a granuloma,  (d) In situ hybridization with the NOD2 antisense 
strand  riboprobe  demonstrates  positive  signal  in  lamina  propria  monocytes 
(arrows),  which  are  identified by  their  nuclear  morphology,  but  not  in  other 
leukocytes,  (e)  No positive  signal  is  detected  in  sections  hybridized with  the 
control sense strand riboprobe.  (f) Immunohistochemical staining using an anti- 
CD68 antibody verifies the identity of lamina propria monocytes (arrowed). All 
sections  were  counter  stained  with  haematoxylin,  and  viewed  under  the  4  Ox 
objective (a) to (c), or the lOOx objective (d) to (f).
1534.2.2.2 NOD2 expression is regulated in mononuclear cells in vitro
My observations on NOD2 expression in tissue granulomata add to the evidence 
that  NOD2  expression  in  mononuclear  cells  changes  as  these  cells  undergo 
maturation and differentiation.  Gutierrez and colleagues  (2002) have  shown that 
in myelomonocytic  cells, NOD2  expression is much lower in the immature cell 
precursors and that NOD2 expression in these cells increases as they mature and 
differentiate towards monocytes. In addition, other studies have shown that NOD2 
mRNA expression, as determined by Northern blot analysis, was easily detected 
in peripheral  blood mononuclear cells  (PBMC),  whereas  little  or no  expression 
was  detected  in  macrophage-rich  organs  such  as  the  liver  and  spleen  (Ogura 
2001a).  I  therefore  investigated  the  regulation  of NOD2  expression  in  PBMC, 
obtained  from  healthy  volunteers,  which  were  maintained  in  culture  to  allow 
monocytes  to  differentiate  into  macrophages.  Using  quantitative  real-time  RT- 
PCR, I showed that NOD2 expression decreases with time in PBMC maintained 
in tissue culture (figure 4.7). NOD2 mRNA levels declined steeply initially, and 
were approximately 10% of the starting level after 24 hours of culture. Thereafter, 
the  decline  was  more  gradual  but  could  still  be  detected  in  PBMC  that  were 
maintained in culture for 5 days. This decline in NOD2 expression was not due to 
a decrease in the relative number of monocytes or macrophages, which remained 
constant  as  determined  by  immunocytochemical  detection  of CD68  antigen  in 
cytospin preparations (figure 4.8).
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Figure 4.7. NOD2 mRNA expression in peripheral blood mononuclear cells.
NOD2 mRNA  expression was quantified in freshly isolated PBMC and in cells 
maintained  in  culture for  24,  48  and  72  hours,  using  real-time  RT-PCR  with 
intron-spanning primers.  Results were normalized using  GAPDH mRNA  as  an 
internal standard. NOD2 mRNA levels are shown as a percent relative to the level 
in  freshly  isolated  PBMC.  The  lower  panel  shows  NOD2  and  GAPDH 
amplification products from  mRNA  extracted from freshly  isolated PBMC,  and 
cells maintained in culture for 24,  48 and 72 hours,  using RT-PCR with intron- 
spanning  primers.  PCR  products  were  separated  using  agarose  gel 
electrophoresis  and visualized  using  ethidium  bromide  staining.  The  expected
155PCR  amplicon  size  (base pairs)  was  used to  confirm  the  identity  of the  PCR 
products: GAPDH 693; NOD2 402.
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Figure 4.8. Percentage of CD68 positive cells in primary PBMC maintained 
in culture. Cytospin preparations of  freshly-isolated PBMC and those that were 
maintained in culture for 24,  48,  72 and 120 hours were stained for the CD68 
antigen.  The percentage of CD68-positive cells in these preparations was: 42.9 % 
in freshly isolated PBMC,  40.4% in PBMC cultured for 24 hours,  40.6 in PBMC 
cultured for  48  hours,  46.8%  in  PBMC  cultured for  72  hours,  and 44.9%  in 
PBMC culturedfor 120 hours.
To confirm that NOD2 expression decreases as PBMC are maintained in culture, I 
extracted  PBMC  from  blood  that  had  been  removed  by  venesection  from 
polycythaemic patients who were otherwise healthy. Using quantitative real-time 
RT-PCR, NOD2 expression decreased to 67% of the starting levels after 24 hours
156of culture.  After  48  hours  of culture,  NOD2  expression  decreased  by  50%  in 
PBMC and after 72 hours of culture, expression decreased by 56% (Figure 4.9). 
Although NOD2  mRNA  expression did not decrease  as  dramatically  in PBMC 
extracted from polycythaemic patients compared to PBMC extracted from healthy 
volunteers  for  reasons  that  are  unclear,  these  results  confirm  an  association 
between NOD2 mRNA expression levels and the length of time of PBMC culture. 
These  results  suggest  that  NOD2  expression  decreases  in  monocytes  as  they 
differentiate into macrophages in vitro.
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Figure 4.9. NOD2 mRNA expression in PBMC extracted from polycythaemic 
patients. NOD2 mRNA expression was quantified in freshly isolated PBMC and 
in cells maintained in culture for 24,  48 and 72 hours,  using real-time RT-PCR 
with intron-spanning primers.  Results were normalized using GAPDH mRNA as 
an internal standard. NOD2 mRNA levels are shown as a percent relative to the 
level in freshly  isolated PBMC which  is set as  100%.  Values  in  the figure  are 
expressed as the mean ± SEM (Standard error of the mean).  Experiments were 
performed seven  times  (n=7),  and differences  between  stimulated and  control 
cells  were  analyzed  by  two-tailed,  non-paired  t  test,  with  a  P  value  <0.05 
indicative of  statistical significance.
1574.2.2.3 Regulation of NOD2 expression in PBMC
Next, I determined whether it is possible to regulate NOD2 expression in PBMC 
that were stimulated with pro-inflammatory cytokines  and bacterial  antigens.  In 
PBMC  obtained  from  healthy  volunteers,  NOD2  expression  was  generally 
difficult to  detect  in these  cells that were  maintained  in  culture  for  at least 24 
hours.  To  facilitate detection  of  NOD2  expression  in  PBMC  maintained  in
culture,  I  obtained a  larger  number  of  PBMC  from  otherwise  healthy
polycythaemic patients undergoing venesection.
4.2.2.4 NOD2  mRNA expression in  PBMC  stimulated with  TNFa and 
dexamethasone
Treatment  with  steroids  and  anti-TNFa  antibodies  often  induce  remission  in 
Crohn’s  disease-affected  patients  suffering  from  acute  relapses.  I  therefore 
determined  whether TNFa  and dexamethasone  could  regulate  NOD2  mRNA
expression  in  PBMC.  NOD2 mRNA  expression  was  increased  in  PBMC
stimulated with TNFa (100 ng/mL) compared to control cells. By real-time RT- 
PCR  analysis,  NOD2  mRNA  levels  were  approximately  25%  and  60%  higher 
after  24  and  72  hours  of culture  in  TNFa-stimulated  PBMC  as  compared  to 
control cells. Dexamethasone treatment (1  pg/mL), on the other hand, appeared to 
decrease  NOD2  expression.  In  dexamethasone-treated  PBMC,  NOD2  mRNA 
levels could not be quantitated and NOD2 PCR products could not be visualised 
by gel electrophoresis in PBMC maintained in culture for at least 24 hours (Figure 
4.10).
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Figure 4.10. TNFa and dexamethasone regulate NOD2 expression in PBMC.
RT-PCR  analysis  of GAPDH and NOD2  expression  in  PBMC  maintained  in 
culture  shows  that  NOD2  expression  is  decreased  in  PBMC  stimulated  with 
dexamethasone and increased in cells stimulated with TNFa. PCR products were 
separated  using  agarose  gel  electrophoresis  and  visualised  using  ethidium 
bromide  staining.  The  expected PCR  amplicon  size  (base pairs)  was  used to 
confirm the identity of the PCR products: GAPDH 693; NOD2 402.  (0 hr : freshly 
isolated PBMC; Dexa: dexamethasone; TNF: TNFa).
4.2.2.5  NOD2  mRNA expression  in  PBMC  after stimulation  with  LPS 
and muramyl dipeptide (MDP)
The precise function of NOD2 remains undefined at present. It is postulated that 
NOD2 functions as an intracellular receptor or ‘sensor’  for the bacterial product 
muramyl  dipeptide  (MDP)  although  it  was  originally  proposed  that  NOD2 
facilitated the detection of LPS. I therefore determined whether these ligands had 
an effect of NOD2 expression in PBMC that were maintained in culture.
There  was  no  apparent  difference  in  NOD2  expression  in  PBMC  that  were 
stimulated with LPS (10 ng/mL) for 48 hours (Figure 4.11). In PBMC that were 
stimulated with MDP (20 pg/mL), NOD2 expression was increased after 2 hours 
of stimulation, but expression levels decreased thereafter.  The decline in NOD2
NOD2
159expression,  however,  was  more  gradual  in  MDP-stimulated  PBMC.  NOD2 
mRNA levels declined rapidly so that expression could not be  detected by real­
time RT-PCR in 2 of 3 control samples after 24 hours and 48 hours of culture. In 
MDP-stimulated PBMC, on the other hand, NOD2 mRNA could be detected in all 
samples after 24 hours of culture, and in 1   of 3 samples after 48 hours of culture 
(Figure 4.12).
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Figure  4.11.  NOD2  mRNA  expression  in  LPS  stimulated-PBMC.  RT-PCR 
analysis  of  GAPDH  and  NOD2  expression  in  control  PBMC  and  PBMC 
stimulated with LPS (10 ng/mL) for 48 hours shows  no  apparent difference  in 
NOD2  expression.  PCR  products  were  separated  using  agarose  gel 
electrophoresis  and  visualised  using  ethidium  bromide  staining.  The  expected 
PCR  amplicon  size  (base pairs)  was  used to  confirm  the  identity  of the  PCR 
products: GAPDH 693; NOD2 336.
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Figure  4.12.  NOD2  mRNA  expression  in  PBMC  stimulated  with  MDP.  In
PBMC maintained in culture for 2 hours, NOD2 mRNA  expression was slightly 
lower in unstimulated cells as compared to MDP stimulated cells. After 24 and 48 
hours of culture, NOD2 mRNA levels were expressed at relatively higher levels in 
MDP-treated PBMC although the difference between untreated and MDP-treated 
cells  at  each  time  point  was  not  significant.  NOD2  expression  levels  were 
significantly reduced in control and MDP stimulated cells maintained in culture 
for 24 and 48 hours compared to the levels in freshly isolated PBMC.  The relative 
expression of NOD2 and GAPDH mRNA were determined using intron-spanning 
primers,  and the NOD2: GAPDH ratios calculated for each sample.  Results are 
shown  relative  to  the  expression  in  freshly  isolated  PBMC  where  NOD2 
expression has been defined as 100%.  Values in the figure are expressed as the 
mean ± SEM (Standard error of the mean).  Experiments were performed three 
times (n=3),  and differences between stimulated and control cells were analysed 
by  two-tailed,  non-paired t  test,  with  a  P  value  <0.05  indicative  of statistical 
significance.
1614.2.2.6 NOD2 expression in intestinal epithelial cells
Within the  intestinal epithelium,  I have  shown that NOD2  is most prominently 
expressed in Paneth cells. There is, however, no suitable in vitro or ex vivo model 
to  assess  gene  regulation  in  Paneth  cells  and  I  therefore  determined  whether 
NOD2 is expressed in intestinal epithelial cell lines as they might make a useful 
model to  investigate  the  regulation of NOD2  expression.  I  showed that NOD2 
expression can be detected by RT-PCR in immortalised intestinal epithelial cell 
lines.  Caco-2  intestinal  epithelial  cells,  which  display  some  features  of small 
intestinal  epithelial  differentiation,  constitutively  expressed  the  NOD2  gene  at 
similar levels to PBMC cultured for 24 hours. These Caco-2 cells also expressed 
high levels of secretory phospholipase A2 (5PLA2) and lysozyme mRNA that are 
normally restricted to  Paneth cells  in small intestinal  crypts.  In contrast,  HT29 
cells expressed low levels of NOD2 mRNA that could be demonstrated only by 
quantitative real-time RT-PCR (Figure 4.13).
I then used both Caco-2  and HT29 cells  [and SW480 cells after Hisamatsu and 
colleagues (2003) reported NOD2 expression in these cells] to investigate NOD2 
regulation in intestinal epithelial cells.
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Figure  4.13.  NOD2  mRNA  expression  in  intestinal  epithelial  cells.  NOD2 
mRNA  expression  was  quantified  in  freshly  isolated  PBMC  and  in  cells 
maintained in culture for 24, 48 and 72 hours, and Caco-2 and HT29 cells, using 
real-time RT-PCR with intron-spanning primers.  Results were normalized using 
GAPDH mRNA  as  an  internal standard.  NOD2  mRNA  levels  are  shown  as  a 
percent relative  to  the  level in freshly isolated PBMC.  The  lower panel shows 
NOD2  and GAPDH amplification products from  mRNA  extracted from  PBMC 
and Caco-2 and HT29 cells,  using RT-PCR with intron-spanning primers.  PCR 
products were separated using agarose gel electrophoresis and visualized using 
ethidium  bromide  staining.  The  expected PCR  amplicon  size  (base pairs)  was 
used to confirm the identity of the PCR products: GAPDH 693; NOD2 402.
4.2.2.7  Regulation of NOD2 expression in intestinal epithelial cells
Previously, using in situ hybridisation and immunohistochemistry, I observed that 
NOD2  RNA  and  protein  appeared  to  stain  more  intensely  in  Crohn’s  disease-
163affected tissue as compared to controls, which suggested that NOD2 expression 
may be regulated during inflammation. To potentially mimic the in vivo effect of 
activated  leukocytes  on  the  intestinal  epithelium,  I  treated  Caco-2  cells  with 
conditioned medium containing lymphokine, which are soluble cytokines secreted 
by lymphocytes. I analysed NOD2 mRNA expression in Caco-2 cells, cultured in 
growth medium containing 50% lymphokine, by northern blotting (RNA blotting) 
and RT-PCR. NOD2 mRNA expression was not easily detected by northern blot 
analysis, indicating low basal levels of NOD2 expression in Caco-2 cells (Figure
4.14).
Figure  4.14.  Northern  blot  analysis  of NOD2  and  GAPDH  expression  in 
Caco-2  cells.  NOD2  mRNA  expression  is not easily detected in  Caco-2  cells, 
including  cells  stimulated  with  conditioned  medium  from  PHA-stimulated 
lymphocytes. GAPDH mRNA expression, in contrast, is easily detected in Caco-2 
cells by northern blotting.
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164As the  low levels  of NOD2  mRNA  expression in Caco-2  cells  were  not easily 
detected  by  northern  blotting,  I  used  RT-PCR  to  analyse  NOD2  expression  in 
intestinal  epithelial  cells  stimulated  by  lymphokine.  By  RT-PCR,  NOD2 
expression was  increased  in  Caco-2  cells  and  induced  in HT29  cells  that were 
treated  with  conditioned  medium  from  PH  A  stimulated  lymphocytes  (Figure
4.15).
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Figure  4.15.  NOD2  expression  is  intestinal  epithelial  cells  treated  with 
conditioned  medium.  RT-PCR  analysis  of GAPDH and NOD2  expression  in 
Caco-2 and HT29 cells treated with lymphokine-conditioned medium  (+) shows 
an  increase  in  NOD2  expression  in  Caco-2  cells  that  constitutively  express 
NOD2.  In  HT29  cells,  which  do  not  express  detectable  NOD2  mRNA  under 
normal  culture  conditions,  NOD2  expression  is  induced  in  cells  treated with 
conditioned  medium.  PCR  products,  stained  with  ethidium  bromide,  were 
separated  by  agarose  gel  electrophoresis  and  visualised  by  transillumination 
under UV light.  The expected PCR amplicon size (base pairs) was used to confirm 
the identity of the PCR products:  GAPDH 693; NOD2 402.  (- indicates control 
cells and + indicates cells cultured in lymphokine-containing growth medium)
4.2.2.8  TNFa  and  IFNy  increase  NOD2  expression  in  intestinal 
epithelial cells
In  vitro,  PHA-stimulated  lymphocytes  secrete  various  cytokines,  such  as  IFNy, 
TNFa,  IL-4  and GM-CSF.  To  identify whether these  cytokines regulate NOD2 
expression in intestinal epithelial cells, I quantitated NOD2 expression, using real­
time RT-PCR, in intestinal epithelial cells that were stimulated with recombinant
165human IFNy (103  U/mL), TNFa (100 ng/mL), IL-4 (10 ng/mL) and GM-CSF (10 
ng/mL) proteins.
In intestinal epithelial cell lines, NOD2 expression is increased in cells that had 
been  treated  with  recombinant  TNFa  and  IFNy.  In  Caco-2  cells,  which 
constitutively  express  NOD2,  TNFa  stimulation  increased  NOD2  mRNA 
expression 2.5-fold whilst IFNy stimulation induced a smaller (1.7-fold) increase 
in NOD2  expression.  Stimulation  with  both  TNFa  and  IFNy  increased  NOD2 
mRNA expression 3.5-fold in Caco-2 cells (Figure 4.16). There was no change in 
NOD2 expression in Caco-2 cells that were treated with IL-4 and GM-CSF.
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Figure  4.16.  Regulation  of  NOD2  expression  in  Caco-2  cells.  Using 
quantitative real-time RT-PCR, NOD2 mRNA expression was increased in Caco-2 
cells stimulated by TNFa (P=0.0185) and IFNy (P=0.0004).  Co-stimulation with 
TNFa and IFNy also  increased NOD2 expression  (P=0.0373)  although NOD2 
expression  was  not  regulated  by  IL-4  or  GM-CSF  stimulation.  The  relative 
expression of NOD2 and GAPDH mRNA were determined using intron-spanning 
primers,  and the NOD2: GAPDH ratios calculated for each sample.  Results are 
shown as the relative expression compared to the level in unstimulated (control) 
Caco-2  cells,  which  was  arbitrarily  set  as  1  unit.  Values  in  the figure  are 
expressed as the mean ± SEM (Standard error of the mean).  Experiments were
166performed three times, and differences between stimulated and control cells were 
analysed  by  two-tailed,  non-paired  t  test,  with  a  P  value  <0.05  indicative  of 
statistical significance.
TNFa also induced NOD2 expression in HT29 cells, which do not constitutively 
express  the  gene  (Figure  4.17).  In  HT29  cells,  IFNy  also  induced  NOD2 
expression, albeit to a weaker extent (Figure 4.17). In HT29 cells, TNFa induced 
a 2.6-fold greater increase in NOD2 expression than IFNy, although the relative 
increase in NOD2 expression could not be quantified as there is no constitutive 
NOD2 expression in HT29 cells.
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Figure 4.17. NOD2 expression in HT29 cells. RT-PCR analysis of GAPDH and 
NOD2 expression in HT29 cells treated with  TNFa  (100 ng/mL) and IFNy (103  
U/mL) shows that NOD2 expression is induced in cells treated with TNFa, IFNy, 
or both cytokines. PCR products, stained with ethidium bromide,  were separated 
by  agarose  gel  electrophoresis  and  visualised  by  transillumination  under  UV 
light.  The  expected PCR  amplicon  size  (base pairs)  was  used to  confirm  the 
identity of the PCR products: GAPDH 693; NOD2 402.
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168At the time  of performing these experiments,  Hisamatsu and colleagues  (2003) 
reported that NOD2 mRNA is constitutively expressed at higher levels in SW480 
cells in comparison to other intestinal epithelial cell lines.
I  therefore  investigated  NOD2  mRNA  expression  in  the  SW480  intestinal 
epithelial cell line. In SW480 cells, TNFa stimulation increased NOD2 expression 
1.8-fold  although,  surprisingly,  IFNy  stimulation  did  not  increase  NOD2 
expression (Figure 4.18). NOD2 expression was increased 2-fold in cells treated 
with both TNFa and IFNy.
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Figure  4.18.  Regulation  of  NOD2  expression  in  SW480  cells.  Using 
quantitative  real-time  RT-PCR,  NOD2  mRNA  expression  was  increased  in 
SW480cells stimulated by TNFa (P=0.0178). Stimulation of these cells with IFNy 
alone did not increase NOD2 expression (a significant decrease in expression was 
observed) and co-stimulation with TNFa and IFNy increased NOD2 expression, 
which was not significant.  The relative expression of NOD2 and GAPDH mRNA 
was determined using intron-spanning primers,  and the NOD2:  GAPDH ratios 
calculated for  each  sample.  Results  are  shown  as  the  relative  expression
169compared to the level in unstimulated SW480 cells, which was arbitrarily set as 1 
unit.  Values in the figure are expressed as the mean ±SEM (Standard error of the 
mean).  Experiments  were  performed  three  times,  and  differences  between 
stimulated and control cells were analysed by two-tailed, non-paired t test, with a 
P value <0.05 indicative of  statistical significance.
Overall, these results  show that TNFa increases NOD2  expression in intestinal 
epithelial  cells.  These  increases,  however,  appear modest  in  comparison to  the 
increases  in  IL-8  mRNA  measured  in intestinal  epithelial  cells  stimulated with 
TNFa.  In  Caco-2  cells,  stimulation  with  either  TNFa  or  IFNy  increased  IL-8 
mRNA expression 5.8-fold and 1.9-fold respectively. Stimulation with both these 
cytokines  increased  IL-8  expression  5.9-fold  in  Caco-2  cells  (Figure  4.19).  In 
HT29  cells,  much  larger  increases  in  IL-8  mRNA  expression were  noted  after 
stimulation with TNFa and IFNy (Figure 4.20). In these cells, TNFa stimulation 
induced a 43.5-fold increase in IL-8 expression, and IFNy stimulation increased 
IL-8 expression approximately 5-fold. Treating HT29 cells with both TNFa and 
IFN  synergistically  increased  IL-8  expression 200-fold.  In  SW480  cells,  TNFa 
increased  IL-8  mRNA  expression  5.9-fold  whereas  IFNy  increases  expression 
modestly  (1.3-fold).  IL-8  expression  was  increased  13-fold  in  cells  stimulated 
with both cytokines (Figure 4.21).
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Figure 4.19. IL-8 expression in  Caco-2 cells.  Using quantitative real-time RT- 
PCR,  IL-8  mRNA  expression  was  significantly  increased  in  Caco-2  cells 
stimulated by TNFa (P=0.0003). A smaller but significant increase was seen in 
cells stimulated with IFNy and TNFa and IFNy also synergistically increase IL-8 
mRNA  in these cells (P=<0.0001).  The relative expression of IL-8 and GAPDH 
mRNA  were  determined using intron-spanning primers,  and the  IL-8:  GAPDH 
ratios calculated for each sample.  Results are shown as the relative expression 
compared to the level in unstimulated Caco-2 cells, which was arbitrarily set as 1 
unit.  Values in the figure are expressed as the mean ±SEM (Standard error of the 
mean).  Experiments  were  performed  three  times,  and  differences  between 
stimulated and control cells were analysed by two-tailed, non-paired t test, with a 
P value <0.05 indicative of  statistical significance.
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Figure  4.20.  IL-8  expression  in  HT29  cells.  Using quantitative  real-time  RT- 
PCR, IL-8 mRNA expression is significantly increased in HT29 cells stimulated by 
TNFa (P<0.001).  A  smaller but significant increase  is seen  in  cells stimulated 
with IFNy alone (P=0.004) and TNF  a and IFNy also synergistically increase IL-8 
mRNA  in  these  cells  (P=0.020).  The  relative  expression  of IL-8  and  GAPDH 
mRNA  were  determined using  intron-spanning primers,  and the  IL-8:  GAPDH 
ratios calculated for each sample.  Results are shown as the relative  expression 
compared to the level in unstimulated HT29 cells, which was arbitrarily set as 1 
unit.  Values in the figure are expressed as the mean ±SEM (Standard error of the 
mean).  Experiments  were  performed  three  times,  and  differences  between 
stimulated and control cells were analysed by two-tailed, non-paired t test, with a 
P value <0.05 indicative of  statistical significance.
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Figure 4.21. Regulation of IL-8 expression in SW480 cells.  Using quantitative 
real-time  RT-PCR,  IL-8  mRNA  expression  is  significantly  increased in  SW480 
cells stimulated by TNFa (P=0.05) and a smaller nonsignificant increase is seen 
in  cells  stimulated  with  IFNy  .  Stimulation  with  both  TNFa  and  IFNy 
synergistically increase IL-8 expression (P=0.05).  The relative expression of IL-8 
and GAPDH mRNA were determined using intron-spanning primers,  and the IL- 
8:  GAPDH ratios calculated for each sample.  Results are shown as the relative 
expression  compared  to  the  level  in  unstimulated  SW480  cells,  which  was 
arbitrarily set as  1  unit.  Values in the figure are expressed as the mean ± SEM 
(Standard  error  of the  mean).  Experiments  were  performed  three  times,  and 
differences  between  stimulated and control  cells  were  analysed  by  two-tailed, 
non-paired t test, with a P value <0.05 indicative of statistical significance.
In PBMC, NOD2 expression appears to be regulated by dexamethasone treatment, 
which  decreases  NOD2  expression.  I  therefore  determined  whether 
dexamethasone treatment could regulate NOD2 expression in intestinal epithelial 
cells.  In Caco-2  cells, dexamethasone treatment decreased NOD2  expression by 
approximately  35%  whereas  TNFa  stimulation  increases  NOD2  expression  by 
approximately  2.5  fold  (Figure  4.22).  Dexamethasone  did  not  induce  NOD2 
expression in HT29 cells, which do not constitutively express the gene.
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Figure  4.22.  Regulation  of  NOD2  expression  in  Caco-2  cells  by 
dexamethasone.  Using quantitative real-time RT-PCR, NOD2 mRNA expression 
is significantly decreased in Caco-2 cells stimulated by dexamethasone (P=0.01), 
and significantly increased in cells stimulated with TNFa (P=0.02).  The relative 
expression of NOD  2 and GAPDH mRNA were determined using intron-spanning 
primers,  and the NOD2:  GAPDH ratios calculated for each sample.  Results are 
shown  as  the  relative percentage  of expression  in  unstimulated  Caco-2  cells, 
which was defined as  100%.  Values  in the figure  are  expressed as the  mean ± 
SEM (Standard error of the mean). Experiments were performed three times, and 
differences  between  stimulated and control  cells  were  analysed  by  two-tailed, 
non-paired t test, with a P value <0.05 indicative of  statistical significance.
4.2.2.9  NOD2  mRNA expression in intestinal epithelial cells stimulated 
with lipopolysaccharide (LPS)
Previous  investigators  that  have  demonstrated  NOD2  expression  in  intestinal 
epithelial  cells  have  postulated that NOD2  function as  an  intracellular bacterial 
‘sensor’  (Inohara 2003a). Although controversial, some investigators describe the 
expression of toll-like receptors (TLRs) in intestinal epithelial cells and speculate 
that  intestinal  epithelial  cells  may  respond  to  stimulation  by  bacterial  antigens 
(Cario 2000). I therefore determined whether NOD2 mRNA changes in intestinal 
epithelial cells that were stimulated with the bacterial products LPS and MDP.
174Initially, using real-time RT-PCR, I could not demonstrate any change in NOD2 
and IL-8 mRNA expression in Caco-2 and HT29 cells that were stimulated with 
LPS.  Next,  I  pre-treated  Caco-2  and HT29  cells  with  TNFa  and  IFNy  for  48 
hours,  which  is  reported  to  increase  TLR4  and  MD-2  expression  and  LPS 
responsiveness in intestinal epithelial cells (Abreu 2002), before stimulation with 
LPS. After taking into account the increase in NOD2 expression induced by TNFa 
and  IFNy  treatment,  there  was  no  further  change  in  NOD2  expression,  as 
measured  by  real-time  RT-PCR,  in these  pre-treated  cells  that were  stimulated 
with  LPS.  IL-8  mRNA  expression  increased  in  response  to  TNFa  and  IFNy 
stimulation but there was no change in expression in pre-treated cells that were 
stimulated  with  LPS.  In  addition,  Caco-2  and  HT29  cells  were  grown  to 
confluence in transwell plates and I pre-treated these cells in a basal direction with 
TNFa and IFNy. These pre-treated cells were then apically stimulated with LPS. 
Using RT-PCR, NOD2 mRNA expression was increased after pre-treatment with 
TNFa  and  IFNy,  and  additional  LPS  stimulation  did  not  appear  to  markedly 
influence  NOD2  expression  (Figure  4.23).  Overall,  these  results  indicate  that 
Caco-2 and HT29 cells are generally unresponsive to stimulation with LPS, and a 
potential role for LPS in NOD2 regulation in intestinal epithelial cells cannot be 
analysed in the system that I used.
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Figure  4.23.  NOD2  expression  in  intestinal  epithelial  cells  stimulated  with 
LPS. RT-PCR analysis of GAPDH and NOD2 expression Caco-2 and HT29 cells 
treated with IFNy (10s U/mL) (Lanes 2 and 7) and TNFa (100 ng/mL) (Lanes 4 
and 9); and in LPS-stimulated cells that were pre-treated with IFNy (Lanes 3 and 
8) or TNFa (Lanes 5 and 10).  Untreated control cells are shown in Lanes I and 6. 
PCR products,  stained with  ethidium  bromide,  were  separated by agarose gel 
electrophoresis and visualised by transillumination under UV light.  The expected 
PCR amplicon  size  (base pairs)  was  used to  confirm  the  identity  of the  PCR 
products: GAPDH 693; NOD2 402.
4.2.2.10  NOD2  mRNA  expression  in  intestinal  epithelial  cells 
stimulated with muramyl dipeptide (MDP)
Next,  I determined whether MDP could regulate NOD2 expression in intestinal 
epithelial  cells.  By  real-time  RT-PCR  analysis,  a  modest  (2-fold)  increase  in 
NOD2 mRNA expression was noted in Caco-2 cells stimulated with MDP (Figure 
4.24). Next, I pre-treated Caco-2 and HT29 cells with TNFa, to increase NOD2
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176expression, before stimulation with MDP. In Caco-2 cells that were treated with 
TNFa, MDP stimulation increased NOD2 mRNA expression 3.3-fold whereas a 
2-fold increase was noted in cells treated with TNFa only (Figure 4.24).
In  HT29  cells,  which  do  not  constitutively  express  NOD2,  MDP  stimulation 
induced NOD2 mRNA expression in TNFa-treated cells that was  1.5-fold greater 
than the level of NOD2 expression in cells treated with TNFa only. NOD2 mRNA 
expression was not regulated in SW480 cells treated with MDP.
The  nuclear  factor  kB  (NF-kB)  is  an  important  transcription  factor  that  has  a 
central role in coordinating the expression of a wide variety of genes that control 
immune  responses  (Li  2002).  For  example,  NF-kB  induces  transcription 
activation  of IL-8,  a  chemokine  that  functions  as  a  neutrophil  chemoattractant 
(Hoffmann  2002).  As  MDP  is  postulated  to  induce  NF-kB  activation  after 
interacting  with  NOD2  (Girardin  2003),  I  therefore  quantitated  IL-8  mRNA 
expression  in  intestinal  epithelial  cells  stimulated  with  MDP.  In  Caco-2  cells 
stimulated with  MDP,  IL-8  mRNA  expression  increases  modestly  (1.6-fold)  in 
comparison to  a  5-fold increase  seen in cells  stimulated with TNFa.  In Caco-2 
cells  that  were  pre-conditioned  with  TNFa,  MDP  stimulation  increased  IL-8 
mRNA  expression  17-fold  (Figure  4.25).  SW480  cells  were  unresponsive  to 
stimulation  with  MDP  and  showed  no  increases  in  NOD2  or  IL-8  mRNA 
expression.
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Figure  4.24.  Regulation  of NOD2  and  IL-8  expression  in  Caco-2  cells  by 
MDP.  Using  quantitative  real-time  RT-PCR,  NOD2  mRNA  expression  is 
increased in Caco-2 cells stimulated by TNFa and MDP although the increase in 
expression was not statistically significant.  TNFa induced a larger increase in IL- 
8 expression than MDP,  which also increased IL-8 expression.  The increases in 
IL-8  expression  induced  by  MDP  and  TNFa  are  statistically  significant.  A 
synergistic increase, which is statistically significant, was seen in cells stimulated 
with TNFa and MDP.  The relative expression of NOD, IL-8 and GAPDH mRNA 
was determined using intron-spanning primers,  and the NOD2:  GAPDH and IL- 
8:  GAPDH ratios calculated for each sample.  Results are shown as the relative 
expression  compared  to  the  level  in  unstimulated  Caco-2  cells,  which  was 
arbitrarily set as  1  unit.  Values in the figure are expressed as the mean ± SEM 
(Standard  error  of the  mean).  Experiments  were  performed  three  times,  and 
differences  between  stimulated and control  cells  were  analysed by  two-tailed, 
non-paired t test, with a P value <0.05 indicative of  statistical significance.
Overall,  these  results  show that MDP  stimulation  induces  modest responses  in 
NOD2  and  IL-8  mRNA  expression  in  intestinal  epithelial  cells.  Also,  NOD2 
regulation  appears  to  be  regulated  to  a  greater  degree  by  TNFa  in  intestinal 
epithelial  cells  (although  the  overall  response  to  TNFa  stimulation  is  also 
modest). Stimulation with the bacterial antigens LPS and MDP does not increase 
IL-8 mRNA transcription in intestinal epithelial cells to the same level does TNFa
178stimulation.  MDP,  however,  appears  to  cause  a  synergistic  increase  in  IL-8 
mRNA  in  Caco-2  pretreated  with  TNFa  (which  increases  baseline  NOD2 
expression),  suggesting that NOD2 may play a role  in mediating MDP-induced 
cellular responses.  This  hypothesis,  however,  can be  more  accurately  tested  in 
cells expressing wild-type and mutant NOD2 proteins.
1794.3 Discussion
4.3.1  N0D2 gene quantitation in Paneth'bells
Paneth cells express the NOD2 gene at levels that are approximately a third of the 
levels in circulating monocytes, which express NOD2 most abundantly. By in situ 
hybridisation and immunohistochemistry, NOD2  is  most prominently expressed 
in Paneth cells and lamina propria mononuclear cells. NOD2 gene quantitation in 
primary  intestinal  epithelial  cells  was  difficult  to  determine  as  NOD2  is  not 
readily detected  in intestinal tissue by RT-PCR.  Gene  quantitation by real-time 
RT-PCR  was  only  ascertained  after  obtaining  large  numbers  of  intestinal 
epithelial  cells,  using  calcium  chelation  and  mechanical  dissociation,  from 
resected  intestinal  tissue.  NOD2  is  most  prominently  expressed  in  intestinal 
crypts, and the level of expression in Paneth cells are approximately 30-40% of 
levels measured in freshly isolated PBMC.
NOD2  expression  could  not  be  quantitated  in  LCM-acquired  epithelial  cells 
although I was able to confirm that NOD2 is specifically expressed in Paneth cells 
by nested RT-PCR. It is likely that insufficient amounts of RNA were extracted 
from LCM-captured Paneth cells in tissue sections to permit accurate quantitation 
using real-time RT-PCR. For gene quantitation in LCM-acquired cells, sufficient 
amounts of RNA should be obtained from captured cell populations. Stappenbeck 
and colleagues  (2002a)  estimate that,  in murine  intestinal tissue,  approximately 
500 cell equivalents, with each cell yielding  10-30 pg of RNA,  are required for 
real-time  RT-PCR  gene  quantitation  in  LCM-acquired  cells.  In  human  tissue 
sections, I was unable to dissect more than 250 Paneth cells per section and it is 
also likely that significant RNA degradation occurs in resected human intestinal 
tissue  prior  to  tissue  fixation.  To  optimise  RNA  extractions,  I  digested  tissue 
sections  with  Proteinase  K  (using  variable  concentrations  and  varying  time 
periods) and used a commercial kit (Qiagen) to extract RNA from LCM-acquired 
cells but these methods did not increase the RNA yield. I used several methods to 
optimise gene quantitation in LCM-acquired cells without success. These methods 
include performing reverse transcription with a highly thermostable, cloned avian 
RNase  H-  reverse  transcriptase  enzyme  (ThermoScript®  RT,  Invitrogen),  and
180priming with random hexamers or gene-specific primers. PCR amplification was 
performed  with  different  sets  of oligo-primers  but  gene  products  could  not  be 
amplified without using nested PCR. Newer techniques, which amplify extracted 
RNA sequences by in vitro transcription prior to quantitation using real-time PCR 
may permit  gene  quantitation  in Paneth cells  acquired  by  LCM  from  paraffin- 
embedded  tissue  sections.  Presently,  the  commercial  kits  available  for  gene 
quantitation  in  paraffin-embedded  tissue  (Paradise  kit,  Arcturus)  are  very 
expensive.
Although  I  was  able to  quantitate NOD2  mRNA expression in Paneth cells by 
isolating large numbers of intestinal crypts from surgically resected tissue, I was 
unable to quantitate protein expression in these cells by immunoblotting. NOD2 
protein  is  difficult  to  detect  in  primary  cells,  even  in  PBMC  that  abundantly 
express  NOD2,  and  other  laboratories  report  similar  difficulties  (G  Nunez, 
personal  communication  2003).  NOD2  protein  has  been  detected  by 
immunoblotting  in  primary  colonic  epithelial  cells  from  patients  with  Crohn's 
disease but not in healthy controls (Rosenstiel 2003) but these immunoblots have 
been very difficult to perform (Philip Rosenstiel, personal communication, 2003). 
Thus,  NOD2  gene  quantitation  in  patients  with NOD2-related  Crohn’s  disease 
appears to be only really feasible in resected tissue.
Unexpectedly,  I  found  that  NOD2  expression  was  not  prominent  in  tissue 
macrophages. NOD2 mRNA was not directly measured in macrophages isolated 
from  intestinal  tissue  although,  by  in situ  hybridisation,  NOD2  expression was 
most prominent in monocytes located in the lamina propria and on the periphery 
of granulomata  in  comparison to  mature  macrophages  located  in  the  centre  of 
granulomata.  Further evidence to  suggest that NOD2  expression is regulated in 
monocytic  cells  was  obtained  from  in vitro  studies,  which  showed a decline  in 
NOD2  mRNA  levels  in  PBMC  that  were  maintained  in  culture  to  allow 
monocytes to differentiate towards macrophages. It is unclear whether this decline 
in NOD2  levels  is  a programmed feature of monocyte  maturation and terminal 
differentiation or is consequent on adhesion of cells to a substrate, which requires 
further investigation.
1814.3.2 N0D2 regulation in PBMC and intestinal epithelial cells
Overall,  the  highest  levels  of  NOD2  expression  in  Crohn's  disease-affected 
terminal ileal tissue are seen in Paneth cells and lamina propria mononuclear cells, 
which suggest that these  cells play a role  in the pathogenesis  of NOD2-related 
Crohn's disease. However, although the NOD2 gene is prominently expressed by 
Paneth cells,  there  are  no  suitable  in  vitro  models  to  assess  gene  regulation  in 
these cells.  I  determined that intestinal epithelial  cell  lines  also  express NOD2, 
and  I  therefore  used  these  cells  to  investigate  the  regulation  of NOD2  gene 
expression.  NOD2  expression  is  more  prominent  in  immortalised  intestinal 
epithelial  cells  treated  with  a  solution  containing  lymphokine,  and  using 
recombinant  cytokines,  I  determined  that  TNFa  regulates  NOD2  expression, 
albeit weakly, in Caco-2, HT29 and SW480 cells. IFNy is a major constituent of 
lymphokine but NOD2 expression is not significantly enhanced or increased after 
treatment  with  IFNy.  IFNy  may,  however,  act  synergistically  with  TNFa  to 
increase NOD2 expression in intestinal cells, and may account for the increased 
NOD2 expression observed in Crohn's disease.
The results obtained in the present study are consistent with results published by 
other  investigators.  These  reports,  which  were  published  at  the  time  that  I 
performed  my  experiments,  also  show that  TNFa  stimulation  increases  NOD2 
expression  in  intestinal  epithelial  cells  (Gutierrez  2002,  Rosenstiel  2003, 
Hisamatsu  2003).  Hisamatsu  and  colleagues  (2003)  demonstrated,  by Northern 
blot  analysis,  that  TNFa  increased  NOD2  mRNA  expression  in  a  time-  and 
concentration-dependent manner in SW480 cells. NOD2 mRNA expression was 
not increased after stimulation with IFNy,  IL-lp, IL-4 or TGFp.  Rosenstiel and 
colleagues (2003) showed that TNFa induced an increase in NOD2 mRNA and 
protein expression in various colon cancer cell lines. IFNy did not induce NOD2 
expression  although  co-stimulation  with  TNFa  and  IFNy  induced  a  synergistic 
increase  in  NOD2  expression.  These  investigators  also  demonstrated  NOD2 
protein expression in primary colonic epithelial cells isolated from patients with 
Crohn’s disease but not in cells isolated from healthy controls.
182The  results  from  the  present  study  also  show  that  TNFa  increases  NOD2 
expression in PBMC maintained in culture. TNFa also induces NOD2 expression 
in  myeloblastic  HL-60  cells  (Gutierrez  2002)  although,  surprisingly,  I  am  not 
aware  of other  studies  analysing  NOD2  regulation  in  PBMC  stimulated  with 
TNFa.  As NOD2  levels  decrease  in PBMC  maintained  in  culture,  I  found that 
PBMC need to be extracted from a considerable volume of blood (200 -  250 mL) 
to allow for NOD2 quantitation in cells maintained in culture for at least 24 hours. 
I  analysed responses  in PBMC  obtained  from otherwise  healthy polycythaemic 
patients,  which  may  be  different  to  responses  seen  in  PBMC  obtained  from 
healthy volunteers.
The reason that TNFa increases NOD2 expression in intestinal epithelial cells is 
not known, but it is  likely that TNFa increases NOD2  expression by activating 
NF-kB.  The NOD2 promoter contains three DNA elements with high homology 
to the NF-xB-binding consensus  sequence that are  located at position -674 (5’- 
GGGGAAGCCC-3’,  kB I),  -301  (5’-GGGCCTCCCC-3\  kB2)  and  -26  (5’- 
GGGAATTTCC-3’,  kB3)  (Rosenstiel  2003).  Rosenstiel  and  colleagues  (2003), 
using cell transfectants expressing mutant forms of the NOD2 promoter, showed 
that deletion of the kB3 site markedly reduced TNFa or TNFa/IFNy induced NF- 
kB  activation.  A  similar,  but reduced,  effect was  noted when  kB2  was  deleted 
from the NOD2-promoter sequence. Site-directed mutagenesis of the kBI  site did 
not affect TNFa  or  TNFa/IFNy-induced  NF-kB  activation,  indicating  that this 
sequence is not a functional NF-kB-binding site. Earlier, Gutierrez and colleagues 
(2003) had also shown that the kB3 sequence, which is only responsive to the p65 
subunit of N F-kB, mediates TNFa-induced NOD2 expression in cell transfectants 
(Gutierrez  2003).  In  this  study,  overexpression  of a  dominant  negative  IxBa 
mutant also leads to a loss of induced NOD2 promoter activity,  suggesting that 
NF-kB is involved in the regulation of the NOD2 gene by TNFa.
In  the  present  study,  stimulation  with  dexamethasone,  which  inhibits  NF-kB 
activity  (Carlsen  2002),  decreases  NOD2  expression  in  PBMC  and  Caco-2 
intestinal  epithelial  cells.  Although  there  are  no  other  studies  to  confirm  this 
observation, these results suggest that NOD2 expression may be regulated by NF-
183kB  in  PBMC  and  intestinal  epithelial  cells.  In  intestinal  inflammation,  NOD2 
expression may be  increased in intestinal  epithelial  cells  in response  to NF-kB 
activation,  and  it  is  possible  that  mutant NOD2  proteins  may  abrogate  NF-kB 
activation induced by cytokines such as TNFa.
In the present study,  MDP  stimulation enhances  IL-8  and NOD2  expression in 
PBMC  maintained  in  culture  for  at  least  24  hours.  Interestingly,  although 
enhanced NOD2  expression  may  occur  secondarily  to  NF-kB  activation,  there 
was no enhancement of NOD2 expression in PBMC stimulated with LPS (in the 
present  study),  which  is  known to  activate NF-kB  (Palsson-McDermott  2004). 
These results,  however,  do  not  confirm  a role  for NOD2  in  mediating  cellular 
responses to MDP as I could not assess responses in PBMC that express mutant 
NOD2 proteins.
MDP is generally regarded as a putative intracellular ‘ligand’ for NOD2 although 
there is no direct evidence for this.  Girardin and colleagues  (2003) showed that 
microinjection of MDP caused NF-kB activation in RAW cells, but not in HeLa 
epithelial cells. There was no NF-kB activation in RAW or HeLa cells stimulated 
extracellularly with MDP  and these  investigators postulate that NOD2 mediates 
intracellular  ‘sensing’  of MDP.  However,  these  investigators  also  showed  that 
NF-kB  activation  occurs  in  cell  transfectants  that  abundantly  express  native 
NOD2 protein but not mutant NOD2 protein. Furthermore, Inohara and colleagues 
(2003)  show that MDP  induced NF-kB  activation  in human PBMC  containing 
wild-type, but not mutant, NOD2 proteins. There is thus no clear explanation for 
difference in responses seen in RAW cells and human PBMC after extracellular 
MDP stimulation, but these differences may reflect species-specific differences in 
monocyte responsiveness to MDP.  Overall, however, these  studies do  suggest a 
role for NOD2 in mediating cellular activation in response to MDP stimulation.
It  is  hypothesised  that,  within  intestinal  epithelial  cells,  NOD2  acts  as  an 
intracellular  ‘sensor’  that  mediates  NF-kB  activation  in  response  to  MDP  and 
induces  cellular  activation.  The  experiments  required  to  test  this  hypothesis, 
however,  require  microinjection and are  technically  difficult to  perform.  In the
184present study, intestinal cell lines are generally unresponsive to stimulation with 
LPS, confirming the observations made by Gutierrez and colleagues (2002). I pre­
treated intestinal epithelial cells with TNFa and IFNy, which reportedly increases 
TLR4  expression  (Abreu 2002),  and then  stimulated these  cells  with LPS.  The 
pre-treatments increased NOD2 expression, which is expected, but there were no 
further changes in NOD2 or IL-8 expression in response to LPS stimulation. MDP 
induced  weak  increases  in  NOD2  and  IL-8  mRNA  expression  in  Caco-2  and 
HT29, but not SW480 cells, which suggests that intestinal epithelial are generally 
unresponsive to MDP stimulation. In the present analysis, it is possible that NF- 
kB  activation  is  underestimated  as  protein  secretion  (for  example  IL-8 
measurement by ELISA)  was  not measured. Nonetheless, NF-kB  activation,  as 
assessed by immunostaining of the p65 subunit of NF-kB, is not detected in cells 
stimulated  with  MDP,  suggesting  that  intestinal  epithelial  are  unresponsive  to 
MDP (Girardin 2003).
Paneth cells, on the other hand, respond to stimulation with extracellular MDP by 
secreting  antimicrobial  peptides  (Ayabe  2000).  Importantly,  MDP  induces 
antimicrobial secretion from Paneth cells that is comparable to secretions induced 
by other bacterial antigens such as LPS, LTA and Lipid A. To assess the potential 
role  of Paneth  cells  in NOD2-related  Crohn’s  disease,  however,  is  difficult  as 
there is no  suitable  in vitro model to  analyse Paneth cell  function.  An assay to 
assess  antimicrobial  secretion  by  human  Paneth  cells  [similar  to  the  assay  (in 
murine Paneth cells) that was initially described by Ayabe and colleagues (2000)], 
is difficult to perform and it is likely that it will take a considerable length of time 
to collect intestinal tissue  from patients with Crohn’s  disease  and controls.  The 
role  of NOD2  in  Paneth  cell  function  may,  however,  be  assessed  in  murine 
models in which NOD2 gene expression is disrupted: for example, the Paneth cell 
secretion assay may be assessed in response to MDP and LPS stimulation in wild- 
type mice and those lacking NOD2.
185Chapter Five
5.  Expression  of Paneth cell-antimicrobial  peptides 
and  enzymes  in  NOD2-associated  Crohn's  disease 
and necrotizing enterocolitis
5.1  Introduction
Although  the  biology  of Paneth  cells  is  not  well-defined,  these  cells  are  very 
likely to be integral components of the enteric innate defence and may play a role 
in the pathogenesis  of Crohn's disease and necrotizing enterocolitis  (Lala 2003, 
Keshav 2003).
In Crohn’s disease, I have shown that Paneth cells express NOD2, an intracellular 
protein  that  mediates  cellular  activation  in  response  to  stimulation  with  the 
bacterial  antigen  muramyl  dipeptide  (MDP).  Mutations  in  the  NOD2  gene 
predispose  to  the  development  of  Crohn's  disease  in  susceptible  individuals 
although the reasons for this are unclear. Fellermann and colleagues (2003) have 
postulated that a lack of mucosal defensin peptides predispose to the development 
of Crohn's  disease  -  these  investigators have  shown that beta defensin 2  and  3 
expression  is  reduced  in  Crohn's  disease  but  not  ulcerative  colitis.  These 
investigators  postulate  further  that  abnormalities  in  NOD2  mediated  NF-kB- 
transcription  may  cause  reduced  defensin  expression  (Fellermann  2003),  and 
interestingly, have presented preliminary data showing that human alpha defensin 
5  (HD5)  and  6  (HD6)  expression  is  reduced  in NOD2-related  Crohn’s  disease 
(Wehkamp 2004). Using in situ hybridisation, I therefore determined HD5, HD6, 
lysozyme and secretory phospholipase A2 Group IIA (5PLA2) expression in tissue 
sections obtained from patients carrying two, one or no mutations in the NOD2 
gene.
I  also  analysed  Paneth  cell  antimicrobial  enzyme  expression  in  necrotizing 
enterocolitis  (NEC),  which  is  a  serious  and  often  fatal  disease  that  most 
commonly affects prematurely bom-newboms (Kliegman 1984). In NEC, there is
186gross  necrosis  of  the  intestinal  wall,  often  containing  perforations,  and  the 
disorder  is  microscopically  characterised  by  an  acute  inflammatory  infiltrate, 
haemorrhage and ischaemic necrosis.
The aetiology of NEC is unknown but it is postulated that the disorder develops 
when  enteric  pathogens  trigger  an  excessive  and  unregulated  inflammatory 
response in the host (Neu 2005). Bacterial infection is common in NEC, and on 
microscopic examination, bacteria are often identified invading the intestinal wall 
(Ballance  1990).  In  addition,  bacteria  are  implicated  in  causing  pneumatosis 
intestinalis,  large  areas  of gas-filled  cysts  within the  intestinal  wall,  which  are 
characteristic features of NEC (Ballance 1990).
Paneth cells may play a role in the pathophysiology of NEC as newborn infants 
have a lower number of Paneth cells than adults, which may predispose newborns 
to infection. Interestingly, in necrotizing enterocolitis (NEC), there appears to be a 
lack of lysozyme expression in Paneth cells, which suggests that these cells may 
play a role in the pathophysiology of this disorder (Coutinho  1998). Paneth cells, 
which  express  pro-inflammatory  molecules  such  as  TNFa  and  5PLA2,  may 
therefore also play a role in inflammation -  interestingly, although NEC can affect 
the  small  and  large  intestine,  inflammation  is  almost  always  initiated  in  the 
terminal ileum, where Paneth cells are most numerous (Kliegman 1984).
In neonates, a lack of enteric colonisation by commensal flora may predispose to 
infection and NEC  (Fell 2005). Interestingly, in the mouse intestine, Paneth cell 
antimicrobials,  such as angiogenin 4, have specific antimicrobial killing activity 
and  can  potentially  regulate  the  composition  of  the  enteric  microflora  by 
favouring  the  growth  of commensal,  instead  of pathogenic,  bacteria  (Hooper 
2003).  Abnormal  expression  of  Paneth  cell  antimicrobials  may  therefore 
predispose neonates to NEC, and intriguingly, there is some evidence to suggest 
that Paneth cell-antimicrobials are be selectively expressed in NEC: Salzman and 
colleagues  (1998)  have  shown  that  HD5  and  HD6  expression  is  apparently 
increased although lysozyme expression is apparently not detected within Paneth 
cells  (Coutinho  1998).  Expression  of  the  antimicrobial  enzyme,  secretory 
phospholipase A2 Group IIA (5PLA2) has, however, not been analysed in NEC. I
187therefore determined whether 5PLA2, an antimicrobial enzyme that may also play 
a  role  in  inflammation  (Six  2000),  is  expressed  in  Paneth  cells  in  NEC  and 
analysed the  expression of 5PLA2,  lysozyme  and TNFa  in tissue  sections  from 
newborns with NEC and intestinal atresia.
I  also analysed NOD2  expression in NEC  and intestinal  atresia tissue  sections. 
Although  patients  with NEC  apparently  do  not  carry NOD2  mutations  (Habib 
2005),  in  contrast  to  Crohn’s  disease,  the  level  of NOD2  expression  may  be 
reduced or deficient in neonates in whom Paneth cell numbers are reduced.
In  the  last  section  of  this  thesis,  I  analysed  the  expression  of  Paneth  cell 
antimicrobials in intestinal epithelial cell lines. Although Paneth cell function can 
be  assessed  in  mice  by  measuring  antimicrobial  secretion,  these  assays  are 
difficult to perform (Ouellette, personal communication).  I therefore determined 
whether  the  expression  of  Paneth  cell  antimicrobials  could  be  regulated  in 
intestinal epithelial cell lines, which are more convenient to use.
1885.2  Results
5.2.1  The expression  of Paneth  cell  antimicrobial  peptides  and 
proteins in NOD2-related Crohn's disease
In  histologically  normal  terminal  ileal  sections,  in situ  hybridisation confirmed 
that Paneth cells strongly expressed HD5 and HD6 (Figure 5.1).
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Figure 5.1. Paneth cells express HD5 and HD6 RNA. In terminal ileal sections 
hybridised with the HD5 and HD6 anti-sense strand riboprobes (T7 riboprobes), 
positive staining is confined to Paneth cells located at the bases of the intestinal 
crypts.  Parallel sections hybridised with HD5 and HD6 sense stand riboprobes 
(T3 riboprobes) show no positive staining, confirming the specificity of detection. 
All sections were  counter  stained with haematoxylin and viewed under  the  2  Ox 
objective.
189To analyse Paneth cell  antimicrobial peptide  and enzyme  expression  in NOD2- 
related Crohn’s disease, I determined HD5, HD6, 5PLA2 and lysozyme expression 
in tissue sections of 4 patients who were homozygous or compound heterozygous 
for  the  NOD2  mutation  (NOD2"7 '),  3  patients  who  were  heterozygous  for  the 
NOD2 mutation (NOD2+/‘), and 3 patients with no NOD2 mutations (NOD2+/+).
By in situ hybridisation,  HD5  and HD6  expression was  evident in the terminal 
ileum  in  all  Crohn's  disease-affected  patients  regardless  of  NOD2  genotype 
(Figure 5.2). InNOD2'/" patients, however, the staining intensity of HD5 and HD6 
RNA was less than wild-type or control patients (Figure 5.3). Paneth cells stained 
positively  for  lysozyme  and  5PLA2  RNA  in  all  patients,  and  no  difference  in 
staining intensity was noted.
Intriguingly,  Paneth  cells  were  aberrantly  distributed  along  the  crypt  axis  in 
NOD2"7 ' patients. Instead of localising to the base of the crypt, Paneth cells were 
abnormally  distributed  and  located  at  the  crypt  base  and  further  up  the  mid­
portions of the crypt (Figure 5.2).
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Figure 5.2. sPLA2, lysozyme, and HD5 and HD6 RNA expression in NOD2- 
related  Crohn’s  disease.  Column 1:  (A) In situ hybridization with the digoxigenin- 
labelled sPLA2 (i),  lysozyme (ii),  HD5 (iii),  and HD6 (iv) antisense strand riboprobes 
demonstrates  positive  brown  staining  in  small  intestinal  crypts  (arrowheads)  in 
histologically normal terminal ileum.  Column B: Hybridization with the control sense 
strand sPLA2  0),  lysozyme  (ii),  HD5 (iii),  and HD6 (iv)  riboprobes shows no signal, 
confirming specificity of detection.  Column C:  (c) In Crohn's disease patients without 
NOD2 mutations (NOD2+ /+ ), positive staining for sPLA2  (i), lysozyme (ii), HD5 (iii), and 
HD6 (iv)  RNA  is present in Paneth  cells  located at the  crypt base  (arrowheads)  in 
sections hybridized with the digoxigenin-labelled antisense strand riboprobes. Column D: 
Terminal  ileal  sections,  obtained from patients  who  are  homozygous for  the  NOD2 
mutations  (NOD2f~)  were  hybridized  with  digoxigenin-labelled  antisense  strand 
riboprobes. Positive staining for sPLA2 (i), lysozyme (ii), HD5 (iii), and HD6 (iv) RNA is 
localized to Paneth cells located in the intestinal crypts (arrowheads) and further away 
from  the  crypt  base,  scattered among  non-Paneth  cell  lineages  (open  arrows).  All 
sections were counterstained with haematoxylin, and viewed under the 20x objective.
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Figure 5.3. HD5 expression in Crohn’s disease. In Crohn's disease (NOD2+  +, 
NOD2+ A ,  NOD2'a),  Paneth  cells  stain positively for  HD5  RNA.  The  staining 
intensity  is greatest  in  histologically  normal  tissue  (Control),  and weakest  in 
NOD2+ a and NOD2 A sections. All sections were hybridised with HD5 anti-sense 
strand riboprobes,  and counter  stained with haematoxylin and viewed under the 
lOOx objective.
5.2.2  Quantitating alpha defensin expression in Crohn's disease
Although the staining intensity of HD5 RNA is less in patients with N0D2-related 
Crohn’s disease,  in situ  hybridisation  is  not  a quantitative technique  and  alpha 
defensin expression is more accurately quantitated,  using real-time RT-PCR,  in 
tissue biopsies or  specimens  obtained  from  patients with  Crohn's  disease.  This
192analysis  is,  however,  hindered  by  the  lack  of  information  concerning  NOD2 
genotype  in  most  patients  that  have  surgical  treatment  or  endoscopic 
examinations. During the time taken to complete the present thesis, I could only 
obtain fresh tissue from one patient who is homozygous for the frameshift NOD2 
mutation.  In this  patient,  HD5  and HD6  mRNA  expression was  approximately 
12% and 21% of the  levels  in a Crohn's disease-affected patient without NOD2 
mutations (Figure 5.4). This preliminary observation suggests that further analysis 
is needed to  determine  whether HD5  and HD6  expression  is  altered  in NOD2- 
related Crohn's disease.
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Figure  5.4.  HD5  and  HD6  expression  in  a  Crohn's  disease-affected  patient 
with  no  NOD2  mutations  and  a  patient  homozygous  for  the  NOD2 
fsl007insC  mutation.  Using  quantitative  real-time  RT-PCR,  HD5  and  HD6 
mRNA  expression  is  reduced  in  the patient  that  is  homozygous for  the  NOD2 
frameshift mutation (fs NOD2) as compared to a patient carrying wild-type NOD2 
gene  (wt NOD2).  The  relative  expression  of NOD2  and  GAPDH mRNA  were 
determined  using  intron-spanning  primers,  and  the  NOD2:  GAPDH  ratios 
calculated for  each  sample.  Results  are  shown  as  the  relative  expression 
compared to expression  in the patient with no NOD2 mutations,  which  is set at 
100%.
1935.2.3  Paneth  cell  antimicrobial  expression  in  necrotizing 
enterocolitis
Tissue sections were obtained from paraffin embedded intestinal tissue taken from 
20  neonates  with  NEC  and  7  with  intestinal  atresia  (representing  neonatal 
controls),  as  well  as  5  adult  control  subjects.  The  neonates  were  treated  for 
necrotizing  enterocolitis  and  intestinal  atresia  at  the  Chris  Hani-Baragwanath 
Hospital, Johannesburg, South Africa, and ethical permission for use of this tissue 
was obtained from the Ethics Committee of the University of the Witwatersrand, 
Johannesburg.  Histologically  normal  adult terminal  ileal  sections  was  obtained 
from 5 patients treated for colorectal cancer at the Royal Free Hospital, London, 
and  ethical  permission  for  use  of  this  tissue  was  obtained  from  the  Ethics 
Committee of the Royal Free Hampstead NHS Trust.
NEC was diagnosed according to the modified Bell criteria (Walsh 1986), which 
included radiological  confirmation.  The majority of neonates  (19/20) with NEC 
were premature, and all had severe disease i.e. confirmed Bell Stage IIIB (Walsh 
1986)  at the  time  of surgical  treatment.  NEC  was  commonly  diagnosed  at  an 
advanced stage  of disease,  and the  mortality rate  in this  group  was  50%.  NEC 
most commonly involved the terminal ileum (19 of 20 cases) and proximal colon 
(12 of 20 cases). Most neonates with intestinal atresia were full-term (6/7) and all 
required curative  surgical treatment within the first week of life.  One patient in 
this  group,  diagnosed  with  jejunal  atresia,  died  several  weeks  later  from 
septicaemia.
All  NEC  sections  were  characterised  by  the  presence  of acute  inflammation, 
haemorrhage and necrosis, which was confined by the muscularis propria in the 
majority of sections (19 of 20) obtained from the margins of surgically resected 
tissue.  Transmural  inflammation  and necrosis  was  commoner  in those  sections 
obtained  from  areas  of macroscopic  necrosis  (15  of 20  sections).  The  mucosal 
epithelial layer was extensively damaged by ulceration in 6 of 20 NEC sections; 
moreover,  in all of the remaining NEC  sections,  a significant proportion of the 
epithelial layer was damaged by ulceration or necrosis, which is likely to result in 
an underestimation of Paneth cell-gene and protein expression.
1945.2.3.1  Secretory  phospholipase  A2  Group  IIA  (sPLA2)  mRNA 
expression in NEC
By  in situ hybridization, sPLA2   mRNA was  detected  in Paneth cells  in 2  of 7 
neonatal atresia and all histologically normal adult tissue sections. sPLA2 mRNA 
was detected in  12  of 14 NEC  sections,  and the hybridisation  signal was  more 
intense  compared  to  control  neonatal  sections.  However,  the  strongest  sPLA2 
RNA  staining intensity was observed in control  adult  sections  (Figure  5.5).  By 
immunohistochemistry,  sPLA2  protein  was  detected  in  6  of 7  neonatal  atresia 
sections and in  12  of 14 NEC  sections,  and all adult sections.  Although in situ 
hybridisation  is  not  quantitative,  these  observations  suggest  that  sPLA2 
transcription is increased in NEC as compared to control neonates (Table 5.1).
Number of cases with 
positive sPLA2 mRNA 
hybridisation signal 
(Percentage)
Number of cases with absent 
sPLA2 mRNA hybridisation 
signal 
(Percentage)
NEC 12(85.71%) 2 (14.29%)
Neonatal atresia 2* (28.57%) 5 (71.43%)
*Neonate with ileal atresia with ulceration, inflammation and perforation of the terminal ileum.
Table 5.1. sPLA2 mRNA expression in NEC and neonatal atresia sections. A
positive  sPLA2  mRNA  hybridisation  signal was  more  readily  detected in NEC 
cases  than  control  neonates  (p<0.001,  Chi-squared),  suggesting  increased 
transcription in NEC. All NEC, neonatal and adult tissue sections were hybridised 
in parallel to control for variations in the in situ hybridisation protocol and probe 
concentration.
195196Figure  5.5.  XPLA2  expression  in  necrotizing  enterocolitis  (page  196).  (a)  In
NEC,  in  situ  hybridisation  with  digoxigenin-labelled  anti-sense  strand  SPLA2 
riboprobe  demonstrates  positive  staining  with  diaminobenzidine  peroxidase 
substrate mainly in the infra-nuclear region of Paneth cells (thick arrow),  where 
rough endoplasmic reticulum is localised, while the granule-rich apical cytoplasm 
is unstained,  (b) In NEC, hybridisation with the sense-strand riboprobe shows no 
signal,  confirming specificity of detection,  (c) Less intense staining in the Paneth 
cells  is  noted  in  neonatal  intestinal  sections  hybridised  with  the  anti-sense 
riboprobe  (d)  In  adult  tissue,  intense  staining  of the  Paneth  cells,  which  are 
numerous  and  crowd  the  intestinal  crypt,  is  seen  with  anti-sense  strand 
hybridisation.  (e)  Using  a  rabbit  anti-  SPLA2  antibody,  positive 
immunohistochemical  staining  in  the  apical  cytoplasm  is  seen  in  Paneth  cells 
(open arrow) (f) Fewer Paneth cells stain positively for protein in neonatal tissue 
compared to (g) adult tissue. All sections were counterstained with haematoxylin, 
(a)  to  (e)  were  imaged under the  lOOx objective,  and (f)  and (g)  under the 20x 
objective.
5.2.3.2  Lysozyme expression in NEC
Lysozyme mRNA is detected by in situ hybridisation in Paneth cells in 7 of 14 
NEC sections, but not in control neonatal sections. An intense hybridisation signal 
is noted in Paneth cells in all adult sections (Figure 5.6). In NEC, the presence of 
lysozyme  is  confirmed  by  immunohistochemical  detection  of  protein  in  the 
secretory granules of the Paneth cells, and lysozyme protein was also detected in 
lamina  propria  leukocytes.  (Figure  5.6)  These  results  suggest  that  lysozyme 
transcription is increased in NEC as compared to control neonates.
197198Figure 5.6. Lysozyme expression in necrotizing enterocolitis (page 198). (a) In
NEC,  in  situ  hybridisation  with  anti-sense  strand  lysozyme  riboprobe 
demonstrates positive staining mainly in the infra-nuclear region of Paneth cells 
(thick arrow),  (b) control hybridisation with the sense-strand riboprobe shows no 
signal  in NEC,  confirming specificity  of detection,  (c)  No  staining  is  noted in 
neonatal intestinal sections hybridised with the anti-sense strand riboprobe.  (d) In 
adult tissue,  intense staining of the Paneth cells is seen after hybridisation using 
the  anti-sense  strand  riboprobe.  (e)  In  NEC,  positive  immunohistochemical 
staining,  in  the  apical granules,  is  seen  in  Paneth  cells  (open  arrow)  using a 
rabbit  anti-lysozyme  antibody  (f)  Lysozyme  peptide  is  also  detected  in 
inflammatory leukocytes. All sections were counterstained with haematoxylin, and 
imaged under the lOOx objective
5.2.3.3  Tumour necrosis factor (TNFa) mRNA expression in NEC
In neonatal sections, Paneth cells constitutively expressed TNFa mRNA in 6 of 7 
cases. In NEC, TNFa mRNA expression in Paneth cells was observed in 12 of 14 
sections, and a strong hybridisation signal was evident in infiltrating leukocytes 
and tissue macrophages (18 of 20 cases). TNFa RNA expression was especially 
prominent  in  infiltrating  leukocytes  surrounding  regions  of  pneumatosis 
intestinalis  (Figure  5.7),  and  also  observed  in  circulating  leukocytes.  We  were 
unable  to  detect  TNFa  protein  using  commercially  available  anti-TNFa 
monoclonal  or  polyclonal  antibodies,  consistent  with  experience  of  other 
investigators.
199lumen
200Figure  5.7.  TNFa  expression  in  necrotizing  enterocolitis  (page  200).  (a)  A
representative NEC section,  highlighting transmural necrosis and haemorrhage 
within the intestinal wall. An area of  pneumatosis intestinalis (PI), which are gas- 
filled cysts  thought to  be  caused by the products  of bacterial metabolism,  is a 
typical histological feature of NEC.  (b) Numerous macrophages  (thick arrows), 
identified by  CD68  immunohistochemical staining are present around areas  of 
pneumatosis  intestinalis  [see  asterisk  in  (a)],  (c)  In  NEC,  intense  TNFa 
expression  is seen  in  macrophages  (thick arrow)  and lymphocytes  (thin arrow) 
after hybridisation using the anti-sense strand riboprobe.  (d) No staining is noted 
in  inflammatory  cells  in  control  sections  hybridised  with  the  sense  strand 
riboprobe.  (e)  In  neonatal  intestine,  in  situ  hybridisation  using  the  anti-sense 
strand riboprobe  shows  TNFa  expression  in  epithelial  crypt  cells  (f)  Control 
hybridisation using the sense strand riboprobe shows no staining in the intestinal 
crypts.  Image  (a),  stained with haematoxylin and eosin  is viewed under the  lOx 
objective  while  images  (b)  to  (f)  were  counterstained  with  haematoxylin  and 
viewed under the lOOx objective.
5.2.3.4  NOD2 expression in NEC
I  used  immunohistochemistry,  using  the  monoclonal  2D9  anti-NOD2  antibody 
(Ogura  2003),  to  detect  NOD2  protein  in  NEC  and  control  intestinal  atresia 
sections. In NEC, NOD2 was detected in Paneth cells in 3 of 14 sections and in 3 
of 7 atresia sections (Figure 5.8).
Number of case with positive NOD2 
protein staining 
(Percentage)
Number of cases with negative 
NOD2 protein staining 
(Percentage)
NEC 3(21.43%) 11  (78.57%)
Neonatal atresia 3 (42.86%) 4(57.14%)
Table  5.2.  NOD2  protein  expression  in  NEC  and  neonatal  atresia  sections.
Positive NOD2 protein staining was more readily detected in control atresia than 
NEC sections  although  this  difference  was  not significant  (Chi-squared =1.03; 
p=0.31).
I expected that NOD2 protein expression would be more readily detected in cases 
of NEC, which is characterised by severe inflammation, than cases of atresia, but
201this was not so. I also did not detect NOD2 mRNA expression in NEC or atresia 
sections by in situ hybridisation. Immunohistochemistry and in situ hybridisation, 
however, may not detect low levels of NOD2 expression in neonates and further 
analyses are therefore required to confirm this observation as low levels of NOD2 
expression in neonatal Paneth cells may predispose neonates to enteric infection 
and the development of NEC.
a  b
Figure  5.8.  NOD2  expression  in  necrotizing  enterocolitis,  (a)  In  NEC,
immunohistochemical  staining,  using  the  2D9  monoclonal  antibody,  localises 
NOD2 protein to Paneth cells within the intestinal crypts,  (b) In intestinal atresia, 
positive NOD2  staining is noted in Paneth  cells,  (c)  By  comparison,  in  adult 
terminal ileal tissue,  NOD2 protein appears to stain more  intensely in Paneth 
cells (d) Control terminal ileal section stained with an unrelated primary antibody 
shows no positive immunohistochemical staining. All sections were stained with 
haematoxylin and viewed under the lOOx objective.
2025.2.4  Expression  of  Paneth  cell  antimicrobial  proteins  in
intestinal epithelial cells:
In the absence of an in vitro model to assess Paneth cell function, I determined if 
immortalised intestinal epithelial cells may be suitable for this purpose. I therefore 
determined  the  baseline  expression  of Paneth cell  antimicrobial  proteins,  using 
real-time  RT-PCR,  in  SW480,  Caco-2  and HT29  cells.  These  analyses  showed 
that no specific cell line strongly expressed all Paneth cell antimicrobials. Within 
these cell lines, SW480 cells constitutively expressed HD5 and HD6 at the highest 
levels,  whereas  5 PLA2  expression was  strongest  in  Caco-2  cells,  and  lysozyme 
expression  strongest  in  HT29  cells.  When  normalised  for  GAPDH  expression, 
lysozyme was expressed at higher levels than the other antimicrobials (Table 5.3). 
This relatively high level of lysozyme expression in HT29 cells, however, was at 
least 104-fold lower than the expression in terminal ileal tissue, and HD5 and HD6 
expression is at least 106-fold lower in intestinal cell lines.
HD5 HD6 xPLA2 Lysozyme
SW480 643 25 2 2
Caco-2 25 65 352 30
HT29 1 1 2 1268
Terminal ileum epithelium 3xl09 1.7 x 10y 2.2 x 108 1  x 108
Table 5.3.  Constitutive antimicrobial expression in intestinal epithelial cells.
Quantitation  of HD5,  HD6,  SPLA2  and lysozyme  mRNA  expression  in  SW480, 
Caco-2 and HT29 cell lines, determined by quantitative real-time RT-PCR.  Values 
are normalised  for GAPDH expression, and are relative to the expression of HD5 
and HD6 in HT29 cells, which are arbitrarily set as 1.
5.2.4.1  Regulation  of Paneth  cell-antimicrobial  expression  in  intestinal 
epithelial cells
To determine whether Paneth cell-antimicrobial expression could be enhanced in 
intestinal  epithelial  cells,  I  stimulated  these  cells  with  nutrients,  cytokines  and 
hormones  such  as  zinc,  GM-CSF  and  IL-4.  In  vivo,  Paneth  cells  contain  large 
amounts of zinc (Kobayashi 1983), and have recently been shown to contain GM- 
CSF (Fukuzawa 2003).  I also stimulated intestinal epithelial cells with serotonin
203as  Paneth  cells  express  receptors  for  this  hormone  (Fiorica-Howells  2002). 
Dexamethasone  and  IL-4  were  used  as  stimulants  as  these  substances  are 
postulated to influence maturation of the intestinal epithelial barrier and improve 
host resistance  to  enteric  infection  (Madsen  1997).  Thyroid hormone  (T3)  and 
retinoic  acid were  also  used as  T3  is thought to  regulate  protein  synthesis  and 
secretion  in  cells  that  contain  large  amounts  of  endoplasmic  reticulum 
(Glantschnig 1996) - such as Paneth cells. All cells were harvested after 48 hours 
of stimulation with nutrients, cytokines and hormones.
Zinc  supplementation  caused  a  small  increase  (1.6-fold)  in  HD6  mRNA 
expression in Caco-2 cells, as assessed by quantitative real-time RT-PCR, and did 
not induce or enhance HD5 expression in any cell line tested. Serotonin and GM- 
CSF did not enhance HD5 or HD6 expression in any cell line.  Stimulation with 
dexamethasone  increased HD6  expression 6.5-fold  (Figure  5.9)  in  Caco-2  cells 
and  induced  expression  in  HT29  cells.  In  Caco-2  cells,  co-stimulation  with 
dexamethasone and zinc did not cause a synergistic increase in HD6 expression. 
Dexamethasone  did  not  enhance  HD6  expression  in  SW480  cells  and  did  not 
enhance  or  induce  the  expression  of HD5  expression  in  any  of the  cell  lines. 
Serotonin,  IL-4,  GM-CSF  and  retinoic  acid  did  not  significantly  alter  HD5  or 
HD6 expression in any cell line.
HD6 expression in Caco-2 cells
P=0.03
X
Cont  Zinc  Dex  Dex + Zinc  IL-4  IL-4 + Dex
Figure 5.9.  HD6  expression  in  Caco-2  cells.  Using quantitative  real-time RT- 
PCR,  HD6 mRNA  expression was  enhanced in  Caco-2  cells  after  48  hours  of
204dexamethasone and zinc stimulation.  The increase in HD6 expression induced by 
dexamethasone was statistically significant (P=0.03).  The relative expression of 
HD6 and GAPDH mRNA  were  determined using intron-spanning primers,  and 
the HD6:  GAPDH ratios calculated for each sample.  Results are shown as the 
relative expression compared to the level in unstimulated (control) Caco-2 cells, 
which was arbitrarily set as 1 unit.  Values in the figure are expressed as the mean 
± SEM (Standard error of the mean).  Experiments were performed three times, 
and differences between stimulated and control cells were analysed by two-tailed, 
non-paired t test, with a P value <0.05 indicative of  statistical significance.
Thyroid hormone  (T3)  stimulation enhanced HD5  expression  3-fold  in  SW480 
cells (Figure 5.10), but did not enhance HD6 expression.
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Figure 5.10. HD5 expression in SW480 cells.  Using quantitative real-time RT- 
PCR,  HD5  mRNA  expression  was  enhanced in  SW480  cells  after  48  hours  of 
thyroid hormone (T3) stimulation.  The increase in HD5 expression induced by T3 
was  statistically  significant  (P=0.02).  The  relative  expression  of HD5  and 
GAPDH mRNA  were  determined using intron-spanning primers,  and the HD5: 
GAPDH ratios  calculated for  each  sample.  Results  are  shown  as  the  relative 
expression  compared to  the level in  unstimulated (control)  SW480 cells,  which 
was arbitrarily set as  1  unit.  Values in the figure are  expressed as the mean ±
205SEM (Standard error of the mean). Experiments were performed three times, and 
differences  between  stimulated and control  cells  were  analysed by  two-tailed, 
non-paired t test, with a P value <0.05 indicative of  statistical significance.
There  were  small  but  significant  increases  in  HD6  and  HD5  mRNA  after 
dexamethasone  and  T3  stimulation  in  Caco-2  and  SW480  cells  respectively. 
Overall,  in  intestinal  epithelial  cell  lines,  I  did  not  find  that  HD5  and  HD6 
expression was dramatically regulated by stimulation with various agents.
5.2.4.2  Responses of intestinal epithelial cells to bacterial products
Paneth cells  secrete  antimicrobial peptides  in response to bacteria and bacterial 
products including lipopolysaccharide (LPS) and muramyl dipeptide (MDP). By 
RT-PCR,  I  have  shown  that  intestinal  epithelial  cells  express  Paneth  cell 
antimicrobials, albeit weakly. If these intestinal epithelial cell lines are to be used 
to assess Paneth cell function, these cells should secrete antimicrobial proteins in 
response  to  bacteria  or  bacterial  products.  I  therefore  assessed  if  there  was 
evidence of such a secretory pathway in Caco-2 and HT29 cells.
In  Caco-2  cells  that  were  stimulated  with  LPS,  I  was  unable  to  detect  5PLA2 
protein secretion by immunoblotting.  I also measured  5PLA2 enzyme activity in 
the culture supernatants of LPS-treated Caco-2 cells by measuring the amount of 
radiolabelled palmitate released from a dipalmitoyl phosphatidylcholine (lecithin) 
substrate.  No  free  palmitate  could  be  detected  in  lecithin  substrates  that  were 
incubated with the  cell  culture  supernatants,  whereas  almost  all  of the  lecithin 
substrate (98.85%) was hydrolysed in control preparations containing bee venom 
5PLA2  (This  enzyme  was  used  because  it  is  closely  related  to  human  5PLA2, 
which is not available commercially and cannot be readily isolated from human 
clinical material).  These results suggest that 5PLA2  secretion by Caco-2  cells is 
minimal, and cannot be induced by LPS stimulation. RT-PCR analysis confirmed 
that 5PLA2 expression was not increased in Caco-2 cells treated with LPS.
In  HT29  cells,  which  secrete  lysozyme  into  the  culture  supernatant,  MDP- 
treatment  did  not  alter  the  amount  of  lysozyme  secretion,  as  determined  by
206immunoblotting  (I  acknowledge  the  assistance  of my  colleague,  Dr  Annabel 
Bromfield, who performed the immunoblot analysis). Using quantitative real-time 
RT-PCR,  lysozyme  mRNA  expression  was  not  significantly  different  in  the 
control and MDP-stimulated HT29 cells.
I did not assess HD5 and HD6 secretion by SW480 cells, using immunoblotting, 
as there are no suitable commercial antibodies. Overall, these results suggest that 
intestinal epithelial cell lines cannot be used to assess Paneth cell function in vitro.
2075.3  Discussion
5.3.1  Paneth  cell  antimicrobial  peptide and  enzyme expression 
in NOD2-related Crohn’s disease
The mechanisms that predispose patients with NOD2 mutations to develop ileitis 
are  unknown  although  it has  been postulated  that  alpha  defensin  expression is 
reduced in Crohn’s disease-affected carrying NOD2 mutations (Fellermann 2003). 
In the present study, my results indicate that Paneth cells express antimicrobials, 
irrespective  of NOD2  gene  status.  These  observations  were  made  using  in situ 
hybridisation which is not a quantitative technique although HD5 and HD6 RNA 
staining appeared to be less prominent in patients carrying two NOD2 mutations. 
A preliminary observation also suggests that HD5 and HD6 expression is reduced 
in a patient homozygous  for the NOD2  mutations,  and my observation appears 
consistent  with  the  results  reported  by  Wehkamp  and  colleagues  (2004),  who 
described  reduced  HD5  and  HD6  mRNA  expression  in  patients  with  NOD2- 
related Crohn’s disease.
These  observations,  however,  should  be  interpreted  with  caution  as  gene 
quantitation  of  Paneth  cell  products  in  intestinal  tissue  (biopsy  material  or 
resected  surgical  tissue)  is  not  without  problems.  In  real-time  RT-PCR 
quantitation,  a  housekeeping  gene  is  used  as  the  reference  gene  to  normalise 
expression of the target gene. The level of expression of a housekeeping gene is, 
however,  dependant  on  the  amount  of tissue  analysed  and  Paneth  cell-specific 
mRNA targets may be erroneously over- or underestimated by real-time RT-PCR. 
For example, HD5 expression may be overestimated in small-sized biopsies that 
containing  only  mucosal  tissue,  or  underestimated  in  larger-sized  biopsies 
containing  a  greater  proportion  of  lamina  propria  tissue.  Ideally,  a  suitable 
reference  gene would not be regulated by inflammation or infection and would 
only be expressed in Paneth cells.
To ascertain that Paneth cells play a role in the pathophysiology of NOD2-related 
Crohn’s  disease  will  require  further  studies.  The  regulation  of HD5  and  HD6 
expression  is  not  well  understood  and  it  may  be  possible  that  HD5  and  HD6
208transcription is suppressed if abundant defensin peptides are present within Paneth 
cell granules. Initially, therefore, it will be important to determine the expression 
of HD5  and HD6 peptides in patients with ileitis. Next, the function of Paneth 
cells, containing wild-type  and mutant NOD2 proteins, needs to  be  assessed in 
patients with Crohn’s disease. Secretion assays are a method of assessing Paneth 
cell  function  and  we  have  preliminary  data  showing  that  human  Paneth  cells 
secrete antimicrobial enzymes and peptides in response to stimulation by bacterial 
antigens,  including  LPS  and  MDP  (A.  Bromfield  and  S.  Keshav,  unpublished 
data). Secretion assays can therefore be performed using tissues collected from a 
larger number of patients, including those carrying NOD2 gene mutations, to help 
to clarify a potential role for Paneth cells in the pathophysiology of ileitis (This 
study  would  likely  require  collaboration  between  larger  IBD  centres  so  that 
tissues can be  collected from  sufficient number of patients undergoing surgery, 
including those with the NOD2 mutations).
5.3.2  Paneth  cell antimicrobial  peptide and  enzyme expression 
in necrotizing enterocolitis (NEC)
An increasing body  of evidence  shows that,  with the  intestinal  milieu  at least, 
Paneth cells are important and crucial elements of the innate immune system. My 
findings are consistent with this view, as I showed that in NEC, the expression of 
5PLA2  and  lysozyme  is  enhanced  in  Paneth  cells,  most  likely  in  response  to 
enteric  infection.  In  the  present  study,  in  contrast to  previous  reports,  I  could 
identify lysozyme RNA and protein expression in Paneth cells in NEC sections by 
in situ hybridisation and immunohistochemistry. Although the baseline levels of 
antimicrobial peptides appear to be lower in newborn infants than adults, in NEC, 
Paneth cells are capable of increased antimicrobial production.
I also analysed NOD2  expression in NEC  as  lower levels of NOD2  expression 
may predispose neonates to enteric infection and subsequent NEC. In contrast to 
lysozyme and 5PLA2 RNA expression, I did not detect NOD2 RNA expression in 
NEC  using  in  situ  hybridisation.  It  is  unlikely,  however,  that  NOD2  RNA 
expression is absent in NEC  as NOD2 protein could be detected in some NEC 
sections. Due to the extensive epithelial destruction in NEC, it is likely that I have
209underestimated  gene  expression  in  Paneth  cells,  including  NOD2  expression. 
NOD2 protein could be detected more readily in neonates with intestinal atresia as 
compared  to  those  with  NEC  although  NOD2  protein  was  most  prominently 
expressed in adult Paneth cells. It is probably better, however, to quantitate NOD2 
expression  by  real-time  RT-PCR  in  resected  intestinal  tissue  to  determine  if 
expression is lower in neonates who develop NEC.
Paneth cells may play a role in the development of intestinal inflammation as they 
express  TNFa  (Keshav  1990).  Consistent  with  the  findings  of  previous 
investigators, my results confirm that Paneth cells express this pro-inflammatory 
cytokine.
My  results  also  emphasise  the  difficulty  of using  intestinal  epithelial  cells  to 
assess Paneth cell  function  in vitro.  In the  first instance,  levels  of Paneth cell- 
derived  antimicrobials  are  at  least  104'6-  fold  lower  than  levels  expressed  by 
Paneth cells contained in the mucosal epithelium. I attempted to induce defensin 
expression  in intestinal  epithelial  cells  by maintaining them  in  culture  medium 
enriched with nutrients such as zinc, but met with limited success. Further studies 
need to be undertaken to determine whether the modest increase in HD6 mRNA 
expression, induced by dexamethasone, in Caco-2 can be enhanced further. Even 
if alpha defensin expression is dramatically enhanced in cell lines, evidence of a 
secretory pathway in these cells is required if they are to be used to study Paneth 
cell  function.  I  could  not  demonstrate  that  these  cells  secreted  antimicrobial 
enzymes  in  response  to  stimulation  with  bacterial  products.  Cell  lines  cannot 
therefore be used to assess Paneth cell function at present as they express very low 
levels of HD5 and HD6. Nonetheless, if it is true that alpha defensin deficiency is 
important  in  the  pathogenesis  of  NOD2-related  Crohn’s  disease,  intestinal 
epithelial cell lines could be used to identify agents that enhance HD5 and HD6 
expression.
In the  foreseeable  future,  studies  evaluating  the  role  of NOD2  in  Paneth  cells 
would  have  to  be  performed  in  isolated  Paneth  cells  or  crypt  epithelial  cells 
obtained  from  patients  that  are  wild-type  and  homozygous  for  the  NOD2
210genotype.  These  studies  would  probably  involve  several  centres,  taking  into 
account  the  frequency  of  the  NOD2  mutations  in  Crohn's  disease,  and  the 
proportion  of  patients  that  require  surgical  resection  after  failing  medical 
treatment.  The  effects  of NOD2  mutations  on antimicrobial  secretion could be 
assessed by stimulating these cells with various bacterial products, although to test 
the  hypothesis  that NOD2  functions  as  an intracellular receptor for MDP  who 
require  specialised  technical  expertise  as  Paneth  cells  normally  respond  to 
extracellular  MDP  stimulation.  Also  for  accurate  quantitation,  antimicrobial 
expression should be quantified in isolated Paneth cells or crypt epithelial cells, 
rather than in whole-tissue intestinal segments.
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6. General discussion
Until very recently, the  function of Paneth cells,  first described over  100 years 
ago, has remained obscure. Recently, however, the biological significance of these 
cells appears to be much more clearly defined -  Paneth cells play a critical role in 
the  innate  intestinal  defences  by  affording  protection  against  potentially  lethal 
bacterial pathogens (Salzman 2003). In addition, recent reports suggest that these 
cells  play  a role  in the  pathogenesis  of intestinal  inflammation  (Keshav  1990, 
Kamal  2001),  and Paneth cells may play a role  in the pathogenesis  of Crohn’s 
disease, necrotising enterocolitis and cystic fibrosis  (Lala 2003,  Coutinho  1998, 
Clarke 2004).
There are several hypothetical possibilities in which Paneth cells may play a role 
in the pathogenesis of intestinal inflammation (Keshav 2003). Firstly, Paneth cells 
secrete  antimicrobials  that  may  regulate  the  composition  of  the  intestinal 
microflora and prevent infection by pathogenic bacteria. These cells also produce 
pro-inflammatory mediators, such as 5PLA2 and TNFa, which may interact with 
the surrounding epithelial cells and lamina propria mononuclear cells. In addition, 
Paneth cell products may also regulate stem cell and precursor cell differentiation 
and function, thus  altering the characteristics of the  crypt and villus  epithelium 
(Figure 6.1).
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Figure 6.1. Paneth cells potentially play a role in the development of intestinal 
inflammation  in  the  following  ways:  By  producing  and  secreting  pro- 
inflammatory molecules such as TNFa, SPLA2 and defensins which may interact 
with epithelial cells (1) or lamina propria leukocytes after reabsorption across the 
epithelium  (2);  by  direct  secretion  of pro-inflammatory  molecules  into  the 
basolateral  space  (3);  and  by  regulating  stem  cell  and  precursor  cell 
differentiation  and function,  thus altering the  characteristics  of the  crypt and 
villus epithelium(4). Bacteria and bacterial antigens (generated by the action of 
Paneth  cell  antimicrobials),  such  as  lipopolysaccharide  (LPS)  and  muramyl 
dipeptide  (MDP),  may also trigger inflammation.  Figure adapted from Keshav 
(2003).
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an  important  role  in  intestinal  inflammation  although  recent  data,  which  show 
decreased  alpha  defensin  expression  in  Crohn’s  disease-affected  patients  with 
NOD2  mutations  and  decreased  cryptdin  expression  in  mice  lacking  NOD2, 
suggest that Paneth cells may play a role in the pathogenesis of NOD2-associated 
Crohn's disease (Kobayashi 2005, Wehkamp 2004).
6.1  Paneth cells, NOD2 and Crohn's disease
The  recent  discovery  that  mutations  in  the  NOD2  gene  predispose  to  the 
development of Crohn's disease represent an exciting breakthrough in the efforts 
to define the genetic basis of common, polygenic human diseases  (Ogura 2001, 
Hugot  2001).  The  NOD2  gene  encodes  for  an  intracellular  protein  that  is 
postulated to regulate cellular activation after interacting with muramyl dipeptide 
(MDP).  MDP  is  a  component  of the  peptidoglycan  cell  wall  layer  of  gram- 
positive  and  gram-negative  bacteria  (Inohara  2003,  Girardin  2003).  It  is 
hypothesised  that  mutant NOD2  proteins  do  not  regulate  cellular  activation  in 
response  to  MDP  stimulation,  leading to  the  development  of chronic  intestinal 
inflammation.  The  function  of the  NOD2  protein,  however,  is  not  definitively 
established and the pathogenic mechanisms whereby mutant NOD2 proteins lead 
to the development of Crohn’s disease remains to be defined (Murray 2005).
In  this  thesis,  I  showed  that  Paneth  cells  prominently  express  NOD2  -   I  had 
earlier hypothesised that these cells are  likely to  express NOD2  as Paneth cells 
secrete  antimicrobial products, by as yet undefined mechanisms,  in response to 
stimulation  with  bacteria  or  bacterial  products  including  MDP.  In  addition, 
intestinal  inflammation  in  NOD2-associated  Crohn's  disease  localises 
predominantly to the terminal ileum, which was not easily accounted for by the 
prevailing  view  that  NOD2  expression  is  restricted  to  circulating  monocytes 
(Ogura 2001). Paneth cells, on the other hand, are most numerous in the terminal 
ileum and also prominently express NOD2 (Lala 2003, Ogura 2003). There is now 
evidence to suggest that Paneth cells are implicated in the pathogenesis of NOD2- 
associated Crohn's disease, although the mechanism by which NOD2 influences 
Paneth cell function requires elucidation.
214Paneth  cells  secrete  an  array  of potent  antimicrobial  proteins,  such  as  alpha 
defensins  5  (HD5)  and  6  (HD6),  in  response  to  stimulation  by  bacteria  and 
bacterial products (Ayabe 2000). Interestingly, Wehkamp and colleagues (2004) 
have  shown that HD5  and HD6 mRNA expression is reduced in NOD2-related 
Crohn's disease. These investigators analysed Paneth cell-antimicrobial expression 
in intestinal biopsies  from patients with Crohn's  disease,  and  showed that HD5 
and  HD6,  but  not  5 PLA2  and  lysozyme,  mRNA  expression  was  reduced  in 
inflamed regions of the terminal ileum. Moreover, a more profound reduction in 
HD5  and  HD6  mRNA  expression  was  noted  in  patients  with  NOD2-related 
Crohn's  disease.  In the  colon,  which contains  metaplastic  Paneth cells, there  is 
increased expression of HD5 and HD5 mRNA in patients carrying the wild-type 
NOD2  gene,  but  not  in  patients  homozygous  for  the  NOD2  mutations.  The 
expression of the  pro-inflammatory cytokine  TNFa  was  similar  in  all  patients, 
irrespective  of NOD2  genotype.  Notwithstanding  the  difficulties  in  accurately 
quantitying Paneth cell gene expression, Wehkamp and colleagues (2004) results 
suggest that further studies  are required to  determine  the  mechanism by which 
alpha defensin expression might be regulated by NOD2.
Using a murine model, Kobayashi and colleagues (2005) provide further evidence 
that  NOD2  regulates  alpha  defensin  expression.  By  disrupting  the  central 
nucleotide  oligomerisation  domain  (NOD)  of the  NOD2  gene,  they  generated 
mice that do not express NOD2 protein (Nod2'7 ' mice). These Nod2'7 ' mice were 
outwardly  healthy  and  displayed  normal  lymphoid  and  myeloid  cellular 
composition in the thymus  and spleen.  In addition,  these  mice  did not develop 
intestinal  inflammation  and  were  not  more  susceptible  to  dextran  sulphate- 
induced colitis. In Nod2'7 ' mice, however, some Paneth cell alpha defensins were 
expressed at much lower levels as compared to control mice.
Kobayashi  and  colleagues  (2005)  infected  Nod2‘7 ‘  and  control  mice  with  the 
pathogen Listeria monocytogenes by intravenous  or peritoneal  injection and by 
intragastric  dosing.  Interestingly,  Nod2"7 '  and  control  mice  were  equally 
susceptible  to  L.  monocytogenes  introduced  intravenously  or  via  peritoneal 
injection,  but  Nod2'7 '  mice  showed  increased  susceptibility  to  intestinal  L.
215monocytogenes infection. In intestinal L. monocytogenes infection, increased rates 
of bacterial translocation were measured in Nod2'A  mice.
These investigators then used microarray analysis to identify the genes induced in 
intestinal  infection,  and  showed  that  a  subgroup  of murine  alpha  defensin  (or 
cryptdin) genes was induced by L. monocytogenes infection. Interestingly, Paneth 
cell defensin-related cryptdin 2 (Defer!) and Defcr-related sequence  10 (Defcr-rs 
10) expression was low in Nod2‘/‘ mice, as compared to controls, prior to enteric 
infection. Surprisingly, in Nod2~/~  mice, intestinal infection further lowered Defcr2 
and Defcr-rs  10 expression.  Overall, these results suggest that the expression of 
certain  cryptdins  is  dependant  on  NOD2.  It  is  possible,  therefore,  that NOD2 
plays  an  important  and  specific  role  in  protecting  against  intestinal  bacterial 
infection by regulating Paneth cell defensin expression.
The potential regulation of alpha defensin expression by NOD2, however, must be 
more clearly defined to show that Paneth cells play a role in the pathophysiology 
of Crohn's disease.  Presently, the regulation of alpha defensin expression is not 
well understood: there is evidence to suggest that specific bacterial pathogens may 
regulate HD5 expression (Salzman 2003b) and an analysis of HD5 expression in 
human diseases  such as  necrotising enterocolitis  (Salzman  1998),  inflammatory 
bowel  disease  (Cunliffe  2001),  HIV-related  cryptosporiodis  (Kelly  2004, 
Dhaliwal 2003) and intestinal metaplasia of the upper gastrointestinal tract (Shen 
2005) may also provide further clues.
Salzman and colleagues (2003b) have shown that specific enteric pathogens can 
inhibit  Paneth  cell  alpha  defensin  expression  in  mice.  These  investigators 
determined that the  human pathogen Salmonella  serovar  Typhimurium  inhibits 
cryptdin 1   and lysozyme expression in mice that were orally inoculated with this 
pathogen.  The  reduction  in  cryptdin  1   expression  was  not  due  to  a  general 
dysfunction  of Paneth  cells,  and  does  not  occur  as  a  generalised  response  to 
enteric  or  gram-negative  bacterial  infection.  Instead,  it  appears  that  Cryptdin  1  
expression is decreased in response to a specific interaction between Salmonella 
serovar Typhimurium and the intestinal epithelium. This interaction is dependant 
on the Salmonella pathogenicity island 1   (SPI1) that encodes a type III secretion
216system and activates the p38 MAPK pathway in the intestinal epithelial cells. This 
finding  therefore  suggests  that  specific  bacterial  pathogens  can  regulate  alpha 
defensin expression and it remains to be established if the reduction in HD5 and 
HD6  expression  in  NOD2-associated  Crohn’s  disease  occurs  secondarily  to 
infection by specific (as yet unidentified) bacterial pathogens.
In HIV-related cryptosporidiosis, Kelly and colleagues  (2004)  show that Paneth 
cells contain less secretory granules and are reduced in number. The depletion in 
Paneth cell  granules,  which contain HD5  and HD6 peptides,  is  associated with 
HIV  infection,  reduced  body  mass  and  decreased  plasma  zinc  levels.  The 
depletion of Paneth cell granules may be explained by the increased episodes of 
intestinal  infections  associated  with  HIV  infection,  malnutrition  and  zinc 
deficiency. If this were true, then I would expect that HD5 and HD6 transcription 
is increased (as in neonates with necrotizing enterocolitis). Instead, HD5 mRNA 
transcription,  as  assessed  by  in  situ  hybridisation  and  quantitative  RT-PCR, 
appears unchanged compared to controls suggesting that nutritional factors, such 
as zinc, may regulate alpha defensin expression (Kelly 2004).
Paneth  cells  are  zinc-containing  cells  and  in  the  rat,  intravenous  injection  of 
diphenylthiocarbazone (dithizone), a zinc chelator, results in Paneth cell depletion 
(Sawada  1991).  In  addition,  in  patients  with  zinc  deficiency,  Paneth  cells 
demonstrate  ultrastructural  abnormalities  (Kobayashi  1983).  Zinc  deficiency  is 
common in Crohn’s disease (Goh 2003, Griffin 2004) and zinc supplementation 
may  prevent  relapse  in  patients  with  Crohn's  disease  (Stumiola  2001).  It  is 
plausible that zinc may play a role in maintaining normal Paneth cell function and 
it would be  interesting to  determine whether reduced alpha defensin in NOD2- 
associated Crohn’s disease is associated with zinc status.
In Crohn's disease, NOD2 may regulate HD5 and HD6 expression through direct 
or indirect  mechanisms.  For instance,  it is possible  that the  decreases  in alpha 
defensin expression, seen in Nod2'7 ' mice and NOD2-related Crohn's disease, are 
secondary to  intestinal  infection by pathogenic  bacteria or aberrant colonisation 
by  commensal  bacteria.  In  mice,  pathogenic  bacteria  decrease  cryptdin  1  
expression  (Salzman  2003b)  and  commensal  intestinal  microflora,  specifically
217Bacteroides  thetaiotamicron,  can  induce  specific  Paneth  cell-antimicrobial 
proteins  (Hooper  2003).  In  this  scenario,  aberrant  NOD2  proteins  alter  the 
composition  of  the  intestinal  microflora  or  predispose  to  bacterial  infections 
through  mechanisms  that  are  independent  of alpha  defensin  production:  alpha 
defensin  expression  is  subsequently  regulated  by  specific  bacterial  pathogens. 
Considering  that  NOD2  may  mediate  the  killing  of  intracellular  bacteria 
(Hisamatsu 2003), it is possible that the antibacterial properties of NOD2 are not 
mediated via alpha defensin peptides, which are secreted proteins.  Furthermore, 
Defer2  and  Defcr-rs  10  expression  is  decreased  in  NOD2'7 '  mice  prior  to  L. 
monocytogenes  infection  (which  further  depress  expression)  and  it  would  be 
important  to  confirm  whether  any  differences  in  Defer2  and  Defcr-rs  10 
expression are seen in wild-type and NOD2"/‘ mice that are reared in a germ-free 
environment.
NOD2 may also directly regulate HD5 and HD5 expression although, at present, 
there  is  no  evidence  for  this.  One  hypothesis  though,  based  on  the  recent 
identification of transcription factor 4 (TCF4) binding sites on the HD5 and HD6 
promoter regions, is that NOD2 may regulate defensin expression by interacting 
with the canonical Wnt signalling cascade (Abeya, manuscript in preparation).
Van Es and colleagues (2005) have recently shown that Paneth cell maturation in 
the  intestinal  crypt  is  dependant  on  Wnt  signalling,  which  is  mediated  via  p- 
catenin and transcription factor 4 (TCF4).  Interestingly, these investigators have 
identified  a  highly  conserved  TCF  binding  site  in  the  promoter  region  of the 
murine  cryptdins  and  human  HD5  and  HD6  genes.  In  addition,  Andreu  and 
colleagues (2005) have shown that the cryptdin and alpha defensin gene family, 
including  HD5  and  HD6,  are  direct targets  of p-catenin  signalling.  Using  cell 
transfectants, these investigators show that HD5 and HD6 expression is regulated 
by a p-catenin/ TCF4-dependent pathway (Andreu 2005). This therefore raises the 
possibility that HD5 and HD6 expression may be regulated by cross-talk between 
NOD2 and the Wnt-P-catenin/TCF4- pathway.
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crypt in NOD2-related Crohn's disease may also suggest that NOD2 may interact 
with  the  Wnt-P-catenin/  TCF4  signalling  cascade  (Abeya,  manuscript  in 
preparation).  Paneth  cells  express  the  TCF4  target  molecule  EphB3,  an  ephrin 
receptor, which is a member of the tyrosine kinase (RTK) receptor family. EphB3 
is essential for the correct positioning of Paneth cells at the bases of the intestinal 
crypts (Batlle 2002).  Batlle and colleagues (2002) have  shown that mutations in 
the  EphB3  gene,  which  contains  a TCF  site  in  the  promoter  region,  results  in 
malpositioning  of  Paneth  cells  along  the  crypt-villus  axis.  Thus,  both  the 
reduction in HD5 and HD6 expression and the malpositioned Paneth cells seen in 
NOD2-associated Crohn's disease may be accounted for by an altered interaction 
between (mutant) NOD2 and Wnt-p-catenin/TCF4 pathways.
Finally,  it  remains  to  be  determined  whether  the  reductions  in  alpha  defensin 
expression  are  physiologically  important  in  NOD2-associated  Crohn's  disease. 
HD5  and  HD6  are  potent  antimicrobials  and,  in  murine  models,  Paneth  cell- 
defensin deficiency does not result in the development of intestinal inflammation 
(Wilson  1999).  An  alternate  explanation,  therefore,  is  that  mutant NOD2  may 
predispose to Crohn's disease by primarily affecting the functioning of monocytes 
rather than Paneth cells.
6.2  Mononuclear cells, NOD2 and Crohn's disease
Maeda  and  colleagues  (2005)  generated  mice  that  expressed  mutant  NOD2 
(Nod22939lC ) proteins, analogous to mutant protein encoded by the Leul007fsinsC 
mutation  in  humans.  These  investigators  primarily  analysed  the  effects  of the 
frameshift NOD2  mutation on MDP-induced NF-kB  activation in isolated bone 
marrow-derived macrophages (BMDMs), and assessed intestinal inflammation in 
dextran sodium sulphate (DSS)-treated Nod22939lC  mice.
Maeda and colleagues (2005) showed that in BMDMs isolated from control and 
Nod22939lC  mice, MDP induced greater NF-kB  activation and IL-ip  secretion in 
Nod22939lC  macrophages. These investigators showed enhanced NF-kB activation
219and  intestinal  inflammation  in  DSS-treated  Nod22939,c  mice  in  comparison  to 
DSS-treated  wild-type  mice,  and  suggested  that  the  increased  inflammation  in 
Nod2  mice  is  mediated  by  the  pro-inflammatory  cytokine  IL-ip.  Perhaps 
surprisingly,  these  results  suggest  that  the  frameshift  mutation  is  a  gain-of- 
function allele, and are contrary to both in vitro studies using overexpression of 
the frameshift mutant (Ogura 2001, Inohara 2003, Girardin 2003, Abbott 2004), 
and  human  genetic  studies  that  suggest  that  the  analogous  mutation  in  human 
NOD2 is a loss-of-function allele (Lesage 2002).
Earlier, Watanabe and colleagues (2004), using NOD2-deficient and control wild- 
type mice, showed that bacterial peptidoglycan evoked increased secretion of the 
ThI  cytokines  IL-12,  IL-18  and  IFNy  in  NOD2-deficient  splenocytes  than  in 
control  splenocytes.  In  addition,  NOD2-deficient  splenocytes  secreted  greater 
amounts  of  ThI  cytokines  in  response  to  MDP  and  Par^Cys  or  Pani3CSK4 
(synthetic  TLR2  agonists).  MDP  lowered  IL-12  secretion  in  NOD2-replete 
splenocytes  that  were  stimulated  with  bacterial  peptidoglycan  or  Pau^Cys.  In 
contrast,  MDP  did  not regulate  IL-12  secretion  in NOD2-deficient  splenocytes 
that  were  stimulated  with  bacterial  peptidoglycan  or  Par^Cys.  Similar 
observations were made in vivo, higher serum levels of IL-12 were measured in 
NOD2-deficient  mice,  than  in  controls,  after  intravenous  administration  of 
peptidoglycan. These results show that peptidoglycan stimulation increases IL-12 
secretion in NOD2-deficient mice.
Using  flow  cytometry  to  analyse  cell  populations  present  in  the  splenocyte 
preparations,  these  investigators  identified  macrophages  as  the  main  sources  of 
IL-12  and  IL-18,  and  T-cells  and  macrophages  as  the  main  sources  of IFNy 
(Watanabe  2004).  Leukocytes  may  therefore  also  play  a  key  role  in  the 
pathogenesis of NOD2-related Crohn’s disease.
The results  from murine  studies reveal the  complexity of understanding NOD2 
function  and  its  role  in  the  pathogenesis  of  Crohn's  disease.  Several  of  the 
hypotheses  that have  been  advanced  to  explain the  observations  in the  murine 
studies can be divided conceptually into those  suggesting that mutant NOD2  is
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(“loss-of-function”), and those proposing that mutant NOD2 proteins activate pro- 
inflammatory pathways  (“gain-of-function”). However, these hypotheses are not 
mutually exclusive and may be valid in combination, particularly as the function 
of NOD2 is elucidated.
6.3  Elucidating NOD2 function
At present, NOD2 is postulated to play a role in intracellular pathogen recognition 
and in modifying signal transduction (Murray 2005).  As NOD2 contains a LRR 
motif, similar to plant R proteins and Toll-like receptors, it is postulated to detect 
bacterial  products.  Indeed,  based  largely  on  the  results  of transfection  studies, 
NOD2  is often described as an intracellular receptor for MDP.  However, direct 
binding of MDP to the NOD2 LRR domain has never been demonstrated although 
it is possible that NOD2 functions as a “guard” protein.  In this scenario, NOD2 
detects  a  modified  host  protein,  which  perhaps  complexes  with  MDP,  with 
subsequent  signal  transduction  that  triggers  cellular  defence  mechanisms 
(McDowell 2003, Murray 2005).
Candidate proteins that interact with NOD2 include GRIM-19 (Bamich 2005) and 
TAK1 (Chen 2004). These interactions, however, have only been demonstrated in 
transfected cells,  which express these proteins  in abundance.  In epithelial  cells, 
NOD2  interacts  with  GRIM-19,  a  subunit  of the  NADH:ubiquinone  complex 
(Feamley 2001) and a suppressor of STAT3 transcriptional activity (Zhang 2003). 
This interaction contributes to NOD2-dependent NF-kB  activation in these cells 
(Bamich  2005),  although  suppression  of  STAT3  activity  may  augment 
programmed cell death, of which NF-kB is a potent inhibitor (Karin 2002). TAK1 
plays  a role  in  IL-1  and  TNFa-induced  IKK  and NF-kB  activation  and NOD2 
appears to inhibit the ability of TAK1  to activate NF-kB in the absence of RIP2 
(Chen  2004).  The  precise  role  that  NOD2  plays  in  cellular  activation  and 
apoptosis  remains  to  be  defined,  and  much  remains  to  be  learned  about  the 
physiologically relevant mechanisms of NOD2 signal transduction.
221Although MDP causes a very weak response, measured relative to TLR pathway 
activation in primary macrophages, MDP can synergize with other TLR agonists 
to promote a synergistic response usually measured by cytokine secretion (Murray 
2005).  This  MDP-TLR  agonist  synergy  is  dependent  on  NOD2  because 
macrophages from NOD2-deficient mice are refractory to MDP stimulation, either 
when given in high concentrations (Pauleau 2003) or with small amounts of TLR 
agonists (Murray 2005). Molecules other than NOD2 may, however, also ‘sense’ 
MDP. Recently, NALP3/cryopyrin, in addition to NALP1  and NALP2, has also 
been  claimed to  respond  to  MDP  (Martinon  2004).  Interestingly,  macrophages 
isolated  from  a  patient  with  Muckle-Wells  syndrome,  a  dominant 
autoinflammatory  disease  caused  by mutations  in Nalp3,  overproduce  IL-lb  in 
response to  MDP  stimulation (Martinon 2004).  Therefore,  the  mechanisms that 
govern the NOD2-MDP  interaction are likely to reveal the  functions of NOD2 
and  potentially  other  proteins  involved  in  MDP  sensing.  In  addition,  it  is 
important  to  understand  how  NOD2  regulates  the  synergistic  induction  of 
cytokine release when cells are exposed to both MDP and a TLR agonist.
6.4  Paneth cells,  TNFa and Intestinal inflammation
Another aspect of Paneth cell function that may be important in the pathogenesis 
of Crohn's  disease  is  their putative  role  in  intestinal  inflammation.  Paneth  cell 
hyperplasia occurs in response to signals derived from activated T cells in models 
of enteric infection (Kamal 2001), and in IBD, Paneth cell metaplasia is seen in 
the  colon.  In  mice,  Paneth  cells  constitutively  express  TNFa  RNA  that  is 
apparently not translated into protein, probably because of regulation by the AU- 
rich  element  in  the  3’  untranslated  region  of the  TNFa  gene  (Keshav  1990). 
Interestingly, deletion of this regulatory region in transgenic mice causes terminal 
ileitis,  but  not  generalized  intestinal  inflammation,  suggesting  that  local 
overproduction of TNFa, potentially in Paneth cells, is important (Kontoyiannis 
1999). In addition, Lin and colleagues (2004) have recently reported that certain 
alpha defensin molecules exert pro-inflammatory responses in intestinal epithelial 
cells  by  activating  NF-kB  and  p38  mitogen-activated  protein  kinase  (MAPK). 
Thus, the ability of certain alpha defensins to act as a paracrine regulator of the
222intestinal inflammatory response raises the possibility that dysregulation of Paneth 
cell function may contribute to the development of inflammatory diseases such as 
Crohn's disease.
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Ogura (2001) - - - - - - 8.2 4 3 - - -
Abreu (2002) 2 cohorts 8.1 - 2.9 5.6 - 0.9 5.8 - 1.7 34.4 - 10.9
Ahmad (2002) 12.5 5.2 - 3.3 1.4 - 9.4 1.6 - 38.5 15.8
Cuthbert (2002) 9.1 3.5 3.7 3.3 0.6 1.6 5.4 2.1 1.5 14.6
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Radlmayr (2002) 13.9 1.7 2.1
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Vermeire (2002) B+C 11.5 3.2 - 5 0.6 - 7.8 0.9 - 38.7 8.7
Brant (2003) 3.9
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Louis (2003) 45.5
Mirza (2003) 34.4 14.3
Murillo (2003) 8.5 1
Palmieri (2003) 10.6 6.0 3.1 8.5 2.3 3.1 9.6 1.4 3.1
Roussomoustakaki (2003) 2.7 1.5 0
Sugimura (2003) 8.4 3.5 - 8.4 3.5 - 5.1 1.4 30.1 13.3
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to o o Ulcerative colitisAppendix B: The Vienna Classification of Crohn's 
disease
Age at diagnosis1: Al, <40 years
A2, >40 years
Location2: LI, Terminal ileum3
L2, Colon4
L3, Ileo-colon5
L4, Upper gastrointestinal6
Behavior: Bl, Non-stricturing non-penetrating (i.e. inflammatory)7
B2, Stricturing8
B3, Penetrating9
Adapted from Gasche (2000)
1. Age when diagnosis of Crohn's disease was definitively established by 
radiology, endoscopy, pathology or surgery.
2. The maximum extent of disease involvement at any time before the first 
resection. Minimum involvement for a location is defined as any aphthous lesion 
or ulceration. Mucosal erythema and edema are insufficient. For classification at 
least both, a small bowel and large bowel examination, are required.
3. Disease limited to the terminal ileum (the lower third of the small bowel) with 
or without spill over into cecum.
4.  Any colonic location between cecum and rectum with no small bowel or upper 
gastrointestinal involvement.
5. Disease of the terminal ileum with/without spill over into cecum, or any 
location in the colon.
6. Any disease location proximal to the terminal ileum (excluding the mouth) 
regardless of additional involvement of the terminal ileum or colon.
7. Inflammatory disease which never has been complicated at any time in the 
course of disease.
8. Stricturing disease is defined as the occurrence of constant luminal narrowing 
demonstrated by radiologic, endoscopic or surgical-pathologic methods with 
prestenotic dilatation or obstructive signs/ symptoms without presence of 
penetrating disease at any time in the course of disease.
9. Penetrating disease is defined as the occurrence of intra-abdominal or perianal 
fistulas, inflammatory masses and/or abscesses at any time in the course of 
disease. Perianal ulcers are also included. Excluded are postoperative intra­
abdominal complications and perianal skin tags.
261Appendix C: List of reagents and suppliers
Name of reagent
1.  p-mercaptoethanol
2.  lOOx Antibiotic antimycotic solution: 10 000 U 
penicillin, 10 mg streptomycin, and 25 pg 
amphotericin B per mL
3.  lOx Trypsin-EDTA solution: 5.0 g porcine trypsin, 
2.0 g EDTA-4 Na in 0.9% NaCl
4.  l-palmitoyl-2-[l-I4C]palmitoyl L-3- 
phosphaditylcholine (925 kBq/ml, 1.85-2.29 
GBq/mmol)
5.  32P dCTP (10 mCi/mL) (Redivue deoxycylidine 5’ [a
P] triphosphate, triethylammonium salt;
1  lTBq/mmol, -3000 Ci/mmol)
6.  5X First Strand Buffer [250 mM Tris-HCl (pH 8.30, 
375 mM KC1, 15 mM MgCl2]
7.  Acetic acid
8.  Acrylamide
9.  Agarose
10.  Ammonium acetate (5M)
11.  Ammonium persulphate
12.  Ampicillin
13.  Avidin-biotin peroxidase complex (ABC) reagent
14.  Bacto-agar
15.  Bee venom PL  A2
16.  Biotinylated anti-mouse antibody
17.  Biotinylated anti-rabbit and anti-mouse 
immunoglobulin antibodies
18.  Bovine serum albumin
19.  Bromophenol blue
20.  Calcium chloride (CaCl2)
21.  Chloroform
Supplier
Sigma
Sigma
Sigma
Amersham
Amersham
Invitrogen 
VWR 
Sigma 
Sigma 
Sigma 
Sigma 
Sigma 
Vector 
Appleton Woods 
Sigma 
Vector
Vector
Sigma
Sigma
Sigma
VWR
26222.  Chloroform: isoamyl alcohol (24:1 or 49:1)
23.  Coomassie blue
24.  DAB/ 0.02% hydrogen peroxide
25.  Deoxyadenosine triphosphate (dATP) 100 mM
26.  Deoxycytidine triphosphate (dCTP) 100 mM
27.  Deoxyguanosine triphosphate (dGTP) 100 mM
28.  Deoxythymidine triphosphate (dTTP) 100 mM
29.  Dextran sulphate
30.  DH5a E.Coli
31.  Diethyl ether
32.  Diethyl-pyrocarbonate (DEPC)
33.  DIG RNA labeling Kit
34.  Dimethyl formamide
35.  Dipalmitoyl phosphatidylcholine stock solution:  120 
mM dipalmitoyl L-a-phosphatidylcholine (1, 2- 
dipalmitoyl-sn-glycero-3-phosphocholine)
36.  Dithiothreitol (DTT)
3 7.  DMEM/F12 medium
38.  DNase 1  (10 U/pL; RNase-free)
39.  Dulbecco PBS
40.  Dulbecco’s modified Eagle medium (DMEM)
41.  Eel 13611 restriction endonuclease
42.  EcoRI restriction endonuclease
43.  Ecoscint A scintillation fluid
44.  EDTA (pH 8.0) Ethylenediaminetetraacetic acid
45.  Ethanol
46.  Ethidium bromide
47.  Ficoll 400
48.  Foetal calf serum
49.  Formaldehyde (37%)
50.  Formamide
51.  Glucose
52.  Glycerol
Sigma 
Sigma 
Sigma 
Invitrogen 
Invitrogen 
Invitrogen 
Invitrogen 
Amersham 
Invitrogen 
VWR 
Sigma 
Roche Diagnostics 
VWR
Sigma
Sigma
Sigma
Sigma 
Royal Free 
Hospital Pharmacy
Sigma
Helena Biosciences 
Invitrogen 
Phillip Harris 
Sigma 
VWR 
Sigma 
Sigma 
Sigma 
Sigma 
Sigma 
Sigma 
Sigma
26353.  Glycine
54.  Goat Serum
55.  H202 (30%)
56.  Haematoxylin
57.  Hanks’ balanced salt solutions (HBSS)
58.  HEPES [N-(2-Hydroxyethyl)piperazine-N'-(2- 
ethanesulfonic acid) hemisodium salt]
59.  Hexane
60.  Hindlll restriction endonuclease
61.  Histopaque® 1077
62.  Horse Serum
63.  Hydrochloric acid (HC1)
64.  IPTG (isopropylthio-p-D-galactoside)
65.  Isopropanol
66.  Klenow fragment
67.  L-Glutamine, 200 mM
68.  Maleic acid
69.  Methanol
70.  Magnesium chloride (MgCl2)
71.  Moloney Murine Leukemia Virus Reverse 
Transcriptase (M-MLV RT) (200 units/ pL)
72.  MOPS [3-(N-Morpholino)propanesulfonic acid]
73.  Mouse anti-digoxigenin monoclonal antibody
74.  Neutral buffered formalin (10%)
75.  Nuclease-free water
76.  01igo(dT)i2_i8 primer
77.  Paraformaldehyde
78.  Phenol: chloroform: isoamyl alcohol (25:24:1 or 
50:49:1)
79.  Phosphate Buffered Solution (PBS)
80.  Phytohaemagglutinin (PHA)
81.  PIPES (1,4-Piperazinediethanesulfonic acid)
82.  Polyvinyl pyrrolidone
Sigma
Sigma
VWR
VWR
Sigma
Sigma
VWR
Invitrogen
Sigma
Sigma
VWR
Sigma
VWR
Helena Biosciences 
Sigma 
Sigma 
VWR 
Sigma
Invitrogen 
Sigma 
Roche Diagnostics 
VWR 
Invitrogen 
Invitrogen 
Sigma
Sigma
Sigma
Sigma
Sigma
Sigma
26483. Pooled human AB serum Invitrogen
84. Porcine pancreas PLA2 (Type IB) Sigma
85. Protease inhibitor Sigma
86. Proteinase K Sigma
87. PstI restriction endonuclease Invitrogen
88. pUC 18 plasmid DNA Helena Biosciences
89. PvuII restriction endonuclease Invitrogen
90. Qiaprep® Spin Miniprep kit Qiagen
91. Random hexamers Invitrogen
92. RNase A Sigma
93. Roswell Park Memorial Institute (RPMI)-1640
Medium Sigma
94. Salmon sperm DNA Sigma
95. Smal restriction endonuclease Invitrogen
96. Sodium acetate (3M; pH 5.2) Sigma
97. Sodium chloride (NaCl) Sigma
98. Sodium deoxycholate Sigma
99. Sodium dodecyl sulfate (SDS) Sigma
100. Sodium hydroxide (NaOH) pellets VWR
101. SstI restriction endonuclease Invitrogen
102. TEMED (Tetramethylethylenediamine) Sigma
103. Transfer RNA (tRNA) Roche Diagnostics
104. Tris-Cl (pH 8.0) Tris(hydroxymethyl)aminomethane Sigma
105. Tris-HCl (pH 7.4) Sigma
106. Triton X-100 Sigma
107. Trizol reagent Invitrogen
108. Tryptone Appleton Woods
109. Tween 20 Sigma
110. X-gal (5-bromo-4-chloro-3-indoyl-p-D-galactoside) Sigma
112. Xylene VWR
113. Xylene cyanol Sigma
114. Yeast extract Appleton Woods
265List of Suppliers:
Amersham Biosciences UK Limited
Amersham Place 
Little Chalfont 
Buckinghamshire 
HP7 9NA 
United Kingdom
Anachem Limited
Anachem House
20 Charles Street
Luton
LU2 OEB
United Kingdom
Phone: 01582 747 500
Fax: 01582 745 105
Email: bioscience@anachem-ltd.com
Appleton Woods
Lindon House 
Heeley Road 
Selly Oak 
Birmingham 
B29 6EN 
United Kingdom 
Phone: 01214 727 353 
Fax: 01214 141 075
Bio-Rad Laboratories Limited
Bio-Rad House
Maylands Avenue
Hemel Hempstead
Hertfordshire
HP27TD
United Kingdom
Phone: 0208 328 2247
Email: techsupport.uk@bio-rad.com
DakoCytomation Limited
Denmark House 
Angel Drove 
Ely
CB74ET 
United Kingdom 
Phone: 01353 669 911 
Fax: 01353 668 989Eppendorf Scientific Incorporated
One Cantiague Road
P.O. Box 1019
Westbury
New York
11590-0207
USA
Phone: 00 1  800 421 9988 
Fax: 00 1  516 876 8599 
Email: eppendorf@eppendorfsi.com 
UK distributor: VWR International
Helena BioSciences Europe
Colima Avenue 
Sunderland Enterprise Park 
Sunderland 
Tyne & Wear 
SR5 3XB 
United Kingdom 
Phone: 01915 496 064 
Fax: 01915 496 271
Invitrogen Limited
3 Fountain Drive 
Inchinnan Business Park 
Paisley 
PA4 9RF 
United Kingdom 
Phone: 01418 146 100 
Fax: 01418 146 260
LCG Promochem
Queen's Road 
Teddington 
Middlesex 
TW11 0LY 
London
United Kingdom 
Phone: 0208 943 7000
Perbio Science UK Limited
Century House
High Street
Tattenhall
Cheshire
CH39RJ
United Kingdom
Phone: 01829 771 744
Fax: 01829 771 644
Email: uk.info@perbio.com
267Philip Harris Scientific
Findel House 
Excelsior Road 
Ashby Park 
Ashby de la Zouch 
Leicestershire 
LE65 1NG 
United Kingdom 
Phone: 08451 204 520 
Fax: 01530 419 492
Qiagen Limited
Qiagen House 
Fleming Way 
Crawley 
West Sussex 
RH10 9NQ 
United Kingdom 
Phone: 01293 422 911 
Fax: 01293 422 922
Roche Diagnostics Limited
Bell Lane
Lewes
East Sussex
BN7 1LG
United Kingdom
Phone: 01273 480 444
Sigma-Aldrich Company Limited
The Old Brickyard
New Road
Gillingham
Dorset
SP8 4XT
United Kingdom
Phone: 0800 717 181
Fax: 0800 378 785
Email: ukorders@europe.sial.comThermo Electron GmbH
Sedanstrasse 18 
89077 Ulm 
Germany
Phone: +49 (0)731 935 79 290 
Fax: +49 (0)731 935 79 291 
Email: sales.oligos@thermo.com
Vector Laboratories Limited
3 Accent Park 
Bakewell Road 
Orton Southgate 
Peterborough 
PE2 6XS 
United Kingdom 
Phone: 01733 237 999 
Fax: 01733 237 119
VWR International Limited
Merck House
Poole
Dorset
BH15 1TD
United Kingdom
Phone: 01202 660 444
Fax: 01202 666 856Publications
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